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The cell state transitions that occur during complex processes, such as development of the human
brain, require precisely controlled changes in gene expression. Major regulators of these
developmental events include transcription factors (TFs), which bind the genome in a sequencespecific manner, as well as chromatin modifying proteins and complexes that alter TF access to
the genome by modulating the DNA-histone protein structure of chromatin. Improper function of
these classes of regulatory proteins as a result of genetic mutation represents a major contributor
to neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD), intellectual
disability (ID), and epilepsy. It is therefore necessary to understand both how gene expression is
regulated during normal brain development, and how impairment of this process contributes to
NDDs.
Imbalances in excitatory and inhibitory neuronal activities in the cerebral cortex often occur when
development of either cortical excitatory projection neurons (cExNs) or inhibitory interneurons
(cINs) is disrupted. Thus, altered development of these neuronal cell types represents a major
xvii

contributor to ASD, ID, and epilepsy etiology. Here, we applied human pluripotent stem cell
(hPSC)-based differentiation methods to study the development of human cExNs and cINs in vitro.
These approaches enable the study of aspects of human brain development which are otherwise
intractable due to lack of access to and inability to experimentally manipulate human fetal material.
In my graduate work, I first used these in vitro differentiation models to produce cExNs and cINs
from induced PSCs (iPSCs) derived from several first-degree relatives in a multiplex ASD family.
This work identified cellular and molecular correlates of ASD affectation, including abnormal
expression of high-confidence ASD-associated genes in the most severely affected individuals.
Next, I studied the role of the chromatin remodeler CHD2 in cIN development, which when
mutated causes NDDs, including ASD and epilepsy. Here, I investigated its genomic targets during
cIN differentiation, the histone modification state changes associated with these CHD2 binding
events, and the consequences of CHD2 haploinsufficiency. This work suggests that CHD2 is
important both for maintaining expression of genes required to modulate the transitions from
pluripotency through neurectoderm induction and for progenitor specification and proliferation, as
well as playing a later role in activation of genes required for hcIN differentiation and maturation.
Finally, in addition to studying gene regulation of cortical development, I also studied this process
in a different context, the developing mouse limb. Conditional loss of Geminin (Gmnn), which
encodes a regulatory nucleoprotein, resulted in improper spatial and temporal expression of Hox
genes during limb bud patterning, causing dramatic later defects in limb patterning. Taken
together, this work advances our understanding of how gene regulation occurs during multiple
developmental processes and how its disruption can contribute to developmental disorders.
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Chapter 1: Introduction
Contributions: Emily M.A. Lewis wrote this chapter and Kristen L. Kroll edited it.
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1.1 Overview of the dissertation
The development of complex structures such as the human brain is a complicated process,
involving many layers of regulation, which ensure that genes are expressed at the right time and
place. Regulatory proteins, including transcription factors and chromatin modifying proteins, play
key roles in controlling these events. Their importance is evidenced by the fact that many
developmental disorders occur as a result of mutations in genes encoding these regulatory proteins.
These include neurodevelopmental disorders (NDDs), such as autism spectrum disorder (ASD),
intellectual disability, and epilepsy, with mutations in genes encoding epigenetic regulatory
proteins highly over-represented among high-confidence ASD genes (Lewis & Kroll, 2018; Loke
et al., 2015). However, there is still much we do not understand about the regulation of brain
development, particularly in humans. This is largely due to our lack of access to human fetal brain
material and inability to experimentally manipulate the developing human fetus. Although we have
learned a substantial amount about brain development from murine and other animal model
systems, human brain development is significantly more complex, and differs in many respects
from animal models of brain development (Ardhanareeswaran et al., 2017; Clowry, 2015; Nestler
& Hyman, 2010). Many regions of the human genome sequence have also diverged from other
animals, particularly in the non-protein coding space (Capra et al., 2013; del Rosario et al., 2014;
Kostka et al., 2018; Pollard et al., 2006). These human-specific aspects necessitate human models
of brain development, including in vitro differentiation of human pluripotent stem cells (hPSCs)
into different neural cell types. Chapter 2 and 3 of this dissertation review key aspects of the
regulation of human brain development. Chapter 2 provides an overview of how hPSCs have been
used to model NDDs involving disrupted epigenetic regulation. Chapter 3 includes a curation of
existing datasets relating to epigenetic regulation of human cortical development, focusing on
2

histone modification state changes and chromatin accessibility, providing comparisons of data
available for fetal brain versus stem cell-based models of aspects of brain development.

My early graduate work involved assessing several aspects of human cortical interneuron (hcIN)
development, using small molecule-based differentiation of human embryonic stem cells (hESCs)
to assess how transcriptional changes and the binding of a key transcription factor, NKX2-1,
regulate this process (Meganathan et al., 2017). This differentiation model was further used in the
work presented in Chapter 4 and 5 of this dissertation, to study both normal and aberrant human
cortical development. Similar hPSC-based differentiation approaches can be used to produce
hcINs and cortical excitatory projection neurons (cExNs), by adjusting the small molecule
composition to induce ventral or dorsal telencephalic regional brain character, respectively. In the
cortex, cINs and cExNs normally balance neuronal inhibition versus excitation, respectively; this
balance is essential for proper brain function, as imbalanced neuronal excitation and inhibition is
thought to contribute to many NDDs (Donovan & Basson, 2017; Lunden et al., 2019; Zikopoulos
& Barbas, 2013). Therefore, for the first main research project of my thesis studies, I differentiated
these two neuronal cell types from induced PSC lines (iPSCs) that were derived from several firstdegree relatives in a multiplex ASD family, identifying cellular and molecular correlates of
affectation (Lewis et al., 2019). For the second main research project of my thesis studies
(presented in Chapter 5 of this dissertation), I followed up on my early work (Meganathan et al.,
2017), characterizing the role of a chromatin modifying protein, CHD2, in hcIN development. We
had previously shown that CHD2 was a direct target of NKX2-1 and exhibits increased expression
during hcIN differentiation. As pathogenic mutation of CHD2 results in NDDs including ASD and
epilepsy, understanding the mechanisms by which this chromatin remodeler controls
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neurodevelopment was of high interest. Therefore, here I identified CHD2 genomic targets,
defined the histone modification state associated with CHD2 binding, and identified the
transcriptional and epigenetic consequences of CHD2 haploinsufficiency (similar to the
pathogenic human condition) at multiple time points during hcIN differentiation from hESCs
(Lewis, Antony, et al., 2021). The data obtained in both of these studies, as well as the methods
developed, can be used for multiple lines of future research, which are outlined Chapter 6 of this
dissertation. This includes using testing the activity of putative enhancers identified in Chapter 5
of this dissertation by using a massively parallel reporter assay (MPRA).

In addition to studying gene regulation in the context of cortical development, I also studied this
process in a different body region; the mouse limb. The Kroll Lab has a long-standing interest in
studying the role of the regulatory nucleoprotein Geminin (GMNN) in neural development
(Caronna et al., 2013; Kroll et al., 1998; Lim et al., 2011; Patterson et al., 2014; Yellajoshyula et
al., 2011). My initial work involving GMNN related to elucidating its role in medulloblastoma, a
common type of pediatric brain tumor (Sankar et al., 2017). Interestingly, while exploring the role
of GMNN in various aspects of embryonic development in conditional mouse models, we learned
that GMNN loss during the early pattering of the fore- and hindlimb buds resulted in significant
limb defects. I performed experiments to understand how GMNN loss affected the normal patterns
of gene expression required for proper limb development, and identified that Hox genes did not
retain their proper spatial and temporal patterns of expression in our mouse models of conditional
GMNN loss (Lewis et al., 2020). Taken together, the work presented in this dissertation furthers
our understanding of multiple aspects of development, including normal regulatory events and
how these can go wrong and result in abnormal cells, body regions, and organs. The following
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sections provide some background about the motivation for the topic of each chapter, as well as a
summary of the main takeaways.

1.2 Chapter 2 – Development and disease in a dish: The
epigenetics of neurodevelopmental disorders
This chapter was adapted from a review article (Lewis & Kroll, 2018) and provides key
background materials for the research findings presented in Chapters 4 and 5 of this dissertation.
This work was motivated by a desire to broadly survey the field of hPSC-based modeling of NDDs,
including understanding which disease-associated genes and/or mutations have been studied,
which experimental designs were used, and how their findings are connected to disease phenotype.
This review focuses in particular on genes encoding chromatin modifying proteins, which are a
prominent class of ASD genes. As background, we first outline the main events of mammalian
telencephalic development, describing key processes by which cExNs and cINs develop and
discussing important regulators of this process. We next describe some of the main classes of
epigenetic regulation, focusing on proteins involved in this process during cortical development
and how their disruption contributes to NDDs. We provide examples of genes encoding different
classes of epigenetic regulators that undergo pathogenic mutation to contribute to ASD. Such
genes include CHD2, which encodes a chromatin remodeling protein and is a major focus of the
work presented in Chapter 5 of this dissertation. Significantly, this review highlights the relatively
few studies that have been performed with induced PSC (iPSC)-based models carrying pathogenic
mutations in genes that encode epigenetic regulators, particularly involving nonsyndromic NDDs.
Among the mutations that have been modeled in iPSCs, a common theme involves alterations in
the proliferation and differentiation of neural stem cells. Identification of a general lack of iPSC5

based studies involving nonsyndromic and genetically complex forms of ASD motivated the study
presented in Chapter 4 of this dissertation. Here, iPSC-based models of cIN and cExN
development were created using cells from three members of a multiplex ASD family, as well as
an unrelated control, and phenotypes associated with the ASD diagnosis were defined. Such
examples of these common but poorly understood forms of ASD, involving high heritability and
polygenic contributors to liability, remain poorly understood and are therefore especially important
to study.

1.3 Chapter 3 – Epigenetic regulation during human
cortical development: Seq-ing answers from the brain
to the organoid
This second background chapter was adapted from a review article (Lewis, Kaushik, et al., 2021),
in which we curated existing datasets that document histone modification state and chromatin
accessibility during cortical development, elaborating both data obtained from the human fetus,
and from monolayer and three-dimensional (organoid) in vitro models. Since much of my thesis
work focused on epigenetic profiling of hcIN development utilizing in vitro stem cell-derived
models, it is important to determine which aspects of these in vitro stem cell-derived differentiation
schemes mimic the analogous events in vivo. Therefore, here we focused on compiling newly
derived epigenomic data for different regions and neuronal cell types in the human fetal brain and
comparing this to in vitro organoid and neuronal cell type-specific differentiation models utilizing
hPSCs. Since most of these data have been generated in recent years, this review provides a useful
new resource for referencing available data of this type in detail (types and number of samples
etc.), which did not appear to be available in the extant literature. This review also highlights
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current limitations in the availability of these data and the need to derive additional data of this
nature, particularly with respect to the need for histone modification state data in fetal brain and
for data with a greater neuronal cell type or regional specificity. This work will serve as a crucial
resource as we pursue analysis of the histone modification state data described in Chapter 5 of this
dissertation.

1.4 Chapter 4 – Cellular and molecular characterization of
multiplex autism in human induced pluripotent stem
cell-derived neurons
This chapter was adapted from an original research article (Lewis et al., 2019) and represents the
first study of multiplex autism using stem cell modeling. The in vitro differentiation systems to
produce cExNs and cINs from hPSCs developed in our lab (Meganathan et al., 2017) provided a
powerful tool to study ASD using patient-derived iPSCs. As was mentioned above, most extant
iPSC-based models of ASD have focused on monogenic and/or syndromic causalities in simplex
families, so understanding contributors to polygenic/multiplex ASD has largely been neglected.
Significantly, ASD is highly heritable and most cases involve polygenic risk (Gaugler et al., 2014;
Griesi-Oliveira & Sertié, 2017; Weiner et al., 2017), so it is important to study these more complex
but common aspects of ASD etiology. As an example of this under-explored etiology of ASD, we
chose a family with multiple ASD-affected individuals for study. While a shared variant of
unknown pathogenicity in the GPD2 gene was present both the mother and in all her children, they
exhibited dramatically variable degrees of affectation, including a clinically unaffected son and
mother, a mildly affected daughter, and two severely affected monozygotic twin sons, suggesting
additional polygenic and/or non-coding contributors to affectation. We utilized clonal iPSC
7

models derived from the mother, daughter, and one of the twin sons, as well as from an unaffected
unrelated control, differentiating them as cExNs and cINs to identify morphological,
physiological, and transcriptomic alterations associated with these subjects' polygenic liability to
ASD. This work was the first to study multiplex ASD and demonstrates the utility of in vitro
differentiation models to understand the basis of this common but more complex disease etiology.
However, it should be noted that the study of monogenic cases of NDDs, such as those involving
pathogenic variants in genes encoding epigenetic regulators, enables coupled mechanistic and
phenotypic investigation of the role of these proteins in development and disease, as is explored
in Chapter 5 of this dissertation.

1.5 Chapter 5 – Regulation of human cortical interneuron
development by the chromatin remodeling protein
CHD2
This chapter is an original research article currently in preparation for submission for publication
(Lewis, Antony, et al., 2021). As was described above, my early thesis work focused on
understanding the transcriptional profile of hcIN development and studying the role of the
transcription factor (TF), NKX2-1, in this process (Meganathan et al., 2017). In this work, we
identified the gene encoding the chromatin remodeler CHD2 as a direct target of NKX2-1 and
demonstrated that CHD2 is required for proper hcIN development. While this study characterized
the transcriptional changes that accompany hcIN specification and differentiation, it did not relate
these to changes in the epigenomic landscape or define genome-wide locations of CHD2 binding.
To address this, I defined the profiles of H3K27ac, H3K4me3, H3K27me3, and CHD2 binding
across the genome at three stages of hcIN specification and differentiation and integrated this data
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with transcriptional profiling data from our prior publication (Meganathan et al., 2017). To further
understand the contribution of CHD2 deficiency to NDDs such as ASD and epilepsy, I created a
model of CHD2 haploinsufficiency, which mimics the genetics of patients, where homozygous
mutations are incompatible with life. I used this model to study how CHD2 mutation affected gene
expression during hcIN differentiation and explored several potential mechanisms by which these
could have occurred. Briefly, I found that CHD2 is generally associated with active regulatory
elements of genes with increasing expression during hcIN differentiation, particularly when novel
CHD2 binding events occurred in the hcIN progenitors or neurons that were not present in hESCs.
These CHD2 binding events were associated with increased H3K27ac enrichment as specification
and differentiation occurred. Interestingly, CHD2 haploinsufficiency in this model appeared to
result in down-regulation of proliferation and adhesion-associated genes during early stages of
differentiation. This resulted in premature maturation of the hcINs and accordant elevated and
early expression of genes associated with neuronal function, such as synaptic signaling. We
hypothesize that CHD2 plays a role in maintaining proliferation and adhesion-associated genes in
an open chromatin state (i.e. preventing the premature transition to a less accessible chromatin
state). This work will facilitate the future study of pathogenic CHD2 mutations in subject-derived
iPSCs and/or by CRISPR/Cas9 engineering of pathogenic mutations into wild-type hPSCs, and
also provides epigenomic datasets for hcIN differentiation that will be valuable for studying
changes in the epigenomic landscape and enhancer usage that drive hcIN specification and
differentiation.

1.6 Chapter 6 – Conclusions and future perspectives
The data and methods presented in this dissertation provide many opportunities for further study.
For example, it is very important to try and understand the role of non-protein coding regulatory
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regions in controlling gene expression during cortical development. This is particularly crucial for
genetically complex NDDs such as ASD, where non-coding variation likely contributes to risk of
affectation (Turner & Eichler, 2019; Williams et al., 2019). Therefore, determining how
pathogenic variation in these non-coding regions disturbs gene regulatory networks underlying
particular aspects of neurodevelopment is necessary. In this chapter, I describe how histone
modification state data (presented in Chapter 5 of this dissertation) can be integrated with
epigenetic data from the fetal brain (presented in Chapter 3 of this dissertation), as well as with
other datasets obtained from genome sequencing of individuals with NDDs. These include genome
variants specific to ASD probands by comparison with their unaffected siblings, which might
represent genetic liabilities that contribute to disease. I describe how MPRAs (Kwasnieski et al.,
2012) can be used for high-throughput testing of the activity of putative hcIN-specific cisregulatory elements (CREs), to define the constellations of transcription factor binding sites that
control enhancer activity. The impact of ASD proband-specific non-coding variants within these
CREs can also be tested by MPRA. Finally, I discuss how CRISPR-based tools and patient-derived
iPSCs can be used to understand the transcriptomic, epigenetic, and phenotypic impact(s) of the
loss of function of a CRE or gene on hcIN differentiation.

1.7 Appendix – Geminin is required for Hox gene
regulation to pattern the developing limb………
The work presented in the Appendix to this dissertation includes original research describing my
work studying the epigenetic regulation of another developmental process. As was previously
mentioned, substantial prior work in our laboratory has focused on the roles of the regulatory
nucleoprotein GMNN in multiple processes, mostly focusing on GMNN requirements for several
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aspects of embryonic development using stem cell and animal models (Caronna et al., 2013; Kroll
et al., 1998; Lim et al., 2011; Patterson et al., 2014; Yellajoshyula et al., 2011). I was first involved
in work demonstrating that GMNN conditional loss of function selectively suppressed
preneoplastic and tumor cell proliferation in the context of the pediatric brain tumor
medulloblastoma (Sankar et al., 2017). I next studied two other mouse models of GMNN
conditional loss, identifying and characterizing alterations of the limb bud developmental program.
In this work, I determined that misregulation of Hox genes, likely due to requirement for GMNN
for Polycomb-mediated Hox gene regulation, was a main contributor to the observed phenotypes
(Lewis et al., 2020). Phenotypes observed in these models varied based upon the timing and
location of GMNN conditional loss, as well as the timing of development of the fore- versus hindlimb buds. This work therefore represents an interesting example of the importance of time and
location when considering the requirements for key developmental regulators.

1.8 Summary
Taken together, the work presented in this dissertation advances our understanding of multiple
developmental processes, and how their disruption can contribute to developmental disorders. I
largely focus on human cortical development, and particularly hcIN development, an important,
but under-studied human neuronal cell type. In Chapter 2 and 3 of this dissertation, I provide
important background and context for the novel findings presented in the research articles in
Chapter 4 and 5. Together, this work demonstrates the utility and power of using hPSC models to
model aspects of cortical development, to define the regulatory networks that control these
processes, and to elucidate how their perturbation can contribute to NDDs. In addition to the
findings made here, the data and methods presented throughout this dissertation will have high
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utility for a wide variety of future studies focused on understanding the gene regulatory logic and
networks underlying hcIN development.
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Chapter 2: Development and disease in a
dish: The epigenetics of neurodevelopmental
disorders
This chapter is adapted from a review article published in Epigenomics:
Lewis, E. M. A., & Kroll, K. L. (2018). Development and disease in a dish: The epigenetics of
neurodevelopmental disorders. Epigenomics, 10(2), 219–231. https://doi.org/10.2217/epi2017-0113
Contributions: EMAL and KLK equally contributed to conceiving, writing, and editing this
review.
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2.1 Abstract and keywords
Human neurodevelopmental disorders (NDDs) involve mutations in hundreds of individual genes,
with over-representation in genes encoding proteins that alter chromatin structure to modulate gene
expression. Here, we highlight efforts to model these NDDs through in vitro differentiation of
patient-specific induced pluripotent stem cells into neurons. We discuss how epigenetic regulation
controls normal cortical development, how mutations in several classes of epigenetic regulators
contribute to NDDs, and approaches for modeling cortical development and function using both
directed differentiation and formation of cerebral organoids. We explore successful applications
of these models to study both syndromic and nonsyndromic NDDs and to define convergent
mechanisms, addressing both the potential and challenges of using this approach to define cellular
and molecular mechanisms that underlie NDDs.
Keywords: autism spectrum disorder, cerebral cortex, cerebral organoid, chromatin, epigenetic,
genetics, induced pluripotent stem cell, in vitro differentiation, neurodevelopmental disorder,
neuron.

2.2 Introduction
The human cerebral cortex is a complex and highly organized structure with stereotyped neuronal
circuitry, which integrates responses to myriad stimuli through balanced electrophysiological
activity throughout life. Formation of the cortex during embryonic and fetal development involves
ordered processes that allocate pluripotent early embryonic cells to the neural plate, specify
telencephalic regional identity at its rostral end, generate progenitors with regionally restricted
identity, drive their differentiation into distinct neuronal cell types, control their proper integration
into circuits, and modulate neuronal function through later life (Budday et al., 2015; Silbereis et
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al., 2016). The complexity of corticogenesis and the extended time frame involved renders it highly
sensitive to disruption, which contributes to neurodevelopmental disorders (NDDs) including
autism spectrum disorder and intellectual disability (ASD/ID) syndromes, schizophrenia, bipolar
disorder, and inherited epilepsies (Moreno-De-Luca et al., 2013). Recent genomic sequencing
efforts have cataloged many human genetic variants that contribute to the pathogenesis of these
NDDs (Iossifov et al., 2012; LaSalle, 2013; Loke et al., 2015; Neale et al., 2012; O’Roak et al.,
2012; Quadrato et al., 2016; Sanders et al., 2012). Although some syndromic NDDs involve
mutations in a single gene, genetic susceptibility to most NDDs appears more complex; a heritable
component can be defined, but hundreds of individual genes are implicated, with each potentially
pathogenic mutation occurring in only a small fraction of cases. Further underscoring the complex
etiology of these disorders, it remains unclear how relative contributions of pathogenic mutations
interact with other aspects of an individual patient’s genetic background, and with nongenetic or
environmental contributors, to cause these NDDs (Y. S. Kim & Leventhal, 2015; Mandy & Lai,
2016; Tick et al., 2016; Weiner et al., 2017). Examining classes of likely or confirmed highly
penetrant pathogenic gene mutations that contribute to NDD risk has been informative. Some
susceptibility genes encode proteins involved in neuronal function, such as ion channels and signal
transduction pathways involved in synaptic function or neurotransmitters and their receptors.
Mutations in these genes would be predicted to alter the function of neuronal circuits, contributing
to NDDs. However, perhaps unexpectedly, many confirmed or suspected mutations implicated in
NDD causation are in genes encoding proteins that regulate chromatin structure (LaSalle, 2013;
Loke et al., 2015; Rangasamy et al., 2013; Zhubi et al., 2014). Such ‘epigenetic’ regulatory proteins
and complexes act on the nucleosomal histone octamer and genomic DNA architecture of
chromatin to modulate gene expression. For example, in ASD/ID and epilepsy, recent unbiased
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genome-wide studies have revealed contributory mutations in many genes that encode proteins
that remodel chromatin, control histone methylation and demethylation, and recognize methylated
DNA, as well as in histone variants that can alter chromatin accessibility (Ben-David & Shifman,
2013; LaSalle, 2013). Potentially pathogenic variants in genes that regulate chromatin during early
development are highly over-represented in ASD probands but not their unaffected siblings, with
some estimates suggesting that half of the genes with a high confidence link to ASD are involved
in epigenetic regulation (Loke et al., 2015). These findings implicate epigenetic regulation of
neuronal development and/or function as a central contributor to nervous system dysregulation in
NDDs. However, in most cases, neither the role of these epigenetic regulatory proteins in normal
neurodevelopment nor how their disruption contributes to NDD etiology is well understood. This
review focuses on how these questions are being addressed by using in vitro differentiation of
human neurons derived from patient-specific induced pluripotent stem cells (iPSCs), which
provide an experimentally tractable model for defining cellular and molecular mechanisms that
underlie NDDs.

2.3 Formation and patterning of the mammalian
telencephalon
The mammalian cortex is built by stepwise developmental processes that begin with formation of
the neural plate during the third week of human embryogenesis (Patestas & Gartner, 2016; Stiles
& Jernigan, 2010). Many aspects of corticogenesis have been extensively studied in mouse models
and appear to be conserved in primates, including humans. Therefore, while the structure and
patterning of the rodent and primate cortex differs in several respects, we have briefly summarized
central, conserved aspects of corticogenesis below, to provide a context for describing how these
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processes are presently modeled with human iPSC-derived neurons and organoids in vitro. For an
in-depth description of human cortical development, we refer the reader to excellent reviews on
this topic (Silbereis et al., 2016; Stiles & Jernigan, 2010). Neurodevelopment begins in early
embryogenesis when pluripotent embryonic cells acquire distinct fates through differential
exposure to growth factor signaling. Signaling through the TGF-β pathway induces nonneural,
mesendodermal fates, while antagonism of this growth factor signaling enables induction of the
neural plate. As development proceeds, the neural plate acquires regional identity along its rostralcaudal axis, delineating territories that form the brain and spinal cord. The neural plate also
develops into the neural tube, through morphogenetic changes whereby a central groove forms,
surrounded by two neural folds, which elevate and fuse at the dorsal midline. Dorsal BMP and
Wnt signaling and ventral SHH signaling centers control the expression of transcription factors
that confer dorsal-ventral regional neural identity along the extent of the neural tube. Within the
forebrain, this regionalization generates a dorsal telencephalic progenitor territory that will
develop into the cerebral cortex, which expresses genes encoding transcription factors such as
EMX1/2, PAX6, and NEUROG1/2, and ventral telencephalic progenitor domains enriched for
expression of different transcription factors such as DLX1/2, NKX2–1, ISL1, SP8, and ASCL1
(Figure 1) (Bakken et al., 2016; Martynoga et al., 2012; Stiles & Jernigan, 2010). Following the
establishment of regional neural progenitor domains within the developing telencephalon,
neurogenesis drives their differentiation into distinct neuronal cell types and subsequent assembly
into circuits. Prior to cortical neurogenesis in the dorsal telencephalon, neural stem cells (NSCs)
proliferate in a simple neuroepithelium at the rostral end of the neural tube through symmetric cell
divisions. These divisions generate a layer of cells called the ventricular zone (VZ), proximal to
the underlying ventricle. Neurogenesis is initiated around gestational week five in humans
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(Budday et al., 2015; Stiles & Jernigan, 2010), as VZ NSCs downregulate epithelial markers and
transition into asymmetrically dividing neural progenitor cells (NPCs) called radial glia (RG)
(Bystron et al., 2008; Stiles & Jernigan, 2010). Radial glia can divide such that one daughter cell
remains in the VZ to maintain the RG population, while the other differentiates, generating
neuronal and glial cortical progenitors. Radial glia progenitors remain attached to both the
ventricular and pial surfaces of the developing cortex, serving as a scaffold for migration of
differentiated cortical neurons. Differentiating RG migrate into a dorsally located subventricular
zone, forming progenitors with more restricted potential and giving rise to postmitotic neurons,
which form the six layers of the cortical plate in an inside-out manner (Budday et al., 2015). In the
ventral telencephalon, neural progenitors likewise acquire regional identities, forming the
ganglionic eminences, from which GABAergic interneurons derive (Figure 1). Activities of
ventrally enriched transcription factors drive specification and differentiation of these future
inhibitory interneurons, which then undergo a long-range tangential migration to the cortex and
establish circuits with cortical excitatory neurons to modulate their activity (Kelsom & Lu, 2013).
Normal progression of neurodevelopment through these complex events results in the formation
of a cortex of the proper size and with stereotypical patterning, in which circuits formed by cortical
excitatory neurons and inhibitory interneurons can properly modulate functional output,
maintaining a finely tuned balance between neuronal excitation and inhibition. Corticogenesis in
humans involves an extended developmental period encompassing much of gestation, with
continued refinement and maturation of cortical structure and function through childhood and
adolescence (Budday et al., 2015). Accordingly, many aspects of these developmental programs
are highly sensitive to disruption, which alters normal cortical function and contributes to NDDs.
These disruptions can involve alterations in the number of neurons that contribute to particular
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brain structures, alteration of the time windows during which NSC expansion, specification, and
differentiation occur to form particular neuronal types and brain structures, and often interrelated
later alterations in cortical size, patterning, neuronal composition, and circuit establishment and
function, any of which can affect the balance between neuronal excitation and inhibition and can
contribute singly or in combination to the emergence of NDDs (Donovan & Basson, 2017).

2.4 Epigenetic regulation of neural development and
contributions of its dysregulation to NDDs ……………
As described above, many disease-causing variants in NDDs have, perhaps surprisingly, been
found in genes that encode epigenetic regulators. During cortical excitatory and inhibitory neuron
development, the interplay between transcription factors and the epigenetic machinery has a
central role in establishing and maintaining regulatory networks that drive neuronal specification
and differentiation programs. Accordingly, many gene mutations that perturb these regulatory
programs appear to alter corticogenesis in some manner, contributing to NDDs. The term
epigenetics generally refers to changes in gene expression and function that do not involve changes
in the DNA sequence (Yao & Jin, 2014). This typically involves post-translational modification
of histone proteins or methylation of DNA, but can also include the activities of noncoding
regulatory RNAs. Several classes of proteins are key regulators of these processes of epigenetic
modification, including chromatin remodelers and histone and DNA methylases and demethylases.
Below, we outline some roles of these modifiers in neural development, to provide a context for
studying how their perturbation may contribute to NDDs. As an example, subsets of genes
encoding epigenetic regulatory proteins in these classes that are mutated in ASD are shown in
Figure 2, with some discussed below.
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2.4.1 Chromatin remodeling
Chromatin is comprised of DNA wrapped around a histone octamer to form nucleosomes. These
can be more loosely packed, as in euchromatin, where the DNA is more accessible to the
transcriptional machinery, or tightly packed, as in heterochromatin, where DNA is more
inaccessible. Modulation of chromatin structure by remodeling proteins and complexes modulates
gene expression at many stages of neural development. For example, ATP-dependent chromatin
remodelers move nucleosomes along the DNA or exchange nucleosome variants (Ronan et al.,
2013). One such family of chromatin remodeling complexes is the mammalian SWI/SNF-like BAF
complexes. The SMARCA2 gene (also called BRM), encodes the core ATPase subunit of this
complex and is mutated to cause a syndromic NDD (Figure 2). BAF complexes play several key
roles in mammalian neurodevelopment. For example, in neural progenitors, they interact with
REST, a repressive transcription factor, to inhibit neural genes and maintain progenitor identity,
while an alternate neural BAF complex is involved in later aspects of neurodevelopment, including
dendritic morphogenesis and neural circuit wiring (Ronan et al., 2013). Another ATP-dependent
chromatin remodeler that is involved in neural development and is among the most frequently
mutated genes in ASD cases is CHD8 (Figure 2). CHD8 binds to trimethylated histone H3 lysine
4 (H3K4me3) at active promoters and may also repress Wnt/β-catenin target genes by recruiting
the linker histone H1. Interestingly, putative CHD8-regulated genes include many other ASD risk
genes, suggesting that many NDD contributory genes act within shared regulatory networks
(Cotney et al., 2015).

2.4.2 Histone modifications
Within the histone octamer, which canonically consists of two copies each of histone subunits
H2A, H2B, H3, and H4, post-translational modifications of the N-terminal tails of several histones
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can alter chromatin structure. These modifications include acetylation, methylation,
ubiquitination, and phosphorylation of histone tail residues (Figure 2). Several classes of proteins
are involved in this process, including those that add or remove histone modifications (sometimes
referred to as ‘writers’ and ‘erasers’), and those that interpret these modifications and mediate
changes in gene expression (‘readers’). For example, histone methyltransferases methylate several
histone residues, while histone demethylases remove these modifications. Although methylation
of several histone residues, such as trimethylation of histone H3 at lysine 9 or 27
(H3K9me3/H3K27me3), facilitates transcriptional repression, other methylation events, such as
trimethylation of histone H3 at lysine 4 (H3K4me3), are associated with active transcription. This
modification appears to facilitate recruitment of protein complexes that promote transcription
(LaSalle, 2013; Ronan et al., 2013). In general, histone acetylation is associated with active gene
transcription, as it counteracts the positive charge of histones and reduces their interaction with
negatively charged DNA phosphate groups to increase accessibility (Tyssowski et al., 2014).

During development, different combinations of histone modifications are used to regulate gene
expression. In particular, stem cells and cells of the early embryo are thought to adopt a ‘bivalent’
histone modification state at genes involved in developmental processes. This involves the
presence of both repressive H3K27me3 and activating H3K4me3 modifications on adjacent
nucleosomes. Bivalent genes are generally not expressed but adopt a ‘poised’ state and can
undergo rapid changes in gene expression in response to developmental signaling. This enables
loss of one modification and retention of the other to readily promote activation or repression of
gene subsets appropriate to the acquisition of particular cell fates (Burney et al., 2013). For
example, genes encoding many transcription factors with roles in neural development, such as the
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NGNs, PAX6, NESTIN, SOX1, SOX3, NKX2.2, and ASCL1, are bivalent in pluripotent early
embryonic cells and in vitro cultured embryonic stem cells (ESCs), but become active during
neural cell specification. This involves the loss of H3K27me3 and retention of H3K4me3, while
genes controlling pluripotency or alternate cell fates instead retain H3K27me3 and lose H3K4me3
to facilitate silencing of these transcriptional programs (Hirabayashi & Gotoh, 2010). Although
Polycomb repressive complex 2 catalyzes the H3K27me3 histone post-translational modification
to repress gene expression, the H3K27-specific demethylase KDM6B is upregulated during the
fate transition from ESCs to neural progenitors and removes the H3K27me3 modification from
neural-specific genes such as PAX6 and NESTIN (Hirabayashi & Gotoh, 2010). Mutations in
KDM6B are associated with ASD, suggesting that disrupting these changes in histone methylation
contributes to NDDs (Figure 2). In association with the resolution of the bivalent state, histone
acetylation can promote and maintain active gene expression. Several histone acetyltransferases
are likewise implicated in ASD, including EP300, KAT2B, and KAT6A (Figure 2). As these
examples illustrate, mutations in genes encoding proteins that control the histone modification
state during neural development could result in misregulation of this developmental program,
contributing to nervous system abnormalities associated with NDDs.

2.4.3 DNA methylation/demethylation
Another layer of epigenetic regulation involves DNA methylation, usually at the fifth position of
cytosine (5mC) in CpG dinucleotides; however, in some contexts, such as ESCs and brain tissue,
non-CpG methylation can also occur (Jang et al., 2017). Although most promoter CpG islands
(regions with high CpG frequency) are unmethylated, high levels of CpG methylation in gene
promoters are typically associated with repression of gene expression. Promoter methylation can
confer chromatin inaccessibility to transcription factors, and can also recruit methyl-binding
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proteins and chromatin-modifying proteins that further inhibit promoter accessibility (Jobe et al.,
2012; LaSalle, 2013). During neurodevelopment, DNA methylation correlates with long-term
repression of both pluripotency- and non-neural fate-related genes in differentiated neurons.
Resolution of the bivalent histone modification state is also highly correlated with an increase in
CpG methylation, as non-neural genes become more permanently silenced (Hirabayashi & Gotoh,
2010). DNA methylation is carried out by DNA methytransferases, with DNMT3A and DNMT3B
establishing de novo methylation, whereas DNMT1 maintains the methylation state during DNA
replication. It is thought that DNMT3B plays an earlier role in neurogenesis, while DNMT3A
likely plays a role in both the prenatal regulation of neurogenesis and in postnatal neural maturation
(Yao & Jin, 2014). The importance of DNMT3A in neural development is evidenced by the fact
that mutations in this gene have been associated with ASD (Figure 2). Mutations in DNMT3B
cause immunodeficiency, centromere instability, and facial anomalies (ICF) syndrome. Although
these patients only have mild cognitive defects, DNMT3B deficiency during iPSC-based neural
differentiation in vitro alters the timing of differentiation and maturation, also supporting the role
of DNMT3B in neural development (Martins-Taylor et al., 2012).

Methyl-binding proteins are responsible for connecting DNA methylation patterns to changes in
gene expression by binding methylated DNA along with protein complexes that repress
transcription. MECP2 encodes a methyl CpG binding protein, and mutations in this gene are
associated with Rett Syndrome (RTT), an NDD (Figure 2). MECP2 appears to have a variety of
functions and binding locations, most commonly binding methylated DNA to act in transcriptional
repression, with other roles involving altering chromatin structure, mediating alternative splicing
of RNA, and perhaps promoting gene activation (R. Li et al., 2016; Tyssowski et al., 2014; Yasui
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et al., 2013). It is highly expressed in the brain and plays a role in neuronal maturation, with BDNF
being one well known target (Jobe et al., 2012). Other Methyl-CpG binding domain (MBD)
proteins have also been implicated in ASD, including MBD1, MBD3, MBD4, and MBD5 (Figure
2). For example, MBD1 is highly expressed in the brain and plays an important role in neural
development; this includes binding directly to the promoter of FGF2, a gene encoding a growth
factor that promotes proliferation of NSCs (Murao et al., 2016). These examples highlight the
importance of epigenetic regulation during neural development and underscore how perturbations
in several types of epigenetic regulators can contribute to NDDs.

2.5 Stem cell models of NDDs involving epigenetic
dysregulation
Since Takahashi and Yamanaka generated the first iPSCs from human fibroblasts in 2007, patientderived iPSCs have held great promise for modeling human disease (Takahashi et al., 2007). This
approach is particularly appealing for studying NDDs, as fetal tissue is inaccessible during
development and neural development is substantially more complex and prolonged in humans than
in the mouse and other model organisms (Ardhanareeswaran et al., 2017; Clowry, 2015), such that
animal models often do not recapitulate human disease phenotypes (Nestler & Hyman, 2010). In
addition, for many complex NDDs, both potentially pathogenic mutations and the genetic
background can interact to contribute to the phenotype and these distinct contributions often cannot
readily be defined or mimicked in animal models (Y. S. Kim & Leventhal, 2015; Mandy & Lai,
2016; Tick et al., 2016). Therefore, developing human, patient-specific models for NDDs is
desirable to model key cellular and molecular features of the underlying biology.
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In vitro approaches to modeling human disease have intrinsic limitations, perhaps especially in the
case of NDDs, which often appear to have a complex etiology involving multiple abnormalities of
fetal brain development at both a structural and cellular level, and consequently complex effects
on neuronal circuit formation and function (Donovan & Basson, 2017). However, several NDDs,
including ASD/ID, schizophrenia, bipolar disorder, and epilepsy, appear to frequently involve an
imbalance between the excitatory activity of glutamatergic projection neurons and inhibitory
GABAergic interneurons in the cerebral cortex (Donovan & Basson, 2017; Zikopoulos & Barbas,
2013). Therefore, some of these defects can be modeled by using both patient- derived and control
iPSCs as starting materials to generate these neuronal cell types and to define cellular, molecular,
and functional changes that correlate with and may contribute to disease. Induced pluripotent stem
cells are readily and efficiently obtained by reprogramming a number of somatic cell types from
patients, including skin fibroblasts (Takahashi et al., 2007), renal epithelial cells (T. Zhou et al.,
2012), blood (Loh et al., 2009), and dental pulp (Tamaoki et al., 2010), via expression of four
transcription factors (OCT4, SOX2, KLF4, and c-MYC) or related strategies (Takahashi et al.,
2007). Both excitatory glutamatergic projection neurons and inhibitory GABAergic interneurons
can be efficiently generated from iPSCs in vitro (Figure 1). To produce cortical excitatory neurons,
a ‘dual SMAD inhibition’ protocol is commonly used that involves the addition of inhibitors of
both BMP signaling through SMAD1/5/8 and TGF-β signaling through SMAD2/3 to induce
formation of NPCs of dorsal telencephalic character (Chambers et al., 2009), which are
subsequently induced to undergo differentiation in two-dimensional monolayer culture. Recent
protocols have also been developed to derive inhibitory GABAergic interneurons from human
iPSCs, which involve the use of a SHH agonist and Wnt signaling antagonist in addition to dual
SMAD inhibition. This promotes the formation of NPCs with a ventral telencephalic character,
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which are subsequently differentiated into GABAergic cortical interneurons (Maroof et al., 2013;
Nicholas et al., 2013).

As these protocols are capable of efficiently producing large numbers of neurons which resemble
cortical excitatory and inhibitory neurons, they can be used to probe many of the molecular,
cellular, and functional abnormalities that correlate with or contribute to disease (Figure 1).
However, two-dimensional monolayer culture of specific neuronal cell types does not recapitulate
many aspects of in vivo cortical development, which involves cell–cell interactions in the context
of a complex three-dimensional structure (Boissart et al., 2013; Tamburini & Li, 2017). Given
these limitations, many recent efforts have focused on the production of cerebral organoids, which
can mimic many aspects of cortical development and organization, including the production and
interaction of tissues with some features of dorsal and ventral telencephalic tissues of the cortex
(Lancaster et al., 2013, 2017; Renner et al., 2017) (Figure 1). These include the formation of
multilayered, stratified organoids that express the forebrain markers PAX6 and FOXG1, wherein
neuroepithelial rosettes differentiate into neurons that express markers of all six cortical layers
(Lancaster et al., 2017; Renner et al., 2017). Until recently, microglia, which play an important
role in CNS development and are involved in synaptic pruning have been absent from these
organoids, due to their embryonic origins in the yolk sac. However, a recent study has
demonstrated that iPSC-derived microglia-like cells are capable of integrating into organoids, an
exciting prospect for studying disorders such as schizophrenia, which has been associated with
abnormal synaptic pruning (Abud et al., 2017).
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A common challenge for both two- and three-dimensional differentiation protocols is that it can
take several months to produce mature neuronal cells that can be assessed functionally (e.g., for
electrophysiological activity) (Lancaster et al., 2013; Mariani et al., 2015). However, as the
following examples indicate, many of the aberrant cellular phenotypes associated with human
NDDs become evident even prior to neuronal maturation and function. The examples below also
illustrate an emerging theme: even among NDDs involving mutations in many different genes,
some of the aberrant cellular phenotypes appear to converge upon similar pathways involved in
early neural development, which may implicate alterations of common core pathways that drive
early neurodevelopment as a driver of many later abnormalities in brain circuitry and function that
accompany these disorders. In addition to the examples below, Figure 1 provides an overview of
some experimental approaches and phenotyping strategies that can be used to model alterations of
neural development and function that contribute to NDDs in iPSC-based models.

2.6 Modeling NDDs in iPSC-derived neurons: Examples
Genes that encode epigenetic regulatory activities have been implicated in both nonsyndromic and
syndromic ASD and other NDDs, some of which have been studied using iPSC-based models.
Syndromic NDDs have been most extensively studied, since the link between causative genes and
these disorders are well established. As introduced above, one such gene associated with
syndromic autism encodes the chromodomain helicase DNA-binding protein 8 (CHD8), a member
of the CHD family of ATP-dependent chromatin-remodeling proteins. As one of the most
commonly mutated genes in ASD, several studies have used iPSC-based modeling to define how
CHD8 mutations alter neurodevelopment to contribute to ASD (P. Wang et al., 2015, 2017). Wang
et al. used both two- and three-dimensional-based differentiation approaches to demonstrate that
a significant number of ASD and schizophrenia candidate genes were differentially expressed in
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CHD8 homozygous knockout-derived cells, compared with heterozygous knockout and unaffected
controls (P. Wang et al., 2015, 2017). Notably, CHD8 knockout lines exhibited upregulation of
TCF4, a transcription factor that mediates Wnt pathway signaling responses and has been
associated with bipolar disorder. The top differentially expressed gene in this study was the long
noncoding RNA DLX6-AS1, which regulates expression of DLX transcription factors, important
regulators of GABAergic interneuron development (P. Wang et al., 2015, 2017). Interestingly, in
a study that derived organoids from patients with idiopathic autism, DLX6-AS1 was also the top
differentially expressed gene after 11 days of terminal differentiation and continued to be among
the top 10 differentially expressed genes after 31 days of terminal differentiation (Mariani et al.,
2015). CHD8 loss has been proposed to contribute to these disorders via dysregulation of direct
and indirect downstream targets, including the aforementioned TCF4 and DLX transcription
factors, as well as Wnt signaling through β-catenin (Sugathan et al., 2014). As other members of
the CHD family have also been implicated in NDDs, including CHD1, CHD2, CHD3, CHD5, and
CHD7, these will be interesting genes for future study using iPSC-based models to determine their
role in normal and altered neurodevelopment (Ronan et al., 2013).

A very well characterized syndromic NDD is RTT, which is caused by heterozygous loss of
function mutations in MECP2. Using a two-dimensional differentiation protocol, Marchetto et al.
showed that RTT patient iPSC-derived neurons exhibited defects in synapse number, spine
density, soma size, calcium signaling, and electrophysiological properties by comparison to
controls, across multiple patient samples (M. C. N. Marchetto et al., 2010). Interestingly, these
investigators also found that iPSC-derived neurons derived from patients with MECP2 duplication
syndrome demonstrated a contrasting cellular phenotype, exhibiting increased dendritic
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arborization and synaptogenesis and more synchronized burst events, as determined by
multielectrode arrays (Nageshappa et al., 2016). The authors suggest that these phenotypes are
related to the reported role of MECP2 in modulating multiple pathways involved in dendritic
plasticity (Nageshappa et al., 2016). Other studies using RTT-derived iPSCs have shown a
reduction in soma size in neurons derived from a clonal iPSC line in which the X chromosome
carrying the mutant MECP2 allele was active, compared with a line in which the X chromosome
with the nonmutant allele was active (Ananiev et al., 2011; Cheung et al., 2011). Using a similar
strategy, Kim et al. found that RTT iPSC-derived neurons have a reduction in neuronal maturation,
as determined by immunostaining for the neuronal marker TUBB3/TuJ1, the NPC marker PAX6,
and sodium channel markers (K.-Y. Kim et al., 2011). Another study showed an increase in
astrocytic differentiation at the expense of neuronal differentiation in a RTT-derived iPSC line and
demonstrated that this results from inability of MECP2 to bind the GFAP promoter and inhibit
astrocyte differentiation (Andoh-Noda et al., 2015). These groups all conclude that their
phenotypes recapitulate some of the nervous system alterations seen in RTT patients, who exhibit
decreased neuron and brain size, reduced synaptogenesis, and deficiencies in dendritic arborization
and spine number (Ardhanareeswaran et al., 2017).

To our knowledge, nonsyndromic NDDs involving mutation of genes that encode epigenetic
regulators have not yet been modeled in iPSCs. However, iPSC-based NDD modeling of mutations
in other gene classes provides insight regarding potentially shared phenotypes. As suggested by
Ernst, a common convergence point for many gene mutations that cause NDDs may involve altered
regulation of cell proliferation and differentiation of neural stem and progenitor cells (Ernst, 2016).
Several studies using iPSCs derived from patients with idiopathic NDDs support this idea. Mariani
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et al. used a three-dimensional organoid differentiation scheme, starting with iPSCs derived from
ASD patients with increased head circumference (Mariani et al., 2015). The authors found a
decrease in cell cycle time in patient-derived iPSCs and early NPCs, and a corresponding increase
in the rate of neuronal maturation and in synaptic overgrowth. They also saw evidence for
increased formation of inhibitory synapses, with no change in formation of excitatory synapses, as
marked by VGAT and VGLUT1, respectively. In this study, transcriptional analysis by RNA-seq
demonstrated that the most significantly perturbed groups of genes were associated with
transcriptional regulation of cell proliferation and cell fate, neuronal differentiation, neurite
outgrowth, and synaptic transmission (Mariani et al., 2015). Using a two-dimensional culture
system, Marchetto et al. also found differences in the proliferation and differentiation of NPCs
derived from iPSCs from multiple idiopathic ASD patients with macrocephaly (M. C. Marchetto
et al., 2017). The authors showed that β-catenin transcriptional activity was reduced in patientderived NPCs. The authors also found differentiation defects in the cells, with a reduction in
excitatory NPCs and an increase in markers for inhibitory neuron progenitors. The mature ASDderived neurons had a reduction in spontaneous activity, leading to a deficiency in network
connectivity (M. C. Marchetto et al., 2017). Aksoy et al. similarly defined NPC proliferation and
differentiation defects using iPSCs derived from a patient affected by a global developmental
delay, speech delay, and language impairments with a disruption in the gene GTDC1 (Aksoy et
al., 2017). Interestingly, this defect involved decreased NPC proliferation, followed by lowered
efficiency of maturation into MAP2-positive neurons, a slight decrease in soma size, and a
reduction in axon thickness in patient-derived cells versus controls. Although they found no
differences in NPC proliferation, Griesi-Oliveira et al. also documented reduced neurite length and
spine density in iPSC-derived neurons derived from an ASD patient with a mutation in TRPC6,
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indicating a differentiation deficit (Griesi-Oliveira et al., 2015). Although these studies do not
represent the full array of iPSC-based studies of nonsyndromic NDDs, they illustrate some
phenotypes that might be shared across a range of mutations that contribute to NDDs, including
those involving mutations in genes that encode epigenetic regulators.

2.7 Challenges and considerations for iPSC-based disease
models
Using neurons derived from iPSCs to model disease presents several challenges, particularly for
modeling aspects of the complex phenotypes seen in NDDs. First, even in cases where evidence
strongly supports a causative role for a mutation, many of these disorders are likely to involve
polygenic contributions to disease penetrance. In particular, the genetic background and other
fundamental characteristics, such as the sex of the patient, may have strong modifier effects on
disease etiology and penetrance (Mitra et al., 2016). Therefore, it is important to select control
iPSCs carefully, with the best control potentially being an isogenic iPSC line with CRISPR/Cas9based correction of a particular mutation, to define its contribution to the phenotype. However, it
is also useful in parallel to study the same mutation across different genetic backgrounds, looking
for alterations in penetrance of any phenotype linked to a potentially pathogenic mutation. In
addition, it is important to ensure that a given phenotype can be observed between different iPSC
clones from the same patient, since iPSCs can display clonal variability (Kilpinen et al., 2017).
Another challenge involves identifying shared cell-based phenotypes across different patients,
both within and across mutations and disorders. These would be advantageous both for
understanding shared mechanisms underlying the disease biology and to define potential targets
for development of therapeutics.
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Another issue that is particularly relevant to this review is how well iPSC-based differentiation
models recapitulate the epigenetic changes that occur during development of any neuronal cell
type in vivo. This is an especially important consideration for mutations of X-linked genes, such
as MECP2, where differences in X chromosome inactivation state in iPSC-derived NPCs versus
in brain tissues in vivo could dramatically influence cell-based phenotypes (Cheung et al., 2011;
Dandulakis et al., 2016). It is also important to consider the epigenetic state of the starting iPSC
cell lines. Although iPSCs and human ESCs (hESCs) exhibit similar gene expression profiles and
overall epigenetic state, several groups have identified differences between these two human
pluripotent cell types. Notably, in iPSCs, megabase-scale regions of chromatin near centromeres
and telomeres appear to be particularly resistant to reprogramming, resulting in aberrant non-CG
methylation. This leads to other epigenetic changes, such as differences in both CG methylation
and in histone modification state changes that are sensitive to DNA methylation status, such as
H3K9me3, resulting in differences in gene expression between hESCs and iPSCs (Lister et al.,
2011). It is also important to note that both iPSCs and so-called ‘primed’ hESCs, which remain
the most widely used in vitro models, generally exhibit genome-wide hypermethylation compared
with the ICM cells of the blastocyst. However, efforts are being made to define culture conditions
that maintain hESCs in a more ‘naive’ state, which may more closely resemble the methylation
state of ICM cells (Theunissen et al., 2016). Finally, iPSCs have been shown to have a bias in
differentiation potential, depending on the cell type from which they were derived (K. Kim et al.,
2011).
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Despite these concerns, human stem cell-based neural differentiation models have been shown to
recapitulate many epigenetic changes expected to accompany neuronal differentiation in vivo, and
resembling that which occurs during neurodevelopment in animal models, including a general shift
from hypomethylated DNA regions in ESCs to more hypermethylated DNA, as the cells undergo
neuronal differentiation (Ziller et al., 2015). Therefore, while iPSC-derived in vitro models cannot
display the full range of defects that contribute to NDD causation in vivo, extant examples support
their high utility for modeling cellular and molecular abnormalities of neuronal development and
function likely to contribute to disease etiology. Epigenetic regulation is a central aspect of neural
development and function, and mutations in these genes play a major role in NDDs. As iPSCbased models can readily be scaled to enable high throughput genomic, epigenomic, and chemical
screening approaches, they may offer a particularly attractive model for defining cellular and
molecular abnormalities that underlie NDDs and developing approaches to modify these
phenotypes to alleviate aspects of the neuronal dysfunction that contribute to the severity of
disease.

2.8 Future perspective
As additional iPSC-based studies of NDDs emerge, using iPSCs derived from additional patients
with both syndromic and nonsyndromic disorders, this work will increase our understanding of
shared cellular and molecular mechanisms that contribute to NDDs, as well as specific
contributory mechanisms stemming from each gene mutation. Both 2D-based methods, which
enable differentiation of specific neuronal cell types, and organoid-based methods, which mimic
the three-dimensional interactions of multiple cell types in the brain, will prove useful in these
studies. Stem cell-based modeling of human cortical development will also enhance our
understanding of transcriptional and epigenetic regulation of normal development and how
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perturbation of these networks may contribute to some NDDs. The ability to reprogram somatic
cells from a variety of different sources will increase the availability of patient-derived samples,
particularly for children with NDDs such as autism, where skin punch biopsies may be prohibitive.
It will be particularly beneficial to build relationships between physicians and researchers and
resources for data sharing, both within and between institutions, to facilitate the availability of
patient-derived cells for further study. Although the full potential of iPSC-based models has not
yet been realized, iPSC-derived human neurons provide an experimentally tractable, scalable, and
genetically and genomically manipulable model with high utility for defining the cellular and
molecular mechanisms that underlie NDDs.

2.9 Executive summary
2.9.1 Background
•

Human cortical development is complex and protracted, increasing its sensitivity to
perturbation.

•

In particular, imbalances between excitatory and inhibitory neuronal activities in the cortex
can contribute to neurodevelopmental disorders (NDDs), with autism and epilepsy as
notable examples.

•

Genome-wide studies have demonstrated mutations in genes that encode epigenetic
regulatory proteins as major contributors to NDDs, with studies focusing on autism
highlighted here.

2.9.2 Formation and patterning of the mammalian telencephalon
•

Involves stepwise developmental process controlled by differential exposure to growth
factor signaling and transcription factor expression, as well as epigenetic regulation.
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•

Normal progression of neural development results in a cortex of the proper size with a
balance of excitation from glutamatergic excitatory neurons and inhibition from
GABAergic interneurons.

2.9.3 Epigenetic regulation of neural development and contributions of its
dysregulation to NDDs……………………………
•

Three major classes of epigenetic regulation are discussed: chromatin remodeling, histone
modifications, and DNA methylation and demethylation.

•

Each of these classes of epigenetic regulators plays important roles in normal cortical
development.

•

Figure 2 provides examples of different types of epigenetic regulators that have been
associated with autism spectrum disorder (based on the SFARI database).

2.9.4 Stem cell models of NDDs involving epigenetic dysregulation
•

Studies have used both two-dimensional-directed differentiation and three-dimensional
organoid models to differentiate patient-derived and control induced pluripotent stem cells
(iPSCs).

2.9.5 Modeling NDDs in iPSC-derived neurons: examples
•

iPSC-based studies largely focus on syndromic NDDs, including Rett Syndrome and
CHD8 mutations.

•

To date, few iPSC-based models have been generated to study effects of mutations in genes
that encode epigenetic regulators, particularly in nonsyndromic cases of NDDs.

•

Among those mutations that have been modeled, a common theme involves alterations in
the proliferation and differentiation of neural stem cells.

35

2.9.6 Challenges and considerations for iPSC-based disease models
•

Controls must be selected with care, because genetic background greatly influences
penetrance of NDDs.

•

When a gene is X-linked, particular consideration must be made regarding X chromosome
inactivation status during reprogramming and differentiation.

•

It remains to be determined how well epigenetic changes that accompany iPSC
differentiation in vitro mimic the in vivo biology.
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2.10 Figures
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2.10.1

Figure 1. Modeling neurodevelopmental disorders with patient-

specific iPSC-derived neurons.………………………
(A) Schematic depicting several stages of human neural development. Crown to rump length of
the embryo is approximately 1.5 mm at 3 weeks, 5 mm at 5 weeks, and 140 mm at 15 weeks of
fetal development. Inset at right schematizes a coronal section through the 15-week telencephalon
along the plane shown in red, highlighting dorsoventral patterning of the telencephalon into the
cortex and ganglionic eminences. Layers of the developing cortex are abbreviated as follows: VZ
= ventricular zone; SVZ = subventricular zone; CP, SP, IZ = cortical plate, subplate, intermediate
zone. Cortical radial glial neural progenitors in the ventricular zone express the marker PAX6 and
differentiate into glutamatergic excitatory neurons. The MGE and LGE are demarcated by
expression of NKX2–1 or ISL1/SP8 and differentiate predominantly into cortical interneurons and
striatal projection neurons, respectively. (B) In vitro neuronal differentiation of patient-derived
iPSCs. Fibroblasts are obtained from both patients with NDDs and related or unrelated healthy
individuals as controls and are reprogrammed to iPSCs expressing the pluripotency marker
OCT4/POU5F1. These can undergo directed differentiation in two-dimensional culture to generate
progenitors and differentiated neurons that resemble types found in the developing cortex,
including glutamatergic cortical excitatory neurons and GABAergic cortical interneurons, and can
also undergo directed differentiation in three-dimensional culture to form cerebral organoids. (C)
Using in vitro differentiated neurons to assess the effects of mutations that cause NDDs. A wide
range of parameters can be assessed and phenotyping can be combined with genetic manipulations,
genomic analysis methods, and high throughput chemical and molecular screening approaches.
Scale bars for the iPSC, cerebral organoid, and neuron immunofluorescence images = 50 µm.
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iPSC: Induced pluripotent stem cell; LGE: Lateral ganglionic eminence; MGE: Medial ganglionic
eminence; NDD: Neurodevelopmental disorder; Tel: Telencephalon.
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2.10.2

Figure 2. Examples of genes encoding epigenetic regulatory

proteins that are mutated in autism spectrum disorder.
Examples shown include proteins that remodel chromatin, post-translationally modify histones, or
recognize methylated DNA. Cartoons at left schematize the types of chromatin modification
involved and are described in greater detail in the text. At right, score assignments in the SFARI
Gene database reflect the strength of evidence linking mutations in each gene to autism: S =
Syndromic, 1 = High confidence, 2 = Strong candidate, 3 = Suggestive evidence, 4 = minimal
evidence, NR = no rating yet available in SFARI. Me: methylation (histone or DNA); P:
Phosphorylation; Ub: Ubiquitination; Ac: Acetylation.
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Chapter 3: Epigenetic regulation during
human cortical development: Seq-ing
answers from the brain to the organoid
This chapter is adapted from an invited review article currently under review for publication in
Neurochemistry International:
Lewis, E. M. A., Kaushik, K., Sandoval, L. A., Antony, I., Dietmann, S., & Kroll, K. L. (2021).
Epigenetic regulation during human cortical development: Seq-ing answers from the brain to the
organoid. Neurochemistry International, under Review.
Contributions: EMAL determined the topics of this review, wrote the introduction, fetal data, and
conclusions sections, and designed the figures. KK wrote the in vitro models section and
produced the figures. LAS wrote the organoid models section. IA contributed to all sections. SD
wrote the human accelerated region section of the fetal data section. KLK helped determine the
topics of this review and edited it.
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3.1 Abstract and keywords
Epigenetic regulation plays an important role in controlling gene expression during complex
processes, such as development of the human brain. Understanding how epigenetic regulation
shapes brain development is of particular interest, as neurodevelopmental disorders are frequently
caused both by mutations in genes encoding chromatin modifying proteins and in the non-protein
coding sequences of the genome, potentially altering transcription factor binding or chromatin
accessibility. While epigenetic regulation of neural development has been extensively studied in
murine models, significant species-specific differences in both the genome sequence and in brain
development necessitate human models. However, access to human fetal material is limited and
these tissues cannot be grown or experimentally manipulated ex vivo. Therefore, models that
recapitulate particular aspects of human fetal brain development, such as the in vitro differentiation
of human pluripotent stem cells (hPSCs), are instrumental for studying these processes. Here, we
examine recent studies that have defined changes in the epigenomic landscape during fetal brain
development. We compare these with analogous data derived by in vitro differentiation of hPSCs
into specific neuronal cell types or as three-dimensional cerebral organoids. These comparisons
can be informative regarding which aspects of fetal brain development are faithfully recapitulated
by in vitro differentiation models and provide a foundation for using these experimentally tractable
in vitro models of human brain development to study neural gene regulation and the basis of its
disruption to cause neurodevelopmental disorders.
Keywords: Human brain development, pluripotent stem cells, epigenetic regulation, chromatin,
neuron, organoid.
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3.2 Introduction
Epigenetic regulation plays a central role in brain development, enabling dynamic control of gene
expression in developmental time and space. During embryonic development, large-scale changes
in gene expression occur, upregulating lineage-specific genes and downregulating pluripotency
genes and genes expressed by cells that differentiate into other lineages. This process involves
extensive changes in chromatin structure. Epigenetic regulation alters gene expression by
enhancing or reducing the accessibility of specific loci for transcription factor (TF) binding. This
can occur by modification of histone tails (for example, adding acetylation or methylation), or by
methylation of DNA. Human brain development is a protracted process, which encompasses much
of gestation and produces a diversity of cell types. Accordingly, many different epigenetic
regulatory mechanisms shape these developmental transitions to generate distinct neuronal and
glial cell types (Zhao & Bhattacharyya, 2018). Epigenetic regulation of neural development is of
particular interest because mutations in genes encoding proteins that modify or remodel chromatin
are highly over-represented as contributors to the etiology of multiple neurodevelopmental
disorders (NDDs), including autism spectrum disorder (ASD) (Lewis & Kroll, 2018; Loke et al.,
2015). Moreover, many NDD risk variants are located in non-protein coding sequences in the
genome, where variation may impact gene regulation by altering TF binding, chromatin
accessibility, or other regulatory mechanisms (J. Zhou et al., 2019). Although epigenetic regulation
of neural development has been extensively studied in murine models, human models are also
essential as there are substantial differences between human and murine brain development. These
include a wider diversity of neural cell types and brain structures in humans, a protracted time
frame during which neurodevelopment occurs throughout gestation, human-specific disease
phenotypes that are not seen when comparable mutations are introduced into mouse models, and
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substantial differences in the genome sequence, particularly in non-protein coding regions of the
genome (Zhao & Bhattacharyya, 2018). An interesting example of these species-specific features
is so-called ‘human accelerated regions’ (HARs), which are regions of the genome where
introduction of sequence variants has occurred at an accelerated rate in humans. Many of these
may represent cis-regulatory elements (CREs) that regulate gene expression in a conserved manner
across most vertebrates, including primates (e.g. chimpanzees), but that are significantly different
in humans (Capra et al., 2013; Pollard et al., 2006). The presence of these human-specific
regulatory elements, as well as additional differences in genome sequence and brain development
between other animals and humans indicate that unique regulatory processes underlie human
neural development, many of which remain to be elucidated.

Human neural development can be studied by using embryonic and fetal cells or tissues or by using
models that mimic particular aspects of this process (Figure 1). Access to human embryonic and
fetal material is limited and these tissues cannot be grown or genetically manipulated ex vivo,
making it challenging to use these materials to understand human brain development. However,
despite these challenges, some large-scale efforts, including the Encyclopedia of DNA Elements
(ENCODE) and NIH Roadmap Epigenomics projects, have transcriptionally and epigenetically
profiled many cell and tissue types from the developing human fetus, including the brain
(ENCODE Project Consortium, 2012; Kundaje et al., 2015). In vitro models that mimic these
developmental processes by differentiation of human pluripotent stem cells (hPSCs, encompassing
both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), the latter of which
are derived by somatic cell reprogramming) can also be used to study aspects of brain
development, but without the limitations of using fetal tissue. Commonly used approaches for
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neuronal differentiation of hPSCs are discussed in more detail below. In general, these protocols
utilize small molecule agonists or antagonists of growth factor signaling or TF overexpression to
mimic developmental signaling and differentiate hPSCs into specific neuronal cell types, such as
excitatory glutamatergic cortical neurons (cExNs) or inhibitory GABAergic cortical interneurons
(cINs) (Lewis & Kroll, 2018). Another recently developed approach involves differentiating
hPSCs as three-dimensional regionally-restricted organoids, such as cerebral organoids (COs); this
approach may more closely mimic some of the cellular interactions and spatial organization of
neuronal cell types that exists in the developing brain in vivo (C. Luo et al., 2016; Qian et al.,
2019). Here, we discuss transitions in the epigenetic landscape during the directed differentiation
of neurons from hPSCs in vitro, and we compare these with data obtained for the analogous cell
or tissue types during fetal brain development in vivo.

The major classes of proteins or protein complexes that modulate the epigenome include those that
write, read, or erase histone protein tail modifications, remodel the histone-DNA structure, and
methylate DNA. Chromatin accessibility is influenced by these regulators, creating either
accessible chromatin (euchromatin), which is transcriptionally permissive, or closed chromatin
(heterochromatin), which is transcriptionally inactive. Although DNA methylation is an important
mechanism of epigenetic regulation, many excellent reviews have already been published on this
topic; therefore, we did not focus on it here but instead refer the reader to other excellent resources
for in depth information regarding DNA methylation in neuronal development (Greenberg &
Bourc’his, 2019; Hirabayashi & Gotoh, 2010; Jang et al., 2017). Instead, we predominantly focus
on epigenetic regulation by histone modification, chromatin remodeling, and associated changes
in chromatin state. Chromatin consists of nucleosomes comprised of a histone octamer, around
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which DNA is wrapped. The ‘tails’ of histone proteins can acquire different post-translational
modifications, influencing overall chromatin structure. Histone modifications that are particularly
important for developmental gene regulation include tri-methylation of histone 3 lysine 27
(H3K27me3), a repressive modification; H3K4me3, a modification associated with active gene
expression; and H3K27ac, a modification associated with active CREs (e.g. enhancers).
H3K27me3 and H3K4me3 are often present together around gene promoters, creating a ‘bivalent
state’ where genes are ‘poised’ for activation (by removal of H3K27me3) or repression (by
removal of H3K4me3) during development (Burney et al., 2013). As development is a dynamic
process during which cells must respond rapidly to cues related to their location and identity,
modulating gene expression in this manner during developmental transitions is particularly
important.

Several assays are commonly used to study chromatin state, each of which has strengths and
limitations. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) uses an antibody
directed against a protein of interest, such as a particular histone modification, to enrich for the
chromatin regions bound by the protein, which are then identified by sequencing. Although ChIPseq is a powerful tool, it often results in a high background of non-selective sequence
immunoprecipitation. Additionally, it requires a large number of cells and an antibody that can
recognize a crosslinked epitope. To assess the general accessibility of chromatin, the Assay for
Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) is commonly
used, as it requires fewer cells, with single-cell analysis now feasible (Buenrostro et al., 2015).
Prior to the development of ATAC-seq in 2015, DNase-seq (also known as DNase
hypersensitivity) and MNase-seq were also commonly utilized to assess chromatin accessibility.
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Like ChIP-seq, DNase/MNase-seq assays require larger cell numbers (tens to hundreds of millions
of cells) in comparison to ATAC-seq. Nonetheless, these approaches have been used to identify
key information about chromatin state changes during human brain development and are
incorporated into this review. The advantages and disadvantages of using these assays to assess
chromatin state in the context of each model (i.e. in fetal tissue, during in vitro differentiation of
hPSCs, or cerebral organoids) are discussed in each section below, especially with respect to
limitations pertaining to the numbers or homogeneity of cells assessed in each model. Below, we
describe extant data that contribute to our understanding of epigenetic regulation of human brain
development, as well as outline knowledge gaps that remain unresolved, particularly related to
understanding regulation of chromatin state at neuronal cell type-specific resolution.

3.3 Epigenetic regulation in the fetal brain
3.3.1 Background
Human brain development begins in the third gestational week (GW) with the formation of the
neural plate (Figure 2) and extends beyond birth (Stiles & Jernigan, 2010). Using human
embryonic or fetal cells or tissues to study epigenetic regulation of human brain development poses
several challenges. These involve both ethical considerations and practical limitations related to
access to human fetal material; specifically, very limited materials can be obtained from each
embryo and these materials cannot be expanded or experimentally manipulated ex vivo. The
consequences of these limitations are that sample size, and therefore biological replicate numbers,
for these studies are often small, encompassing cells or tissues derived from only a few (or
sometimes only one) unique embryo(s) or fetus(es) (Supplementary Table 1). Additionally,
materials for study are obtained from a small, developing embryo with limited numbers of cells
which are not expandable, limiting the number of different chromatin features that can be
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evaluated. This is particularly problematic for methods like ChIP-seq, where assessing enrichment
for each histone modification or chromatin-bound protein requires a large number of cells (more
than one million per experimental replicate). Consequently, different histone modifications must
usually be profiled using material from different embryos, increasing variability and making crosscomparisons more challenging. Given these limitations, studies typically focus on a small number
of histone modifications, or solely on chromatin accessibility, to increase the number of biological
replicate experiments that can be conducted (Table 1; Supplementary Table 1). Finally, since
embryonic development is a dynamic process involving constant changes in cell identity and
physical location, profiling neural development with spatial and cell type-specific resolution is
challenging. Several studies have performed epigenetic profiling on dissected tissues, which
provides some spatial resolution but further reduces cell numbers available for any particular
assessment (Supplementary Table 1).

As ATAC-seq requires far fewer cells than ChIP-seq, it is more amenable to studies using fetal
tissue; however, it does not provide information regarding changes in histone modification state
that centrally regulate development, such as the transition from bivalent to active chromatin
(Buenrostro et al., 2015). Other strategies include combining transcriptional and epigenetic
profiling (either using dissected tissues or single cells), enabling cell type to be inferred from gene
expression (Supplementary Table 1). However, analysis of such data is predicated upon
understanding the transcriptional identity of diverse cell types at each developmental stage; this
information is often unavailable due to our inability to trace and genetically manipulate human
fetal cells. The advent of single-cell sequencing technologies has improved our ability to obtain
transcriptional and epigenetic data with spatial and cell type-specific resolution. Below we survey
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epigenetic studies of human fetal brain development, focusing on profiling of histone modification
state and chromatin accessibility using both bulk and single-cell methods.

3.3.2 ChIP-seq: Histone modifications
Despite the challenges described above, several studies have assessed key histone modifications
in the developing human brain, including H3K4me3, H3K27me3, and H3K27ac (Table 1;
Supplementary Table 1). Initial work to profile these modifications and others was performed as
part of the Human Reference Epigenome Mapping Project and is described with other data from
this project below. In addition to these studies, Yan et al. profiled the epigenomic landscape of
human fetal brain, heart, and liver (Yan et al., 2016). Using two technical replicates from 12 GW
embryos, they used ChIP-seq to assess H3K4me1, H3K27ac, H3K4me3, and H3K27me3, and
performed sequential ChIP-seq for H3K27me3/H3K4me3 to identify bivalent domains. As
expected, many putative CREs identified by H3K27ac enrichment exhibited tissue- and
developmental stage-specific enrichment by comparison of peaks present in fetal brain, heart, and
liver, and with other H3K27ac peak datasets from corresponding adult tissues and from hESCs.
Significantly, both putative fetal brain-specific enhancers and bivalent domains were predicted to
regulate genes important for neural development. The authors also identified several so-called
‘super-enhancers,’ defined as large (20-50 kb) regions enriched for H3K27ac signal. These usually
correspond with and contribute to regulating tissue- and stage-specific gene expression; in this
study, they were predicted to regulate genes known to regulate neuronal development (Yan et al.,
2016). Although this work was limited in terms of the biological replicates utilized and only
analyzed one developmental time point, these data provide a useful resource and excellent example
of the types of analyses and comparisons that can be performed with ChIP-seq and RNA-seq data
generated for the developing human brain.
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Epigenetic profiling of human fetal cortical development over time was also performed in 2018 by
Li et al., in work supported by the PsychENCODE and Brainspan Consortia (M. Li et al., 2018).
This large, collaborative effort assessed the transcriptomic and epigenomic landscape across
human brain regions and cell types through both pre- and postnatal development. Comprehensive
details of the samples, assays, and time points analyzed are provided in Supplementary Table 1.
In short, up to 16 brain regions were dissected in more than 60 postmortem human brains, ranging
from five post-conceptional weeks (PCW) to 64 years of age, and assays including RNA-seq,
single-cell RNA-seq (scRNA-seq) and ChIP-seq for several histone modifications (H3K27ac,
H3K4me3, and H3K27me3) were performed. Although we focus here only on findings from the
prenatal samples, further comparisons to data from the postnatal brain can serve as a useful tool to
identify regulatory mechanisms that are unique to the developing human brain. For the prenatal
samples, the study incorporated histone ChIP-seq data from 17, 19, 21, and 38 PCW embryos with
RNA-seq and other data generated from the developing human brain (such as DNA methylation)
(M. Li et al., 2018). This data can be used to define which developmental stages and brain regions
in vitro cellular models of cortical development most closely resemble based upon histone
modification state.

3.3.3 ATAC-seq
Requiring far fewer cells than ChIP-seq and offering a comprehensive landscape of chromatin
state, ATAC-seq is a useful tool to study in vivo human brain development (Table 1;
Supplementary Table 1). In 2018, de la Torre-Ubieta et al. used this approach to extensively assess
chromatin accessibility and to compare this with changes in gene expression in the developing
human cortex (de la Torre-Ubieta et al., 2018). To accomplish this, they dissected tissue in the
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ventral germinal zone (GZ; a neural progenitor/radial glia-rich layer below the cortical plate (CP))
and the dorsal CP (containing differentiating neurons) from the developing forebrain of three
female embryos between 15-17 PCW. They identified a significant number of differentially
accessible regions between the CP and GZ and demonstrated a high correlation between increased
chromatin accessibility and expression of the associated genes. Importantly, they showed
significant overlap between their data and chromatin accessibility data generated for similar
sample types by the NIH Roadmap Epigenomics Project. They also used previously published HiC data, which analyzed genome-wide chromatin organization in matched stages and tissue types
(Won et al., 2016), to demonstrate that their identified distal CREs were associated with key genes
specific to human cortical neurogenesis, including human-specific enhancers. They were also able
to test the functional significance of two of their predicted enhancers, which regulated the FGFR2
and EOMES genes, by experimentally manipulating their sequences (de la Torre-Ubieta et al.,
2018).

Markenscoff-Papadimitriou et al. recently expanded on this study, assessing chromatin
accessibility in the developing human cortex with increased temporal and anatomical specificity
(Markenscoff-Papadimitriou et al., 2020). They dissected nine regions of the mid-gestation (14-19
GW) telencephalon, including six cortical regions and the medial, lateral, and caudal ganglionic
eminences. They identified predicted regulatory elements with differential accessibility between
the regions and time points studied, and correlated these with gene expression. The functional
significance of these regions was tested in several ways, including by luciferase assay in
neuroblastoma cells and using CRISPR-mediated gene activation (CRISPRa) in a mouse model.
Interestingly, this work identified two separate sequence variants in the same regulatory element

51

associated with SLC6A1, a gene that causes NDDs when mutated. When tested by luciferase assay,
these variants reduced reporter expression (Markenscoff-Papadimitriou et al., 2020). These
chromatin accessibility and gene expression data provide a valuable resource, both for
comparisons with future studies of chromatin accessibility in developing human brain and for
integration with other fetal brain data, including ChIP-seq for histone modifications or TF binding
and transcriptional profiling by single-cell or bulk RNA-seq.

The utility of integrating different types of genome-wide data was demonstrated in a study
comparing bulk tissue ATAC-seq data (de la Torre-Ubieta et al., 2018) with scRNA-seq profiling
of 40,000 cells from the developing human brain, using four female embryos between 17 and 18
PCW (Polioudakis et al., 2019). Combining these high-resolution transcriptome data with
information about chromatin accessibility allowed them to predict binding and co-expression of
TFs previously associated with specific cell types and to identify new regulators of gene expression
in these neuronal cell types. This data integration also enabled associations to be drawn between
genetic variants that affect both risk for neuropsychiatric disorders and regulation of neuronal cell
type-specific gene expression. For example, variants associated with schizophrenia (SZ) risk were
associated with gene regulation in multiple neural cell types, including neural progenitors,
interneurons, and glutamatergic neurons (Polioudakis et al., 2019). This study shows the utility of
integrating transcriptional and epigenetic data to gain a deeper understanding of human cortical
development and to associate these findings with genetic data related to risk for
neurodevelopmental or neuropsychiatric disorders.
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In addition to scRNA-seq, scATAC-seq can provide valuable information about chromatin
accessibility in specific cell types in the developing brain, which bulk analysis cannot resolve. In
a recent manuscript, currently available only as a pre-print, Ziffra et al. profiled chromatin
accessibility by scATAC-seq for cells from distinct regions of the developing human forebrain
(Ziffra et al., 2019). They profiled >75,000 cells from six mid-gestation embryos, preserving
information about anatomical region of origin (eight distinct areas) for three embryos, while also
analyzing bulk tissue from three embryos. Significantly, they could identify differentially
accessible peaks between different cell types and regions, while also observing significant overlap
between their data and enhancers identified in another study of bulk cortex tissue, defined by
H3K27ac enrichment (Reilly et al., 2015), as well as human-specific forebrain enhancers available
through the VISTA Enhancer Browser (Visel et al., 2007). They also analyzed enriched TF binding
motifs in the sequences underlying neuronal cell type-specific H3K27ac peaks and found
enrichment for binding motifs for TFs known to act in that cell type, such as enrichment for binding
motifs for NKX2-1 in medial ganglionic eminence (MGE) progenitors. Although the functional
significance of these predicted enhancers cannot be tested in human embryos, Ziffra et al.
employed the recently developed activity-by-contact (ABC) model, which predicts enhancers by
integrating H3K27ac ChIP-seq, gene expression, chromatin accessibility, and Hi-C datasets (Fulco
et al., 2019). This powerful tool allowed them to identify sets of high-confidence putative
enhancers for each cell type in the human fetal brain and to predict their target genes. As discussed
below, this study also performed scATAC-seq in cortical organoids, identifying a number of
shared peaks between the fetal cerebral cortex and cortical organoids, but also showing that a
significant portion of peaks identified in primary fetal cells were missing in organoids (Ziffra et
al., 2019). While these data are not yet publicly available, they should serve as a resource to
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understand cell type- and region-specific regulation of human cortical development and will also
be useful to compare to other in vitro models of human brain development.

3.3.4 Human accelerated regions
Although ~99% of the DNA sequence is identical in both the human and chimp genome, about
5% of human DNA sequences have been rearranged, copied, or deleted by comparison to their
chimp counterparts. About 5-10% of the human genome is under positive evolutionary selection,
remaining invariant across mammals and thus likely functional. However, some evolutionarily
conserved regions - termed HARs - exhibit significantly accelerated nucleotide substitution rates,
specific only in the human (Pollard et al., 2006) and ape lineages (del Rosario et al., 2014; Kostka
et al., 2018). Other studies have characterized HARs that arose after the divergence of Homo
sapiens from other hominid species (Meyer et al., 2012; Prüfer et al., 2014). The function of most
HARs have not been elucidated, but many are intergenic and located near developmental genes
(Capra et al., 2013); thus they may act as developmental enhancers or long non-coding RNAs.
Mutated HARs have also been implicated in neurodevelopmental disorders, such as ASD. Doan
et al. discovered that individuals with ASD had a 6.5-fold enrichment for rare de novo copy number
variants in HARs than sibling-matched controls (Doan et al., 2016). Furthermore, ASD probands
have an excess of rare biallelic point mutations in HARs; such mutations in HARs that are active
in neurons can contribute ASD risk to approximately 5% of individuals in a family.

In 2015, Prescott et al. epigenetically profiled cranial neural crest cells (CNCCs), using
pluripotent-stem-cell-based in vitro differentiation models in both human and chimp (Prescott et
al., 2015). The authors studied histone modifications associated with active regulatory elements
(H3K4me1, H3K4me3, and H3K27ac) and performed ATAC-seq in both models. Approximately
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6% of human CNCC enhancers showed increased or decreased enhancer activity in chimpanzees.
Interestingly, human CNCC enhancers overlapped with 163 HARs, while functional testing of 20
of these enhancers demonstrated species-biased activity (Prescott et al., 2015). Kanton et al. also
compared potential gene regulatory mechanisms in human and chimpanzee stem cell-derived
cerebral organoids using bulk and single-cell accessible chromatin profiling by ATAC-seq
(Kanton et al., 2019). Differentially accessible peaks had significant numbers of single nucleotide
changes (SNCs) that are conserved in humans and unique versus other primates. Some SNCs are
thought to create new or interfere with current TF binding sites. The authors further annotated
accessible regions, defining species-specific potential regulatory regions near differentially
expressed genes that have human-conserved SNCs or that are HARs, identifying 62 HARs that
intersected with these differentially accessible peaks. Differentially expressed genes like cadherin
7 (CDH7), a gene expressed in human but not chimp neurons, were close to some of these HARs,
and were perhaps linked to their activity (Kanton et al., 2019). In 2015, Reilly et al. also profiled
H3K27ac and H3K4me2 to compare active enhancers and promoters during human, rhesus
macaque, and mouse corticogenesis, pinpointing increases (gains) in their activity in humans.
Eight thousand nine hundred and ninety-six nonoverlapping enhancers and 2,855 promoters in
total exhibited gains of these enhancer-associated histone modifications in humans. Whether such
increases resulted from human-specific sequence changes was also analyzed. While 48 HARs
showed increased H3K27ac or H3K4me2 in the human cortex in general, these gains were not
associated with significant human-only accelerated sequence variation (Reilly et al., 2015).
Nonetheless, these gains were consistently associated with genes important for cortical
development and similar increases in H3K27ac enrichment also occur in regions with ancestral
regulatory activity, such as promoters or enhancers that are also H3K27ac enriched in rhesus and
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mouse cortices. Any human-specific gains not enriched in rhesus or mouse may indicate de novo
regulatory mechanisms developed through human evolution.

The evolution of human-specific gene regulatory features during neural development might further
be driven by transposable elements (Trizzino et al., 2017), which can either act as enhancers or
interfere with transcription (Shapiro, 2017). In 2015, Notwell et al. reported that a specific family
of transposable elements (MER130) was enriched in active enhancers associated with neocortex
development in the mouse (Notwell et al., 2015). Of particular recent interest are Krüppelassociated box (KRAB) domain-containing zinc-finger proteins (KZFPs), a rapidly evolving
family of TFs that can bind transposable elements (Ecco et al., 2016; Imbeault et al., 2017). These
KZFPs transcriptionally silence transposable elements by recruiting other chromatin binding
proteins, such as SETDB1 (Pontis et al., 2019). An evolutionary ‘arms race’ between transposable
elements and KZFPs in turn may contribute to the evolution of human-specific features of gene
regulatory networks, which are of interest for understanding human neural development and
disease.

3.3.5 Other fetal epigenetic data obtained from consortium-based projects
In addition to the previously described PsychENCODE and Brainspan consortia (M. Li et al.,
2018), fetal brain epigenetic data has been collected by other consortia-supported efforts, including
the NIH Roadmap Epigenomics Program and the ENCODE project (ENCODE Project
Consortium, 2012; Kundaje et al., 2015). Many of these datasets are outlined in Supplementary
Table 2. Some of these data are also included in other published analyses, for example, for
comparison to epigenomes of other fetal cell types (Kundaje et al., 2015). Since this work is not
specific to fetal brain development, we focused here on highlighting and summarizing these
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available fetal brain data and creating a curated database (Supplementary Table 2), which may
serve as a resource for readers seeking extant fetal brain epigenetic datasets for their analyses.
These data were collected by researchers at the University of Washington, the Broad Institute, and
a joint University of California San Francisco-University of British Columbia (UCSF-UBC) team.
Most data gathered by the University of Washington team focused on DNase hypersensitivity,
analyzing male and female embryos from gestational day 85 to 142 (~12-20 GW). The research
team at the Broad Institute also used material from these embryos to profile histone modifications
in conjunction with DNase hypersensitivity profiling. The most complete datasets were generated
by the UCSF-UBC team by using twin donors, HuFNSC01 and HuFNSC02 (Shapiro, 2017). This
dataset includes whole brain samples, as well as data derived from cortex and GE neurosphere
cultures, which were collected from either the cortex or the GE at 17 GW and cultured as
neurospheres for approximately three passages in NueroCult + EGF + FGF (Genboree Discovery
System - Project: XML Submissions/UCSF-UBC/SAMPLE/EDACC.5485, n.d.). Although it is not
clear whether a specific structure from the GE, such as the MGE was used, this strategy should
decrease the heterogeneity of cell types assessed by comparison with whole brain-derived samples,
and therefore provides datasets with more tissue-restricted resolution to use for comparisons to
data from in vitro-derived neurons. Histone marks profiled included H3K27me3, H3K4me3,
H3K36me3, H3K9me3, and H3K4me1, and limited data was also obtained for H3K9ac and
H3K27ac. Together with the data discussed previously, this work provides a snapshot of changes
in the epigenetic landscape during human cortical development. However, these data are
understandably limited, as they lack either tissue- or cell type-specific resolution, and include a
limited range of histone modifications, developmental timepoints, and donors. In the conclusions
section of this review, below, we describe additional data that would be highly useful, both to
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understand fetal cortical development and to draw comparisons with in vitro neural differentiationbased studies.

3.4 In vitro cellular models
3.4.1 Background
In vitro models that derive different types of human neurons from PSCs circumvent many
limitations of using fetal material. For example, they can generate a large number of human
neuronal progenitors and neurons of particular types, which can be expanded and experimentally
manipulated. However, it is essential to compare data derived from these models with analogous
data from the fetal brain in order to determine which aspects of fetal development are or are not
faithfully recapitulated in vitro, both by examining gene expression changes and transcriptional
and epigenetic regulation of neurodevelopment. Another advantage of these PSC models is the
ability to use either or both proband-derived iPSCs and genetically engineered PSCs with
introduction of a pathogenic NDD-associated mutation, to study the contribution of a specific
mutation versus the genetic background to NDD etiology. These approaches are particularly wellsuited to studying NDDs, many of which involve mutations in either chromatin modifying proteins
and/or putative CREs (Lewis & Kroll, 2018; Loke et al., 2015). The following sections describe
studies that assess changes in histone modification state and chromatin accessibility during in vitro
neuronal differentiation in several models. By comparison with data from fetal samples,
substantially more histone modifications can be assayed within the same set of experiments, more
timepoints during differentiation can be interrogated, and results from multiple types of assays,
including RNA-seq, ChIP-seq, and ATAC-seq, can be readily integrated. These rich data provide
a more complete picture of the multiple layers of regulatory interactions that drive specification
and differentiation of different types of neurons, and the value of these data is increased by
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comparison with comparable data from the analogous developing neuronal cell types acquired
from the fetal brain.

Many strategies have been developed to produce different neuronal cell types from PSCs in vitro,
most of which involve either treatment of PSCs with small molecule agonists and antagonists of
growth factor signaling or overexpression of neurogenic transcription factors (Figure 3). Neuronal
cell types that can presently be derived from hPSCs include cExNs, which correspond to neurons
found in different layers of the developing neocortex (Shi et al., 2012); cINs (Yan Liu et al., 2013;
Maroof et al., 2013; Meganathan et al., 2017; Nicholas et al., 2013); dopaminergic neurons (Kriks
et al., 2011); and microglia (Muffat et al., 2016). Here, we focus predominantly on summarizing
what is known regarding epigenetic regulation of the development of the two major types of
cortical neuron, cINs and cExNs, as dysregulation of these developmental programs is strongly
implicated in the etiology of NDDs (Zikopoulos & Barbas, 2013). In addition to the directed
differentiation of specific neuronal cell types, COs also provide a promising tool for modeling
human forebrain development (Amiri et al., 2018). Studies examining epigenetic regulation in
these organoids will be discussed below. By comparison with both tissues derived from the fetal
brain and COs, schemes which promote directed differentiation into a specific neuronal cell type
can provide a more homogeneous platform for in parallel assessment of different types of
phenotypic, transcriptomic, and epigenetic data, especially when using bulk analysis approaches
like ChIP-seq, yielding data with stage- and neuronal cell type-specific resolution.

In general, cortical neurons are produced by patterning PSCs into telencephalic neural progenitors
(NPCs) which are then matured into neurons. These differentiation strategies aim to mimic the
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normal developmental signaling pathways that occur in vivo to produce specific cell fates in vitro.
Generation of telencephalic NPCs by directed differentiation is either conducted in monolayer
culture or by formation of embryoid bodies (EBs), three-dimensional spheres of cells which
enhance cell-to-cell contacts and often improve differentiation efficiency (S.-C. Zhang et al.,
2001). A common approach for specifying telencephalic NPCs involves dual-SMAD inhibition in
either monolayer or EB culture (Chambers et al., 2009; Ying et al., 2003). These NPCs can then
be patterned towards a dorsal (cExN) or ventral (cIN) telencephalic fate. Formation of dorsal
progenitors is promoted in some schemes by adding the Sonic Hedgehog (SHH) signaling
inhibitor, Cyclopamine, while ventral fate can be specified using SHH agonists (X.-J. Li et al.,
2009; Yan Liu et al., 2013; Mak et al., 2012; Maroof et al., 2013; Meganathan et al., 2017; Nicholas
et al., 2013). Subsequently, PAX6- and EMX1/2-expressing dorsal telencephalic precursors are
differentiated into cExNs (Eiraku et al., 2008; Shi et al., 2012) while NKX2-1-expressing ventral
telencephalic precursors are differentiated into cINs (Yan Liu et al., 2013; Meganathan et al.,
2017).

As an alternative to the approach described above, forced expression of several neurogenic
transcription factors has also been utilized to differentiate PSCs into cortical neurons.
Overexpression of NEUROD1 or NEUROG2 in PSCs can rapidly convert these cells into cExNs
(Vierbuchen et al., 2010; Yingsha Zhang et al., 2013), whereas overexpression of ASCL1 and
DLX2 can produce cINs (Yang et al., 2017). Somatic cells such as fibroblasts can also be transdifferentiated into induced neurons by introduction of transcription factors, such as PTF1A (Xiao
et al., 2018). It is important to document and note distinctions between methods used to produce
neurons in vitro, as these can complicate comparisons of epigenetic data between studies. This is
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due to differences both in the identity of the starting cell population (PSC lines or somatic cells
from different genetic backgrounds), as well as variation in how each method recapitulates the
epigenetic changes that occur during neural development in vivo and which type of neural identity
is acquired (Schafer et al., 2019).

3.4.2 ChIP-seq: Histone modifications
Pluripotent stem cell-based differentiation methods provide a valuable platform to study changes
in the epigenetic landscape across cortical neural development, as cells can be collected at specific
timepoints for a more granular assessment of this regulatory process (Table 1; Supplementary
Table 1). Although many studies have defined the epigenetic changes that occur during neural
induction of murine ESCs via ChIP-seq, fewer studies have done so during neuronal differentiation
of human PSCs. However, several groups have recently begun to elucidate this process, including
Inoue et al., who used a dual-SMAD-based differentiation method to study early neural
differentiation (Inoue et al., 2019). At six different time points through 72 hours of differentiation
of the H1 ESC line (male), ChIP-seq for H3K27ac and H3K27me3 was conducted to identify
putative enhancers associated with neural differentiation. Regions where H3K27ac and
H3K27me3 peaks overlapped were presumed to be inactive and were removed from analysis.
Since this paper also integrated this data with chromatin accessibility, determined by ATAC-seq,
the main findings are discussed further in a following section of this review. Similarly, Ziller et al.
performed epigenomic and transcriptional analysis of six NPC stages derived from human ESCs,
also by using a dual-SMAD inhibition protocol (Ziller et al., 2015). Assays were performed on
ESCs, neuroepithelial (NE) cells, early radial glial (ERG) cells, mid radial glial (MRG) cells, late
radial glial (LRG) cells, and long-term neural progenitors (LNP). These included both RNA-seq
and ChIP-seq for H3K4me1, H3K4me3, H3K27ac, and H3K27me3, to identify stage-specific
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regulation of neural specification. Significant changes in histone modification state were observed
during the initial specification of NE cell identity, while they also identified an increase in the
repressive H3K27me3 mark at the MRG stage; this was associated with repression of non-neural
gene expression and with activation of many key regulators of neural development and forebrain
specification such as PAX6, OTX2, and FOXG1, as well as multiple SOX transcription factors
(Ziller et al., 2015). These datasets are especially useful for assessing changes in the epigenomic
landscape during the early stages of excitatory neural progenitor specification and differentiation.

The NIH Roadmap Epigenomics Project also includes ChIP-seq data for a large number of histone
modifications, as well as DNase hypersensitivity and RNA-seq data in H1 ESC-derived NPCs.
Together, these data can be utilized to further correlate histone modification status with the
regulation of gene expression during neural cell specification (Inoue et al., 2019). A smaller
number of histone marks have also been profiled during specification of the H9 ESC line (female)
as NPCs (Roadmap Epigenomics Project - Data, n.d.). A summary of these datasets is provided in
Supplementary Table 1. These data do not include mature cExNs or cINs, nor do they focus on
inhibitory NPCs. In order to fill such gaps, additional efforts of this nature will be needed.

3.4.3 ATAC-seq
As with studies using fetal tissues, chromatin accessibility has also been more widely assessed in
in vitro models of neurodevelopment, as it provides a general snapshot of the epigenetic state of
cells and can also be effectively used to determine how genetic perturbations affect chromatin
state, such as in models using NDD proband-derived PSCs. Several studies have used varying time
courses and differentiation strategies to assess chromatin accessibility during directed
differentiation of hPSCs into neurons (Table 1; Supplementary Table 1). For example, Shang et
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al. performed ATAC-seq combined with scRNA-seq analysis at various stages of NPC
specification from iPSCs, both to study cellular heterogeneity and to delineate unexpected features
of neurogenesis (Shang et al., 2018). They analyzed human iPSCs, EBs, early rosettes (Ros-E,
three days after rosette formation), late rosettes (Ros-L, five days after rosette formation), NPCs,
and the original somatic fibroblasts from which the iPSCs were derived. Chromatin accessibility
changes at each cell stage were assessed by tracing novel ATAC-seq peaks that appeared at each
stage of differentiation. Peaks that were conserved across stages were presumed to be associated
with housekeeping genes, while stage-specific peaks were regarded as potential CREs that could
regulate some aspect of the new cell state or transition to this state. In this work, ~10-50% of the
peaks observed at each stage were novel and specific to that stage, while NPC specification
corresponded with a large increase in novel peaks and reduction of numbers of pre-existing peaks.
After integration with ATAC-seq data, genes expressed in a cell stage-specific manner included
those encoding TFs and signaling molecules that regulate cell growth, proliferation, and
morphology (Shang et al., 2018). Thus, this study provides both transcriptomic and epigenetic data
related to human neural cell specification and differentiation and indicates some regulatory
mechanisms underlying acquisition of neuronal fate. In another study, van der Raadt et al.
attempted to identify TFs that might influence chromatin accessibility to promote neural cell fate
when overexpressed in somatic cells (van der Raadt et al., 2019). They performed ATAC-seq to
define differences in chromatin accessibility profiles of human fibroblasts and induced neurons
(iNeurons) produced by overexpressing NEUROG2. Among differentially accessible peaks
between these cell types (accessible in iNeurons versus fibroblasts), they identified a ONECUT
TF binding motif. Accordingly, ONECUT1, ONECUT2, or ONECUT3 overexpression induced
chromatin remodeling in fibroblasts within two days and accelerated neuronal differentiation (van
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der Raadt et al., 2019). This paper demonstrates how epigenetic information can be leveraged to
define activities that can regulate neural development.

The temporal interplay between epigenetic and transcriptional regulatory processes during early
neural induction is another important topic of study. As introduced above, Inoue et al. assessed
transcriptome changes that accompanied neural fate acquisition of hESCs at six time points
between 3 and 72 hours (Inoue et al., 2019). As expected, expression of neural genes increased,
with concomitant decreases in pluripotency gene expression. To identify putative enhancers
involved in neural differentiation, the ATAC-seq analysis described above was accompanied by
ChIP-seq for activating (H3K27ac) and repressive (H3K27me3) histone modifications at all time
points. Changes in these epigenetic modifications over time corresponded with gene expression
changes. A set of putative enhancers predicted using these data were subsequently assessed for
activity by massively parallel array analysis. Active enhancers were enriched for binding sites for
five TFs, BARHL1, IRX3, LHX5, OTX1, and OTX2, predicting that these TFs regulate neural
fate acquisition. Overexpression and knockdown of these TFs respectively up- and down-regulated
expression of neural genes (Inoue et al., 2019). A similar approach could be applied to define
transcriptional regulators that regulate the development of other cortical cell types and/or act at
other temporal stages.

In addition to studying neurodevelopmental processes, several studies have assessed chromatin
accessibility differences between affected and unaffected individuals with NDDs, including ASD
and SZ, to define neurodevelopmental alterations that may contribute to disease etiology. Schafer
et al. performed a time-course analysis in human idiopathic ASD subject-derived iPSCs during
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neural specification as NPCs (16 days) and during their differentiation into mature neurons (during
2-14 days of NPC differentiation) (Schafer et al., 2019). They also directly differentiated iPSCs
into induced neurons (iPSC-iN) by NGN2 overexpression. RNA- and ATAC-seq was performed
in both models to identify alterations in chromatin remodeling during neural development in the
affected individuals. They observed that pathological dysregulation of chromatin remodeling and
transcription prior to the NPC stage was sufficient to induce ASD-associated morphological and
functional changes during later neurodevelopment. Interestingly, they also found that epigenetic
regulatory processes that normally occur during neural specification and differentiation are not
recapitulated during direct conversion of iPSCs into iPSC-iNs (Schafer et al., 2019). Forrest et al.
also assessed chromatin state by ATAC-seq in iPSC-derived neurons from individuals with SZ at
27, 33, and 41 days after neural induction (Forrest et al., 2017). They proposed that non-coding
SZ risk variants in open chromatin regions (OCRs) were likely to affect neural development,
particularly if variants were close to, or within, predicted TF-binding sites within regulatory
elements. Significantly, they could correct a risk allele within the putative MIR137 SZ risk locus,
partially restoring gene expression and reversing the neurodevelopmental anomalies observed in
this model (Forrest et al., 2017). This work demonstrates the importance of identifying non-coding
regulatory regions that control neural development and highlights the role that epigenomic analysis
can play in defining variants in the non-coding space that contribute to disease risk.

Intriguingly, another study of chromatin accessibility during iPSC-derived neural differentiation
also identified allelic imbalance of gene expression (AIE) related to NDDs, a phenomenon in
which the two alleles of a given gene are expressed at different levels in a given cell, due to either
genetic variation in regulatory regions or epigenetic inactivation of one allele (Siwei Zhang et al.,
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2020). Allele-specific open chromatin regions (ASoC) may contribute to AIE. Zhang et al. mapped
these regions using ATAC- and RNA-seq, identifying common non-coding risk variants associated
with neurodevelopmental disorders. They observed that ASoC and AIE are cell-type specific, with
iPSC-derived neurons exhibiting higher levels of ASoC and AIE than iPSCs. They identified
heterozygous single nucleotide polymorphisms (SNPs) that exhibited ASoC in each cell type and
defined two SNPs of interest: one in the 5’UTR of CHRNA5 and one in the promoter of VPS45,
both of which are involved in synaptic transmission and have pathogenic variants that are strongly
associated with NDDs (Siwei Zhang et al., 2020). This study demonstrates a powerful method for
predicting functional non-coding variants associated with NDD risk.

3.5 Cerebral organoids
3.5.1 Background
By comparison with other in vitro differentiation methods, differentiation of multiple neuronal cell
types in structured three-dimensional COs more closely recapitulates the tissue structure and
organization of the developing brain. This approach enables differentiation over very long
timelines (months to years), also enabling more mature neurons to be generated. Cerebral
organoids can therefore serve as an informative tool to study human neural development (C. Luo
et al., 2016; Qian et al., 2019). Many advantages of non-organoid-based in vitro models of cortical
development are also applicable to COs, including the ability to generate large numbers of cells,
perform genetic manipulations, and perform assays at multiple timepoints. However, the structure
and composition of COs are generally not highly reproducible, which, combined with the
heterogeneity of cell types present in each organoid, poses challenges for producing epigenetic
data sets from this model.

66

Initial efforts to construct models of differentiated neurons in three-dimensions date back to the
1990s. Notably, the development in 1992 of methods for culturing various types of neurons as
three-dimensional neurospheres was shown to facilitate their culture and differentiation (Reynolds
& Weiss, 1992). Cerebral organoids, however, are distinct from neurospheres in that they benefit
from a capacity for self-organization of multiple neuronal cell types and therefore more closely
imitate in vivo brain development (Qian et al., 2019). Recently, several techniques have emerged
to produce COs, stemming from the method described by Lancaster et al. in 2013 (Lancaster et
al., 2013). Production of COs generally entails aggregation of PSCs as three-dimensional spheres
and their subsequent specification into neural progenitors and neurons with the desired brain
regional identity. Current methods for deriving COs include both guided and unguided
differentiation approaches. With unguided approaches, the PSCs are formed into spheres, which
are subsequently implanted into extracellular matrix and allowed to spontaneously differentiate
within a spinning bioreactor (Figure 4) (Lancaster et al., 2013). As this method does not direct
specification of a particular regional neural identity, it produces a heterogeneous population of
neuronal cell types from multiple brain regions, and results in organoid-to-organoid variability
within and across experiments. While this heterogeneity and variability can enable studies of
interactions between brain regions or neuronal cell types, it also substantially complicates
quantitative analyses (Qian et al., 2019). Guided approaches to producing COs instead utilize
specialized media and signaling agonist/antagonists to specify a particular regional identity,
enabling derivation of spheroids corresponding with a particular brain region or of a specific
neuron type (Figure 4) (Qian et al., 2019).
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3.5.2 ChIP-seq: Histone modifications
A few studies have characterized histone modification state in COs, although most extant work
focuses primarily on the DNA methylome (C. Luo et al., 2016), transcriptome (Amiri et al., 2018;
C. Luo et al., 2016; Xiang et al., 2017), or chromatin accessibility (Trevino et al., 2020; Xiang et
al., 2017; Ziffra et al., 2019) changes that accompany development (Table 1; Supplementary Table
1). Amiri et al. recently defined transcriptomic changes associated with specific histone
modifications (H3K4me3, H3K27ac, and H3K27me3) in developing COs (Amiri et al., 2018).
They found that differential activity of enhancers is linked to differential gene expression in the
developing organoids, with increased enhancer activity correlating directly with increased gene
expression. This was demonstrated through a clustering analysis of differential enhancer activity,
which closely followed transcriptomic differences (Amiri et al., 2018). Consistent with other
findings, it was observed that the largest change in differential enhancer activity occurred during
the specification of stem cells as NPCs; this work suggests that these enhancers regulate gene
expression during early aspects of brain development, the developmental timeframe that organoids
most closely model. More work is needed in this area to further characterize the relationship
between histone modifications and CO development, as well as to determine how this in vitro
model compares to its in vivo counterpart.

3.5.3 ATAC-seq
ATAC-seq is especially valuable for assessing heterogeneous cell populations like COs as, unlike
ChIP-seq, it can be performed both in bulk and at a single-cell resolution (Table 1; Supplementary
Table 1). In 2017, Xiang et al. employed bulk ATAC-seq to assess epigenomic regulatory
mechanisms in regionally restricted brain organoids modeling the MGE and the cerebral cortex
(Xiang et al., 2017). Unique open chromatin regions corresponding to genes crucial for
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development of the MGE or the cortex were observed, suggesting that changes in chromatin
accessibility actively contribute to transcriptional regulation during development of those
regionally patterned organoids. However, this work did not draw direct comparisons to human
fetal data from analogous tissues (Xiang et al., 2017).

A recent study by Trevino et al. likewise collected 117 bulk ATAC-seq samples encompassing
both COs of dorsal or ventral character generated from iPSC lines (Trevino et al., 2020).
Corresponding human fetal samples were obtained from the dorsal and ventral forebrain at 20 and
21 PCW for comparison. Differences in chromatin accessibility between these CO types were
assessed, with consideration of temporal changes. They observed that gene expression correlated
more closely with the average accessibility of distal enhancers versus proximal promoters. To
assess the relevance of these findings to brain development in vivo, they compared these findings
to the human fetal samples, demonstrating that COs cultured for 188-230 days most closely
resembled human fetal forebrain at 20-21 PCW. Further comparisons with PSYCHENCODE
epigenetic data demonstrated that the COs displayed progressive transformation of their chromatin
landscape, which resembled the changes in chromatin remodeling observed in developing fetal
tissue (Trevino et al., 2020). This study suggests that COs may accurately recapitulate many
aspects of epigenetic regulation in the developing forebrain in vivo and established their relevance
for modeling neurodevelopmental pathologies.

While bulk ATAC-seq has provided data on chromatin accessibility, scATAC-seq had not yet been
used to characterize COs. However, this approach was recently taken in the aforementioned preprint, which compares chromatin accessibility in COs and human fetal tissue (Ziffra et al., 2019).
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These scATAC-seq assays corroborate conclusions drawn in previous studies using bulk ATACseq, demonstrating that changes in enhancer chromatin accessibility predict changes in gene
expression. Based upon assessment of excitatory neuron lineages over time, epigenomic
differences were defined between progenitor cells in different cortical areas, while changes in
accessibility corresponded with neuronal differentiation. Interestingly, the highly dynamic
changes in chromatin accessibility observed here challenge the conventional model of
differentiation as a gradual, progressive process. Furthermore, although COs appear to faithfully
mimic many aspects of fetal development, a limitation of this model observed here is an absence
of increased accessibility during CO neuronal differentiation at thousands of distal regulatory
elements that become active and accessible during fetal brain development (Ziffra et al., 2019).
Therefore, this work illustrates both the strengths and limitations of using COs to model aspects
of fetal brain development.

3.6 Conclusions and future perspectives
3.6.1 Future foci and additional datasets
Although our understanding of epigenetic regulation of human brain development has advanced
considerably in the past 10 years, there remain many substantial gaps in knowledge. In many cases,
these involve the lack of neuronal cell-type specific resolution of extant data, which limits our
understanding of differences in epigenetic regulation across neuronal cell types (Table 1;
Supplementary Table 1). Gathering data from additional donors, samples, and timepoints will also
enable us to identify both common regulatory processes and those that are specific to a certain
timepoint, neuronal cell type, sex, or individual. The sex of most samples (whether fetal brains or
cell lines) is noted in most studies, but data from male and female samples are frequently
aggregated, which can be problematic since there are significant differences in developmental gene
70

regulation related to sex (Manoli & Tollkuhn, 2018). Some of these limitations will be overcome
by technological advancements, for example, the single-cell analysis performed by Ziffra et al.
(Ziffra et al., 2019), which substantially enhances the resolution of analyses that are possible.
Although single-cell sequencing often sacrifices read depth, hampering identification of rare cell
types or low-to-moderate gene expression, this tool can be particularly helpful when combined
with tissue dissection. This enables both single-cell-level and bulk-level analysis, while ensuring
greater homogeneity of each sample, relative to analysis of bulk cortex or whole fetal brain. Future
studies that combine analysis of scATAC-seq and scRNA-seq data will further enable us to define
regulatory networks that control the specification and differentiation of different neuronal cell
types. Finally, assay innovation will enable collection of data that was previously unattainable due
to technical limitations. For example, CUT&RUN (Meers et al., 2019; Skene & Henikoff, 2017)
and CUT&Tag (H. S. Kaya-Okur et al., 2019) enable low-input, high-resolution, profiling of
chromatin state, down to a single-cell level, using MNase- or Tn5 transposase-based methods,
respectively. These approaches will be particularly helpful for fetal samples, allowing histone
modification and TF binding profiles to be obtained for a greater number of samples and cell types.

3.6.2 Studying the epigenetic dysregulation underlying NDDs
Although genome-wide association studies (GWAS) have pinpointed hundreds of NDDassociated SNPs, it is often still unclear which risk variants contribute to disease pathology. More
generally, more than 90% of disease-associated SNPs are located DNA regions that do not encode
proteins (Maurano et al., 2012). These non-coding risk variants likely affect gene expression by
regulating chromatin accessibility for TF binding. Functional genomic assays such as ATAC-seq
and ChIP-seq have identified such candidate CREs (cCREs) in the genome. Integrating SNP
coordinates with these epigenetic datasets can reveal NDD-associated variants that overlap
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putative regulatory elements (An et al., 2018; Markenscoff-Papadimitriou et al., 2020). For
example, since noncoding CREs often coincide with accessible chromatin regions, Forrest et al.
profiled global open chromatin regions in human iPSC models and used these data to define
functional noncoding risk variants for SZ (Forrest et al., 2017). Recently, mutations in the
noncoding space have also been linked to ASD (J. Zhou et al., 2019). Machine learning was used
to analyze whole genome sequences for 1,790 individuals with ASD and their families. Upon
comparing de novo variants in the probands to biochemical data illustrating interactions between
DNA- and RNA-binding proteins (DBPs and RPBs, respectively) and their targets, Zhou et al.
assessed the potential quantitative impact of each mutation on particular transcriptional and posttranscriptional regulatory features, such as histone modification state (J. Zhou et al., 2019). Indeed,
many mutations in ASD probands were found to disrupt binding of DBPs and RBPs and
transcriptional regulation, providing support for the functional role of de novo noncoding variants
in ASD.

3.6.3 Testing the functional significance of identified regulatory elements
While comparison to chromatin-state datasets can help prioritize SNPs that may lie in a regulatory
element, this data alone cannot define functional variants. Epigenomic annotations may be
incongruous even within the same cell type and thus variants must be tested to truly define any
regulatory significance (Benton et al., 2019). Massively Parallel Reporter Assays (MPRAs) are a
high-throughput method used to assess functional activity of predicted regulatory elements and
changes in activity related to sequence variants. Using this assay, thousands of noncoding
sequences can be screened in a single experiment. In an MPRA, candidate regulatory sequences
are inserted before a minimal promoter in a vector with a unique DNA barcode that can be
transcribed (Ashuach et al., 2019). After constructs are introduced into cells, both DNA construct

72

counts and RNA transcript counts are used to approximate the transcription rate of every barcode.
Thus, MPRA testing can provide quantitative measurements of regulatory activity and help
supplement disease predictions associated with cCREs. This approach has been used to
functionally assess cCREs regulating several aspects of neurodevelopment (Grossman et al., 2017;
Inoue et al., 2019; Mulvey et al., 2020; S. Q. Shen et al., 2016). Another approach for functional
testing involves epigenome editing to silence or activate cCREs in situ in their genomic context
(Chavez et al., 2015; Konermann et al., 2015; K. Li et al., 2020).

3.6.4 Conclusions
Modeling epigenetic regulation of human fetal brain development increases our understanding of
and ability to experimentally manipulate these developmental regulatory programs. Recent studies
have generated epigenomic data from neuronal cell and tissue types in the developing human brain
and have compared these datasets to the analogous in vitro-derived neuronal cell types, providing
valuable insights into mechanisms of human brain development and disease etiology. Determining
which aspects of human brain development are or are not recapitulated with in vitro models
indicates where protocol refinements are needed, and these ongoing refinements continue to
enhance the utility of in vitro hPSC differentiation approaches. Together, the increasing amount
of epigenetic data available for human brain development is valuable for elucidating epigenetic
mechanisms and regulatory networks that control these developmental processes, and for
determining how these are disrupted by pathogenic mutations in both TFs and chromatin modifiers
and in the non-coding genome to cause NDDs.
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3.7 Figures

3.7.1 Figure 1. Three models for studying the epigenetic regulation of human
brain development.…..
High-throughput sequencing approaches such as ATAC-seq or ChIP-seq have been used to
interrogate epigenetic regulation and changes throughout human cortical development. Human
brain cells or tissues for use in these assays can be harvested from the developing fetus, or produced
by in vitro differentiation of human pluripotent stem cells into cortical neurons or cerebral
organoids. Figure created using BioRender.com.
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3.7.2 Figure 2. In vivo-derived human fetal cells and tissues.
(A) Studies have performed epigenetic assays on materials derived from human fetuses from 7 to
38 post-conceptional weeks (PCW). (B) Bulk brain tissue, dissected regions, or single cells have
been assayed. The cerebral cortex is of particular focus for this review. Figure created using
BioRender.com.
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3.7.3 Figure 3. In vitro-derived cortical neurons from hPSCs.
Human pluripotent stem cells (hPSCs) can be derived from reprogramming of somatic cells
(induced pluripotent stem cells; iPSCs) or from the inner cell mass of a blastocyst-stage embryo
(human embryonic stem cells; hESCs). Directed differentiation with small molecules or proteins
(via an intermediate neural progenitor cell (NPC) stage) or direct conversion via transcription
factor overexpression can be used to produce cortical neurons. Epigenetic assays have been
performed on cells at varying stages of differentiation. Figure created using BioRender.com.

76

3.7.4 Figure 4. In vitro-derived COs from hPSCs.
Human pluripotent stem cells (hPSCs) can be differentiated into cerebral organoids (COs) using
unguided methods that allow for self-organization or into region-specific (e.g. cortex or medial
ganglionic eminence; MGE) organoids using guided methods with patterning factors. These
hPSCs are formed into embryoid bodies (EBs) and are induced into neurons prior to being
embedded in Matrigel to provide a scaffold, and then matured on a shaker. Epigenetic assays have
been performed on organoids at varying stages of neural induction and maturation. Figure created
using BioRender.com.
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3.8 Tables
3.8.1 Table 1. An overview of papers using three models to study the
epigenetic regulation of human brain development.
(A) Studies using fetal cells and tissues derived from different developmental stages. Postconceptional weeks = PCW. Gestational weeks = GW. (B) Studies using in vitro differentiation of
hPSCs into cortical excitatory neurons, including differentiation method(s) used. (C) Studies using
cerebral organoids, including differentiation method(s) used. hCOs = human cortical organoids.
hMGEOs = human medial ganglionic eminence organoids.
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Chapter 4: Cellular and molecular
characterization of multiplex autism in
human induced pluripotent stem cell-derived
neurons
This chapter is adapted from an original research article published in Molecular Autism:
Lewis, E. M. A.*, Meganathan, K.*, Baldridge, D., Gontarz, P., Zhang, B., Bonni, A.,
Constantino, J. N., & Kroll, K. L. (2019). Cellular and molecular characterization of
multiplex autism in human induced pluripotent stem cell-derived neurons. Molecular
Autism, 10(1), 51. https://doi.org/10.1186/s13229-019-0306-0
Contributions: *EMAL and KM contributed equally to this work. EMAL contributed to the study
design, carried out all cExN experimentation, analyzed data, and prepared the manuscript. KM
contributed to the study design, carried out all cIN experimentation, analyzed data and
contributed to manuscript preparation. DB interpreted clinical exome sequencing data and
contributed to manuscript preparation. PG and BZ performed RNA-seq data analysis. AB
contributed to the study design. JNC contributed to the study design and manuscript preparation.
KLK contributed to the study design, data analysis, and manuscript preparation. All authors read
and approved the final manuscript.
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4.1 Abstract and keywords
4.1.1 Background
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with pronounced heritability
in the general population. This is largely attributable to the effects of polygenic susceptibility, with
inherited liability exhibiting distinct sex differences in phenotypic expression. Attempts to model
ASD in human cellular systems have principally involved rare de novo mutations associated with
ASD phenocopies. However, by definition, these models are not representative of polygenic
liability, which accounts for the vast share of population-attributable risk.

4.1.2 Methods
Here, we performed what is, to our knowledge, the first attempt to model multiplex autism using
patient-derived induced pluripotent stem cells (iPSCs) in a family manifesting incremental degrees
of phenotypic expression of inherited liability (absent, intermediate, severe). The family members
share an inherited variant of uncertain significance (VUS) in GPD2, a gene that was previously
associated with developmental disability but here is insufficient by itself to cause ASD. Induced
pluripotent stem cells from three first-degree relatives and an unrelated control were differentiated
into both cortical excitatory (cExN) and cortical inhibitory (cIN) neurons, and cellular phenotyping
and transcriptomic analysis were conducted.

4.1.3 Results
Cortical excitatory neurospheres from the two affected individuals were reduced in size, compared
to those derived from unaffected related and unrelated individuals. This reduction was, at least in
part, due to increased apoptosis of cells from affected individuals upon initiation of cExN neural
induction. Likewise, cIN neural progenitor cells from affected individuals exhibited increased
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apoptosis, compared to both unaffected individuals. Transcriptomic analysis of both cExN and cIN
neural progenitor cells revealed distinct molecular signatures associated with affectation, including
the misregulation of suites of genes associated with neural development, neuronal function, and
behavior, as well as altered expression of ASD risk-associated genes.

4.1.4 Conclusions
We have provided evidence of morphological, physiological, and transcriptomic signatures of
polygenic liability to ASD from an analysis of cellular models derived from a multiplex autism
family. Autism spectrum disorder is commonly inherited on the basis of additive genetic liability.
Therefore, identifying convergent cellular and molecular phenotypes resulting from polygenic and
monogenic susceptibility may provide a critical bridge for determining which of the disparate
effects of rare highly deleterious mutations might also apply to common autistic syndromes.
Keywords: multiplex autism, iPSC modeling, neurodevelopment, cortical excitatory neurons,
cortical inhibitory neurons, transcriptomics, gene networks.

4.2 Background
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a complex and poorly
understood etiology (Donovan & Basson, 2017; Gaugler et al., 2014; Wing & Gould, 1979).
Behavioral and imaging studies have been valuable for defining deficits in affected individuals
and characterizing alterations at the level of the brain. However, we are extremely limited in our
ability to acquire or experimentally manipulate human brain tissue from living patients or postmortem brain slices. This has hampered efforts to study cellular and molecular abnormalities that
accompany ASD, both during and after fetal and post-natal development. Notably, both the relative
integrity of brain structures in affected individuals and the diversity of ASD genetics suggest that
convergent mechanisms that contribute to affectation in ASD may operate at the level of the cell
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(Donovan & Basson, 2017; Ecker et al., 2015). These may be identifiable in experimental models
derived from affected individuals. In particular, ASD appears to frequently involve abnormal
development and/or function of two major classes of neurons in the cerebral cortex, glutamatergic
excitatory projection neurons (cExNs) and GABAergic inhibitory interneurons (cINs) (Canitano
& Pallagrosi, 2017; Donovan & Basson, 2017; Zikopoulos & Barbas, 2013). In vitro
differentiation-based models of these neuronal cell types can identify cellular and molecular
deficits associated with ASD and provide a tractable platform to screen for pharmacologic agents
that can rescue these deficits.

In recent years, such cellular models of ASD have been generated, either by deriving induced
pluripotent stem cell lines (iPSCs) from affected individuals or by using CRISPR/Cas9-based gene
editing to engineer ASD-associated mutations into wild-type PSCs (Aksoy et al., 2017; Deneault
et al., 2018; DeRosa et al., 2018; Deshpande et al., 2017; Griesi-Oliveira et al., 2015; Kathuria et
al., 2018; X. Liu et al., 2017; M. C. Marchetto et al., 2017; Mariani et al., 2015; Russo et al., 2018;
P. Wang et al., 2015, 2017; Woodbury-Smith et al., 2017). Most of these studies have focused on
syndromic forms of ASD, or on monogenic, de novo cases, where causality is attributed to the
mutation of a single ASD-linked gene (Deneault et al., 2018; Deshpande et al., 2017; GriesiOliveira et al., 2015; P. Wang et al., 2015, 2017; Woodbury-Smith et al., 2017). These forms of
ASD are attractive for cellular modeling, as they streamline study design and reduce many
potential confounding variables. Other studies have included individuals with an unknown genetic
cause of ASD, but with subject selection based upon a shared phenotypic characteristic, such as
macrocephaly (M. C. Marchetto et al., 2017; Mariani et al., 2015; Schafer et al., 2019). Together,
these models have been informative, revealing both cellular and molecular alterations associated
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with affectation. These include shared and model-specific disruptions of gene expression in ASDderived neurons, frequently involving altered expression of genes in key developmental signaling
pathways, and genes that control cellular proliferation and growth (Deneault et al., 2018; DeRosa
et al., 2018; X. Liu et al., 2017; M. C. Marchetto et al., 2017; Mariani et al., 2015; Russo et al.,
2018; Schafer et al., 2019; P. Wang et al., 2015, 2017; Woodbury-Smith et al., 2017). In addition,
differences were observed in neural precursor cell (NPC) proliferation and differentiation (Aksoy
et al., 2017; Mariani et al., 2015), neurogenesis (Aksoy et al., 2017; Deshpande et al., 2017; M. C.
Marchetto et al., 2017; Schafer et al., 2019), synaptogenesis (Griesi-Oliveira et al., 2015; X. Liu
et al., 2017; M. C. Marchetto et al., 2017; Russo et al., 2018), or functional neuronal activity
(Aksoy et al., 2017; Deneault et al., 2018; DeRosa et al., 2018; Deshpande et al., 2017; X. Liu et
al., 2017; Russo et al., 2018). Altered expression of ASD genes, in which a mutation is linked to
ASD causation or risk, is also frequently observed (Deneault et al., 2018; DeRosa et al., 2018; X.
Liu et al., 2017; M. C. Marchetto et al., 2017; Mariani et al., 2015; Schafer et al., 2019; P. Wang
et al., 2015, 2017; Woodbury-Smith et al., 2017).

These cellular modeling studies have revealed potential contributors to affectation and, in some
cases, have identified targets amenable to pharmacological rescue in vitro (Griesi-Oliveira et al.,
2015; M. C. Marchetto et al., 2017). However, they do not encompass the range of contributors to
ASD burden in the general population: no single gene mutation accounts for more than 1% of
overall ASD cases with predicted monogenic causality (Christensen et al., 2016), while the
majority of genetic risk appears to be polygenic or idiopathic (J. N. Constantino et al., 2013; John
N. Constantino, 2014; John N. Constantino et al., 2010; De Rubeis et al., 2014; Gaugler et al.,
2014; Grønborg et al., 2013; Mefford et al., 2012; Ozonoff et al., 2011). Polygenic ASD risk can
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involve both common and rare variation in protein-coding and non-coding regions of the genome,
which may act in a combinatorial manner (De Rubeis et al., 2014; Gaugler et al., 2014; Turner &
Eichler, 2019; Williams et al., 2019). Furthermore, ASD exhibits pronounced heritability in
families (estimated at 50–90% (Griesi-Oliveira & Sertié, 2017)), none of which can be accounted
for by de novo (germline) events. Even within each multiplex ASD family, there is often a
considerable range in the extent of affectation among individuals, and in most multiplex autism
families, a single causative gene mutation cannot be identified (Griesi-Oliveira & Sertié, 2017).

While ASD burden in the general population predominantly involves polygenic or idiopathic risk,
heritability, and variable affectation (Christensen et al., 2016; De Rubeis et al., 2014; Gaugler et
al., 2014; Griesi-Oliveira & Sertié, 2017; Turner & Eichler, 2019; Williams et al., 2019), these
genetically complex forms of the disorder have been largely neglected in cellular modeling studies.
Therefore, we deemed it important to determine whether cellular modeling of these complex but
prevalent forms of ASD could also reveal affectation-related deficits. To test this, we focused on
a multiplex ASD family with variable affectation among family members. We generated iPSC
lines from three first-degree relatives (a male and a female with differing degrees of affectation
and their unaffected mother), as well as an unrelated unaffected female. We used these lines to
perform differentiation into both cExN and cIN neural progenitors and/or neurons. Models from
the affected individuals exhibited compromised cellular responses to differentiation cues and had
disrupted gene expression profiles. This included altered expression of many ASD-associated
genes, genes with roles related to behavior, cognition, and learning, and genes involved in nervous
system development and function, including cell adhesion molecules and ion channels.
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This is, to our knowledge, the first cellular modeling study of multiplex ASD, including graded
affectation among family members. This work demonstrates that even genetically complex forms
of ASD have discernable cellular and molecular abnormalities that track with affectation, some of
which overlap those identified in prior modeling of syndromic, monogenic, and de novo forms of
ASD. Therefore, this novel study design highlights the potential for cellular modeling to identify
convergent hallmarks across the broad diversity and genetic complexity of pathways to affectation.

4.3 Methods
4.3.1 Phenotyping of the multiplex family
The nuclear family consisted of working professional non-consanguineous parents, whose
firstborn child was a daughter with DSM-5 ASD, Level I (requiring support, meeting DSM-5
criteria for Asperger syndrome) who was very high functioning and ultimately attended college,
followed by a pair of monozygotic twin boys with ASD, Level III—one more fluently verbal than
the other but both severely impaired and requiring very substantial support (see below)—followed
by a third son with very subtle autistic traits and predominantly affected by attention deficit
hyperactivity disorder, which improved substantially with stimulant medication treatment. Trio
exome sequencing (ES) of one of the twins and his parents revealed a variant of uncertain
significance (VUS) in GPD2, which was inherited by all of the children from the mother, who is
of above-average intelligence with no dysmorphism and no history of developmental problems.
All pregnancies were uncomplicated, except for the post-natal hospital course of the twins.

The daughter was born at term with no complications or dysmorphia. Her language and motor
development were typical and she was able to read at an early age. By age 5 she was reading at a
fifth-grade level. She has been described as talented in writing and drawing. According to her
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parents, she exhibited social oddities from an early age, mainly in communication, and has
somewhat intense/restricted interests in fantasy games. She has strong language abilities, and
currently attends a 4-year college, but at times uses odd phrases and the rhythm of her speech
includes irregular pauses. She has described feeling alienated and “different”, and was the victim
of bullying in middle school, with few close friends. In late adolescence, she developed major
depressive disorder with moderate severity, which brought her to first psychiatric contact. She is
cognizant of some degree of social awkwardness, which leads to feelings of anxiety and selfconsciousness. The social anxiety inhibits her from activities such as eating in the cafeteria and
pursuing job opportunities for which she is otherwise well-qualified. She has a history of becoming
emotionally dysregulated and overwhelmed in times of stress, which has led to self-injurious
behaviors. She has had ongoing struggles with depressive decompensation and suicidal ideation.
She has above-average intelligence but has struggled academically in college due to depression
and anxiety. She is medically healthy with the exception of supraventricular tachycardia secondary
to atrioventricular node reentry, which was treated with ablation and resulted in subsequent
normalization of her electrocardiogram.

The twin boys were born at 35 weeks, had breathing problems at birth, and spent 10 days in the
newborn intensive care unit. Neither child has any dysmorphic features nor congenital medical
abnormalities, and brain imaging studies were negative. Likewise, neither child has a history of
confirmed seizures; however, there are concerns for possible absence epilepsy. There is no history
of abnormal neurological examination or macro-/microcephaly. Development of both siblings was
delayed, but neither had appreciable regression. The more severely affected twin (designated as
the affected proband, AP, and from whom the induced pluripotent stem cell (iPSC) model of severe
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ASD affectation was acquired) began to exhibit delays in development by 9 months of age. He
was speaking single words at 14 months and was ultimately diagnosed with autism at 3.5 years
old. Research confirmation of the diagnosis was obtained using the Autism Diagnostic Observation
Schedule. Compared to his twin brother, he has had more perseverative interests on odd objects.
Psychological testing at the age of 9 revealed an IQ of 65 using the Leiter International
Performance Scale. Now in late adolescence, he has the ability to engage in reciprocal and
meaningful verbal exchanges, although his language is often echolalic and repetitive. He is socially
motivated and develops superficial friendships with peers. Functionally, he is able to complete
most self-care, dress himself, prepare food and feed himself, and count money. He participates in
a vocational program at school and is able to complete rudimentary tasks assigned to him. His
monozygotic twin was also diagnosed with ASD at 3.5 years old and is less severely affected, but
still requires significant support. Selected clinical characteristics of the family members studied
are summarized in Table 1.

4.3.2 Genotyping of the multiplex family
Standard trio ES was performed by the clinical diagnostic laboratory GeneDx for the unaffected
mother (UM), the AP, and the unaffected father. As described by GeneDx, exons were captured
and sequenced on an Illumina platform with at least 100 base pair read length, followed by
alignment to human genome build GRCh37/hg19 and subsequent variant identification. GeneDx’s
custom-developed tool, Xome Analyzer, was used for variant analysis, as described (Retterer et
al., 2016). This process involves comparing the sequences of each individual to a number of
resources, such as published reference sequences, other family members, and control individuals,
including the 1000 Genomes database, NHLBI Exome Sequencing Project, ExAC, gnomAD,
OMIM, PubMed, and Clinvar. Variant annotations include evolutionary conservation scores,
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results of in silico prediction tools, and references from the published literature. A phenotypebased approach is also used to generate candidate gene lists. This information was interpreted by
GeneDx experts according to the American College of Medical Genetics and Genomics
Guidelines. ES was performed by the Genome Technology Access Center (GTAC) at Washington
University on the intermediate phenotype sister (IS), and variant-specific testing was performed
by GeneDx on the trait-affected brother (TB) to confirm the presence of the identified GPD2
variant.

4.3.3 iPSC generation
Induced pluripotent stem cell lines were generated by the Genome Engineering and iPSC Center
(GEiC) at Washington University. Biomaterials for reprogramming were only available from the
UM, IS, and AP. Briefly, renal epithelial cells were isolated and cultured from fresh urine samples
and were reprogrammed using a CytoTune-iPS 2.0 Sendai Reprogramming kit (Thermo Fisher
Scientific), following the manufacturer’s instructions. At least three clonal iPSC lines were derived
for each subject, and one or two of these clonal lines (clones 1 and 2) were used for all
experimentation involving the UM, IS, and AP. The UC line was previously derived by the GEiC,
and one clonal line was available for use in all experiments involving this cell line. All clones
(clones 1 and 2) used in experiments were assessed for karyotypic abnormalities by the
Washington University School of Medicine Cytogenetics and Molecular Pathology Laboratory,
and were also characterized for pluripotency by immunocytochemistry (ICC) and RT-qPCR. Each
statistically significant experimental finding reported here was made in experiments that used two
different clonal lines per individual (except for the UC, where only one clonal line was available),
with at least three independent biological replicate experiments performed per clonal line.
Statistical comparisons were made by one-way ANOVA or unpaired t-test. Documentation of the
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clone used for each replicate experiment, the replicates performed, and the statistics for each
finding is detailed in Additional file 1: Table S1.

4.3.4 iPSC maintenance and differentiation
Induced pluripotent stem cell lines were grown under feeder-free conditions on Matrigel (Corning)
in mTeSR1 (STEMCELL Technologies). Cortical excitatory neuron and cIN differentiation of
iPSCs was performed using previously described protocols (Meganathan et al., 2017). Briefly, for
cExN differentiation, iPSCs were dissociated to single cells with Accutase (Life Technologies)
and 40,000 cells were seeded in V-bottom 96-well non-adherent plates (Corning). Plates were spun
at 200 x g for 5 min to generate embryoid bodies (EBs) and were incubated in 5% CO2 at 37 °C in
cExN differentiation medium with 10 µM Y-27632 (Tocris Biosciences). Cortical excitatory
neuron differentiation medium components include Neurobasal-A (Life Technologies), 1X B-27
supplement (without Vitamin A) (Life Technologies), 10 µM SB-431542 (Tocris Biosciences),
100 nM LDN-193189 (Tocris Biosciences). On day 4 of differentiation, EBs were transferred from
V-bottom plates to Poly-L-Ornithine- (20 µg/ml) and laminin-(10 µg/ml) coated plates. Media
(without Y-27632) was replenished every other day, and on day 12, Neural Rosette Selection
reagent (STEMCELL Technologies) was used to select neural progenitor cells (NPCs) from within
neural rosettes, per the manufacturer’s instructions. Cortical excitatory NPCs were grown as a
monolayer using cExN differentiation media for up to 15 passages. Cortical interneuron
differentiation media contained the same components as cExN differentiation media, while also
including 1 µM Purmorphamine (Calbiochem) and 2 µM XAV-939 (Tocris Biosciences).
Embryoid bodies were generated as described for cExNs. At day 4 of differentiation, the EBs were
transferred to non-adherent plates and were placed on an orbital shaker (80 rpm) in an incubator
with 5% CO2 at 37 °C. The media was replenished every other day and, at day 10, EBs were
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transferred to Matrigel- and laminin- (5 µg/ml) coated plates. Y-27632 was included in media until
day eight of differentiation. On day 12 of differentiation, NPCs were dissociated with Accutase
and maintained as a monolayer for up to 15 passages. For both cIN and cExN NPC growth analysis,
an equal number of cells were seeded on Matrigel- and laminin- (5 µg/ml) coated plates and total
cells were counted 4 days later when the cells reached 70–80% confluence.

For differentiation of cExN NPCs into neurons for maturation, 40,000 cells per well were seeded
in V-bottom 96-well non-adherent plates. Plates were spun at 200 x g for 5 min and incubated in
5% CO2 at 37 °C in maturation medium with Y-27632. Maturation medium components include
Neurobasal-A, 1X B-27 supplement (without Vitamin A), 200 µM cAMP (Sigma), 200 µM
Ascorbic acid (Sigma), and 20 ng BDNF (PeproTech). After 2 days, EBs were transferred to
Matrigel- and laminin- (5 µg/ml) coated plates and media was replenished every other day (without
Y-27632). On day 12 of neuronal differentiation and maturation, cells were dissociated with
Accutase and seeded in an 8-well chamber for ICC.

For neurosphere size measurement analysis, P values *P < 0.05, **P < 0.01, ***P < 0.001 were
determined by one-way ANOVA.

4.3.5 Sanger sequencing
DNA was isolated from cell lines using the PureLink Genomic DNA Kit (Invitrogen). Primers
were designed to amplify a 248 base pair region of GPD2 flanking the identified point mutation
(forward

primer:

AAGCAGCAGACTGCATTTCA,

reverse

primer:

CACCATGGCACACACTTACC). Sanger sequencing was performed on this PCR-amplified
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fragment using either the forward or reverse primer. CodonCode Aligner software was used to
analyze sequencing results.

4.3.6 Immunocytochemistry (ICC) and immunoblotting
For ICC, cells were plated on 8-well chamber slides coated with Matrigel and laminin (5 µg/mL).
After 1 day, cells were washed once with PBS without calcium and magnesium (PBS - Ca2+/Mg2+)
and fixed in 4% paraformaldehyde for 20 min, followed by washing with PBS + Ca2+/Mg2+. Cells
were blocked with blocking buffer (10% donkey serum, 1% BSA, and 0.1% TritonX-100 in PBS
+ Ca2+/Mg2+) for at least 1 h and incubated with primary antibodies overnight (Additional file 1:
Table S1) in antibody dilution buffer (1% donkey serum, 1% BSA, and 0.1% TritonX-100 in PBS
+ Ca2+/Mg2+). After overnight incubation, cells were washed three times with wash buffer (0.1%
Triton X-100 in PBS + Ca2+/Mg2+). Cells were incubated with corresponding secondary antibodies
(Additional file 1: Table S1), along with DAPI (1 mg/mL; ThermoFisher Scientific), diluted in
antibody dilution buffer for 1 h. Following secondary antibody incubation, cells were washed twice
with wash buffer and once with PBS + Ca2+/Mg2+. Slides were mounted with Prolong Gold antifade agent (Life Technologies). Images were obtained using a spinning-disk confocal microscope
(Quorum) with MetaMorph software and were processed using ImageJ. For immunoblotting, cell
lysate was extracted and 30 µg of protein was used per lane. Antibodies used are listed in
Additional file 1: Table S1.

4.3.7 FACS analysis
For each experiment, approximately 1 million cells were pelleted, washed with PBS – Ca2+/Mg2+,
resuspended in PBS – Ca2+/Mg2+ and fixed by adding 70% ice-cold ethanol dropwise while
vortexing. Cells were stained with 10 µg/mL propidium iodide (PI; Sigma) and 200 µg/mL RNase
A (Fisher Scientific) in FACS buffer (PBS – Ca2+/Mg2+, 0.2% BSA, 1mM EDTA). FACS was
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performed on single-cell suspensions and the cell cycle analysis function of FlowJo was used to
analyze cell cycle composition for each sample, based on PI staining to detect DNA content in
each cell. P values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by one-way ANOVA.

4.3.8 RNA-seq and RT-qPCR
Total RNA was collected from iPSC-derived day 12 cExN and cIN NPCs using the NucleoSpin
RNA II kit (Takara) per the manufacturer’s instructions. RNA was quantified using a NanoDrop
ND-1000 spectrophotometer (Thermo Scientific), and the integrity of RNA was confirmed with
an Agilent Bioanalyzer 2100 to ensure a RIN value above eight. RNA-sequencing (RNA-seq)
library preparation and Illumina sequencing were performed by the GTAC at Washington
University. Single-end 50 base pair reads were obtained using an Illumina HiSeq 3000 sequencer,
obtaining an average of ~30 million uniquely aligned reads per sample. For RT-qPCR, 1 µg total
RNA was reverse transcribed using iScript Reverse Transcription Supermix (Bio-Rad). Equal
quantities of cDNA were used as a template for RT-qPCR, using the Applied Biosystems Fast
Real-Time quantitative PCR system. RPL30 mRNA levels were used as endogenous controls for
normalization. P values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by an unpaired ttest.

4.3.9 Bioinformatics and IPA analyses
RNA-seq data analysis was performed as described in (Meganathan et al., 2017) to curate
differentially expressed gene (DEG) lists. In summary, RNA-seq reads were aligned to the human
genome (assembly hg38) with STAR version 2.5.4b (Dobin et al., 2013). Gene counts were derived
from the number of uniquely aligned unambiguous reads by Subread:featureCount, version 1.6.3,
with GENCODE gene annotation (V27) (Harrow et al., 2012; Liao et al., 2013). All gene-level
transcript counts were then imported into the R/Bioconductor package DESeq2 (Love et al., 2014).
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Genes expressed below a CPM of 1.0 in more than half the samples were excluded from further
analysis. DEG cutoffs were set at a log2-fold change of > 1.0 and a Benjamini and Hochberg FDR
of < 0.05.

To uncover the biological significance of DEGs, network analysis was performed with the data
interpretation tool Ingenuity Pathway Analysis (IPA) (Qiagen). Ingenuity Pathway Analysis’
Ingenuity Knowledge Base uses network-eligible DEGs to generate networks and to define
connections between one and more networks. Based on the number of eligible DEGs, IPA defines
network scores as inversely proportional to the probability of finding the network and defines
significant networks (P ≤ 0.001). Within each network, red symbols indicate upregulated genes
and green symbols indicate downregulated genes, where the color intensity represents the relative
degree of differential expression.

4.3.10

Co-expression and variance analysis

For this correlation analysis, the read counts matrix for DEGs in either the cIN or cExN samples
was log2-CPM transformed. A similarity matrix for these genes was created by calculating the
Euclidian distance among the genes from the log2-CPM matrix in R. The WGCNA R package
“adjacency.fromSimilarity” function with arguments power=12, type=’signed’ was used to create
an adjacency matrix from the similarity matrix (Langfelder & Horvath, 2008). Hierarchical
clustering was performed using the hclust function in R on the distance matrix transformation of
the adjacency matrix using the ward.D2 method. The dendrogram of this gene tree was split into
k = 3 clusters using the cutree function in the stats package of R. The read counts matrix for all
genes in either the cIN or cExN samples was CPM transformed. Genes expressed at < 1 CPM in
over half of the samples were excluded. Average CPM among the four sample types was calculated
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for each gene, and genes with expression ratios of < 1.25 between the highest and lowest expressed
sample type were excluded from further analysis. The filtered gene CPM matrix was log2
transformed, and the Pearson correlation matrix for the remaining genes was calculated using the
cor function from the stats package in R. A gene was considered to be correlated to a DEG cluster
if it had a Pearson correlation coefficient > 0.7 for over half the genes in the DEG cluster. Genes
with expression correlated to a cluster of genes from the DEG clustering were merged with those
genes and fed into the ToppFun GO analysis of ToppGene (Jing Chen et al., 2007). For each
correlated cluster, up to five terms with the most significant Benjamini and Hochberg FDR values
were retained for each biological process, cellular component, and molecular function GO terms.
The top three pathway and disease terms were also retained for each cluster. To assess the impact
of different covariates on expression, the R/Bioconductor package variancePartition was utilized
(Hoffman & Schadt, 2016). The parameters assessed were cell type (cExN versus cIN), subject
(UC, UM, IS, AP), age (young versus old), or sex (male versus female).

4.3.11

Data availability

The RNA-seq data generated during the current study are available in the Gene Expression
Omnibus (GEO) repository as Series GSE129806.

4.4 Results
4.4.1 Phenotyping and genotyping of the multiplex family
The multiplex ASD pedigree selected for study (Figure 1; Table 1) underwent clinical phenotyping
and genotyping (see Methods). From this pedigree, the individuals selected for induced pluripotent
stem cell (iPSC) line derivation and modeling included the affected proband (AP), his sister, who
has an intermediate phenotype (IS), and their unaffected mother (UM) (indicated in Figure 1). As
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described in the Methods, a non-synonymous single nucleotide variant in the GPD2 gene was
identified in the UM and all of the children (chr2:157352686 (hg19) G>A, NM_001083112.2
c.233G>A, p.G78E). This variant is not present in the father. The variant is in exon 3 of the GPD2
gene, within the region encoding the flavin adenine dinucleotide (FAD)-binding domain of the
GPD2 protein (Additional file 2: Figure S1A). The GeneDx interpretation of this variant states that
it was not observed in approximately 6500 individuals of European and African American ancestry
in the NHLBI Exome Sequencing Project and that it is evolutionarily conserved. In addition, in
silico analysis predicts that this variant is probably damaging to the protein structure and function.
Overall, GeneDx designated this as a VUS following the American College of Medical Genetics
criteria. Subsequent mutation-specific testing and Sanger sequencing identified this same variant
in the AP, IS, and UM, while it was absent in an unrelated, unaffected control (UC) (Additional
file 2: Figure S1B). Given the differential affectation of members of this pedigree carrying this
variant, it was apparent that this inherited VUS was insufficient to cause ASD by itself, but may
have contributed to polygenic risk/liability in this family.

4.4.2 Generation of subject-derived iPSC models and directed differentiation
into cortical excitatory neurons
Two clonal iPSC lines were derived from the UM, IS, and AP, and were characterized in parallel
with a single, clonal iPSC line derived from the UC. When grown in stem cell maintenance media,
there were minimal differences observed in the expression of pluripotency markers between these
iPSC lines, as assessed by RT-qPCR (Additional file 2: Figure S1C) and immunocytochemistry
(ICC) (Additional file 2: Figure S1D). In addition, no differences in GPD2 protein levels were
detected in iPSCs by ICC (Additional file 2: Figure S1D) or western blotting (Additional file 2:
Figure S1E). All cell lines used in this study were also shown to be karyotypically normal (Figure
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S1F). Finally, we used FACS analysis of PI-stained iPSCs to assess cell cycle progression and
detected no observable differences between these iPSC lines, which had similar percentages of
cells in each stage of the cell cycle (Additional file 2: Figure S1G-H).

In the cortex, as a result of their abnormal development, imbalances in glutamatergic excitatory
neurons (cExNs) and GABAergic inhibitory interneurons (cINs) are thought to contribute to
neurodevelopmental disorders including ASD (Donovan & Basson, 2017; Lunden et al., 2019;
Zikopoulos & Barbas, 2013). We therefore differentiated iPSCs derived from the UC, and from
three family members (the UM, IS, and AP), in parallel into either cExN or cIN NPCs and/or
neurons, to determine if we observed any alterations in the in vitro development of either or both
of these neural cell types. We performed 12 days of cExN differentiation (4 days as EBs in Vbottom plates, followed by 8 days with the EBs plated for two-dimensional (2D) culture; Figure
2A). At all time points assessed during this differentiation, the IS and AP lines generated
significantly smaller neurospheres than the UC and UM. The UM neurospheres were also slightly
smaller than those of the UC (Figure 2B, C).

To identify whether an increase in apoptosis and/or a decrease in proliferation could be
contributing to these differences in neurosphere size, we performed FACS analysis of PI-stained
cells at day 4 of differentiation and found that the IS and AP neurospheres had a significantly
higher fraction of sub-G1 (apoptotic) cells, compared to neurospheres derived from the UM and
UC lines (< 2 N DNA content; Figure 2D, E, G). There was a corresponding decrease in the
percentage of cells in the G1 phase of the cell cycle in the IS and AP neurospheres (2 N DNA
content; Figure 2D, F–G). However, neurospheres from all lines had similar percentages of cells
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in the S and G2/M phases of the cell cycle, suggesting that their cell cycle characteristics and rates
of progression were otherwise similar (S phase and 4 N DNA content; Figure 2D, G). To determine
whether induction of neural differentiation was a stressor that was contributing to this increase in
apoptosis in the IS and AP line-derived neurospheres, we compared sphere size after culturing
spheres from each line either in stem cell maintenance media (mTeSR) or in neural induction
media. In general, sphere size was larger for all cell lines when kept in mTeSR media rather than
neural induction media, while the differences in sphere size for the IS and AP versus the UC and
UM was much less pronounced in mTeSR, relative to differences seen under neural induction
conditions (Figure 2H, I). These data suggest that, by comparison with the UC and UM, the IS and
AP lines have a slightly elevated propensity to undergo apoptosis upon dissociation and sphere
formation, while this is exacerbated by induction of neural differentiation.

We next maintained these four lines as NPCs after neural rosette selection at day 12 and then
subjected them to PI staining and FACS analysis (Additional file 2: Figure S2A). Unlike the results
from earlier time points, the cExN NPCs showed little difference in cell cycle across the four lines
(Additional file 2: Figure S2B-C), nor in the rate of growth or apoptosis over the course of culture
for 4 days (Additional file 2: Figure S2D). However, morphological analysis by bright-field
imaging indicated a possible adhesion defect in the IS NPCs, as indicated by uneven growth on
the cell culture plate surface (Additional file 2: Figure S2E). At the NPC stage, GPD2 protein
levels remained similar across the four lines, as was shown for iPSCs (Additional file 2: Figure
S2F).
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Finally, to determine if the NPCs derived from the affected individuals exhibited an altered
capacity to differentiate into cExN neurons, NPCs from the four lines were further differentiated
for 12 days as shown (Additional file 2: Figure S3A) and subjected to ICC. No apparent differences
between the four lines were observed in the expression of NPC markers (PAX6, NESTIN, and
SOX1) or markers of immature (TUJ1) and mature cExN neurons (VGLUT, MAP2) (Additional
file 2: Figure S3B). Furthermore, there were no observable differences between the lines in the
fraction of cells expressing Ki-67, a marker of cell proliferation, or cleaved Caspase 3, a marker
of apoptosis (Additional file 2: Figure S3B).

4.4.3 Differentiation of subject-derived iPSCs into cortical interneuron
progenitors
We also characterized cellular phenotypes of these four lines during differentiation into cIN NPCs,
to define any differences between the development of this neural cell type in lines derived from
affected and unaffected individuals. The differentiation scheme to produce cIN NPCs is outlined
in Figure 3A. On day 5 of differentiation in this scheme, neurospheres derived from the IS line
were smaller than those of the UM. Conversely, the AP line-derived neurospheres were slightly
larger than the UM line neurospheres (Additional file 2: Figure S4).

After dissociation on day 12 of differentiation, we assessed the cell cycle of the cIN NPCs using
FACS of PI-stained cells (Figure 3B-E). The IS and AP cIN NPCs had an increased sub-G1 cell
population, compared to the UC and UM NPCs, an indication of increased apoptosis in the cells
from the affected individuals (Figure 3C). Correspondingly, there was a decrease in the proportion
of cells in the G1 phase of the cell cycle (Figure 3D). However, no differences were observed in
frequencies of cells in the S and G2/M phases of the cell cycle between lines, suggesting that these
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lines had similar proliferation rates (Figure 3B, E). This result was supported by analysis of NPC
cell counts after 4 days of growth, which revealed a significant reduction in the number of AP
NPCs, as well as a slight reduction in the number of IS NPCs, compared to the UM NPCs (Figure
3F). These reductions in NPC number may have resulted from the increased NPC apoptosis
detected in our PI FACS analysis. The AP NPCs also exhibited altered morphology that could
indicate impaired adhesion capacity relative to the control UM/UC lines, which could also have
contributed to the reduction in the number of AP NPCs persisting in the culture after 4 days of
growth (Figure 3G).

4.4.4 Transcriptomic differences in neural progenitor cells derived from
affected individuals versus controls
To investigate which classes of genes could be differentially expressed in neural cells from the
affected individuals, by comparison with the unaffected controls, we performed RNA-seq analysis
on both cExN and cIN NPCs on day 12 of differentiation for all four subject-derived lines. Four
biological replicates were analyzed for each sample type and were clustered by principal
component analysis (PCA) of processed reads (Additional file 2: Figure S5A). We defined genes
that were significantly differentially expressed genes (DEGs) in pairwise comparisons of these
four sample types for either cExN or cIN NPCs, selecting DEGs with a log2-fold difference
between sample types of > 1 and a Benjamini and Hochberg FDR of < 0.05 (Additional file 3:
Table S2). In a within-family comparison of the UM, IS, and AP samples, greater numbers of
DEGs were obtained in the cIN NPC pairwise comparisons versus the numbers of DEGs obtained
for cExN NPC pairwise comparisons (Additional file 2: Figure S5B-C). These data indicate that
the cIN samples from the affected individuals (IS/AP) exhibit more transcriptomic differences
from the UM control than the affected individual-derived cExN samples.
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We focused first on identifying classes of genes that were differentially expressed in NPCs derived
from the affected individuals, by comparison with unaffected controls. To do this, we defined the
subset of DEGs that were similarly expressed in samples from both affected individuals (AP/IS)
but that differed in expression by comparison with the unaffected mother (UM) sample. Relative
expression is also shown for the UC, for a full cross-sample comparison. Four hundred fifty-two
and 437 DEGs for the cExN and cIN NPC samples met these criteria, respectively. Hierarchical
clustering and visualization of the relative expression of these DEGs across the four sample types
are shown for the cExN NPCs (Figure 4A; Additional file 4: Table S3). We next used IPA to assess
the potential biological significance of these genes. For the 452 DEGs in the cExN NPCs described
above, the most significant function- and disease-related gene ontology (GO) terms included
‘behavior’, ‘neurological disease’, and ‘embryonic development’ (Figure 4B). Network analysis
using IPA revealed several interesting networks of DEGs related to these GO terms, including
networks related to ‘locomotion’ (from DEGs within the ‘behavior’ GO term) and ‘behavior and
developmental disorder’ (Figure 4C, D). Within the ‘locomotion’ network, most genes were
upregulated in the affected individuals compared to the controls, including genes relating to neural
adhesion and ion channels (Figure 4C; Additional file 5: Table S4). Genes with known roles in
NPCs or neurons, as well as stress-related genes were present in the larger ‘behavior and
developmental disorder’ network (Figure 4D; Additional file 5: Table S4). Interestingly, another
network comprising genes from the GO term ‘neurological disease’ is related to ‘inflammation of
central nervous system’ (Additional file 2: Figure S6A; Additional file 5: Table S4).
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Ingenuity pathway analysis of the cIN DEGs also revealed several interesting classes of genes that
were differentially expressed between the affected participants and unaffected control NPCderived samples. Hierarchical clustering and visualization of the relative expression of DEGs
across the four sample types for the cIN NPCs are shown in Figure 4E (Additional file 4: Table
S3). The top GO terms included ‘developmental disorder’, ‘behavior’, ‘nervous system
development and function’, ‘psychological disorders’, and ‘neurological disease’ (Figure 4F).
Within the term ‘behavior’, a network that includes ‘learning’-, ‘cognition’-, and ‘behavior’related genes was identified (Figure 4G; Additional file 5: Table S4). The network related to the
GO term ‘psychological disorder’ includes genes related to ‘anxiety disorders’, ‘mood disorders’,
and ‘depressive disorder’ (Figure 4H). The ‘nervous system development and function’ network
includes genes involved in the ‘quantity of neurons’ and ‘quantity of synapse’, as well as cell
adhesion genes (Additional file 2: Figure S6B; Additional file 5: Table S4). Finally, a
‘neurological’ network included a number of genes also present in the other networks (Additional
file 2: Figure S6C). We further assessed these affectation-linked DEGs by gene co-expression
analysis and hierarchical clustering, as described in the methods (Additional file 2: Figure S7).
Gene ontology analysis of co-expressed gene clusters identified neuron-related (e.g. neuron
projection, axon, synapse) and neurological disease-related terms (e.g. mental depression, autistic
disorder) as top GO terms (Additional file 6: Table S5). Taken together, this analysis of DEGs in
both cExN and cIN NPCs shows evidence of altered expression of a number of neurological and
psychological disease-relevant gene classes in the AP- and IS-derived lines, relative to lines
derived from the UM and/or UC.
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4.4.5 Within-family comparison identifies a transcriptome signature specific
to neural progenitor cells derived from the ASD-affected proband
As differences in genetic background can confound differential gene expression analysis (Hoekstra
et al., 2017), we also performed a pairwise, within-family data comparison of DEGs that
distinguish the UM-, IS-, and AP-derived samples, focusing on DEGs specific to the AP that could
contribute to the greater degree of affectation observed. Using pairwise comparisons of DEGs, we
defined 190 genes which were uniquely differentially expressed in cExN NPCs from the AP
(Figure 5A). The top GO terms associated with these AP-specific DEGs included ‘psychological
disorders’, ‘behavior’, ‘nervous system development and function’, ‘developmental disorder’, and
‘neurological disease’ terms (Figure 5B). Within the ‘behavior’ term, network analysis showed
genes related to ‘memory’ and ‘learning’ to be dysregulated (Figure 5C; Additional file 5: Table
S4). Within the ‘nervous system development and function’ term, a network of dysregulated genes
related to ‘differentiation of neurons’ was identified (Figure 5D; Additional file 5: Table S4).

A similar analysis was performed on the cIN samples, revealing 384 DEGs unique to the AP
samples in the within-family comparison (Figure 5E). Ingenuity pathway analysis identified
classes of DEGs related to the GO terms ‘psychological disorders’, ‘developmental disorder’,
‘neurological disease’, ‘behavior’, and ‘nervous system development and function’ (Figure 5F).
Within the ‘behavior’ disease term, a network of genes related to ‘behavior’ and ‘cognition’ was
identified (Figure 5G; Additional file 5: Table S4). Within the ‘nervous system development and
function’ term, a network of genes related to ‘development of neurons’ and ‘synaptic transmission’
had altered expression in the AP versus the IS/UM-derived samples (Figure 5H; Additional file 5:
Table S4). Together, this analysis identified AP-unique DEGs in both cExN and cIN NPCs, many
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of which are broadly related to neural development, as well as to specific aspects of ASD, such as
behavioral alterations. These gene expression changes, therefore, correlate with and may
contribute to, the severity of affectation in the AP.

4.4.6 Comparison of differentially expressed genes with ASD-associated genes
and validation
The Simons Foundation Autism Research Initiative (SFARI) (SFARI | SFARI Gene, 2017)
maintains a database of genes that are mutated to cause or that contribute to ASD risk. We
compared our DEGs to these ASD-related genes, to assess whether their dysregulated expression
could contribute to affectation in these individuals. Of the 584 unique DEGs in the cExN
differentiation scheme that were either specific to the AP (Figure 5A) or that had similar expression
in the AP and IS that differed from that seen in the UM (Figure 4A), 30 (5.1%) were SFARI ASD
genes (Figure 6A; Additional file 6: Table S5). For the corresponding cIN NPC comparison, 48 of
692 unique DEGs (6.9%) were ASD genes in the SFARI Gene database (Figure 6B; Additional
file 6: Table S5). Based upon the 1,019 genes present in the SFARI Gene database (SFARI | SFARI
Gene, 2017) and the total of 27,731 genes with > 0.1 RPKM average expression across all cExN
and cIN samples, the number of AP- and IS-specific DEGs that are ASD genes is significantly
greater than would be expected by chance (hypergeometric distribution, P = 3.67 x 10−3 and 3.49
x 10−7 for cExN and cIN data, respectively). A subset of these are associated with syndromic ASD
(NTNG1, ALDH1A3, DMD, EBF3, PRODH, and RNF135) and/or are linked with ASD with the
highest confidence (SFARI gene scores 1–2: KATNAL2, MYT1L, CACNA2D3, GRIA1, SCN9A,
and CNTN4). Comparison with the 465 genes in the Geisinger Developmental Brain Disorder
Gene Database also revealed recurrent association of some of these genes with ASD and/or
intellectual disability, but infrequent association with other neurological disorders (Additional file
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6: Table S5) (Gonzalez-Mantilla et al., 2016). Interestingly, only one (for cExN) or none (for cIN)
of the DEGs overlapped with high-confidence genes unique to adult-onset psychiatric disorders
(e.g., not also associated with neurodevelopmental disorders) identified in the PsyGeNET database
(Additional file 6: Table S5) (Gutiérrez-Sacristán et al., 2015, 2017). Therefore, it is possible that
misregulated expression and consequently the function of ASD genes contributed to the disruption
of neural development and/or continues to contribute to altered neurological function in the IS and
AP.

We validated the differential expression of a subset of the DEGs described above by RT-qPCR
analysis, isolating RNA from NPCs derived from the second set of iPSC clones that differed from
those used for the RNAseq experiments. Expression changes of DEGs selected from the cExN
NPC RNA-seq data (Figure 7A) were robustly recapitulated in these experiments (Figure 7B).
Genes from the ‘behavior and developmental disorder’, from other identified networks, and genes
involved in neurodevelopment were evaluated (Additional file 5: Table S4). We also derived cIN
NPC RNA from the second set of iPSC clones and validated the corresponding RNA-seq data for
a subset of the DEGs (Figure 7C). Differential expression was assessed for SFARI ASD genes
(SFARI | SFARI Gene, 2017), and for genes encoding transcription factors, ion channels, and cell
adhesion molecules (Figure 7D, E and Additional file 5: Table S4). In addition, we validated a
subset of DEGs in cINs which also had differential expression in cExN NPCs (Figure 7E).

Differential gene expression in iPSC disease modeling studies involving female iPSC lines can be
confounded by erosion of X-inactivation, including alteration of sex chromosome-linked gene
expression (Booth et al., 2019; DeBoever et al., 2017; Mekhoubad et al., 2012; Salomonis et al.,
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2016). Therefore, we also assessed XIST expression levels, as an indicator of potential X-erosion
in our female lines. We observed that XIST RNA expression was reduced in the UC but not in
either clonal line derived from the UM or IS, evidence of potential X-erosion in the UC line
(Additional file 2: Figure S8A-B). However, as few of our DEGs are X-linked (Additional file 4:
Table S3), this does not appear to be a major contributor to the differential gene expression
identified in this study. Finally, we performed variancePartition analysis on these RNA-seq data
to quantify contributions of multiple sources of variation to the differential gene expression
obtained. The cell type (cExN or cIN) or subject from whom the sample was derived were the
main contributors to differential gene expression, while the age and sex of the subject were only
minor contributors to the total variance observed in both cExN and cIN RNA-seq datasets
(Additional file 2: Figure S8C). Together, these analyses revealed that relative to unaffected
individuals, samples from affected individuals exhibited altered expression of classes of genes
involved in behavior, learning, cognition, mood disorders, and neurodevelopment, including
perturbed ASD gene expression, suggesting that these differences could contribute to aberrant
neural development or function in the affected individuals.

4.5 Discussion
In recent years, the genetic structure of ASD risk in the general population has been clarified. This
work has confirmed that while, in some cases, deleterious, single gene variants are significant
contributors to ASD, the vast proportion of population attributable risk is polygenic (Gaugler et
al., 2014; Weiner et al., 2017). Furthermore, this risk is highly heritable, and individuals within a
multiplex family typically exhibit variable degrees of affectation (Griesi-Oliveira & Sertié, 2017).
Here, we modeled cellular and molecular correlates of ASD within one such multiplex family,
performing cortical neural differentiation of iPSCs derived from several family members with
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differential affectation. In this family, both polygenic liability and a shared VUS may contribute
to risk. In cells derived from the affected individuals, we identified compromised responses to
differentiation cues and altered gene expression profiles during iPSC differentiation into cExNs
and cINs, compared to related and unrelated unaffected controls. This work demonstrates that
iPSC-based modeling can be used to characterize these more genetically complex but prevalent
forms of ASD, in addition to modeling simplex and monogenic forms, which have been the focus
of most studies to date. Moreover, these data provide information on physiologic and
transcriptomic signatures of multiplex autism, with which cellular models derived from other
families and other combinations of inherited susceptibility factors can be compared in future work.

Our phenotypic analysis of these four iPSC-based models of cortical neural development included
assays conducted in the stem cells, during neural specification, in the proliferating NPCs, and
during neuronal differentiation. During cExN NPC specification and during cIN NPC propagation,
models from both affected individuals exhibited elevated fractions of cells with sub-G1 DNA
content, relative to control-derived models. These data suggest that models derived from the
affected individuals are less resistant to stressors, such as induction of differentiation, with these
stressors increasing the propensity for cells to undergo apoptosis. While the molecular trigger for
the induction of apoptosis here is unclear, expression of stress and apoptosis-related genes, such
as CHCHD2, ANXA1, and SPATA18 are dysregulated in these models (Correia et al., 2014; Y Liu
et al., 2015; Parente & Solito, 2004; Solito et al., 2008; D. B. Wang et al., 2014). These findings
are reminiscent of some observations made in prior work, in which schizophrenia subject-derived
iPSCs exhibited reduced neurosphere size (Toyoshima et al., 2016) and increased apoptosis was
observed in Williams syndrome iPSC-derived NPCs (Chailangkarn et al., 2016). Interestingly, few
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studies report cellular alterations observed prior to the NPC stage, often focusing predominantly
on phenotypes seen in NPCs and mature neurons (Aksoy et al., 2017; Deneault et al., 2018; DeRosa
et al., 2018; Deshpande et al., 2017; Griesi-Oliveira et al., 2015; Kathuria et al., 2018; X. Liu et
al., 2017; M. C. Marchetto et al., 2017; Mariani et al., 2015; Russo et al., 2018; P. Wang et al.,
2015, 2017; Woodbury-Smith et al., 2017). While this may reflect a lack of earlier phenotypic
changes in some models, our findings highlight the importance of tracking neurodevelopmental
alterations from their earliest onset. A recent report underscores the value of using cellular
modeling approaches that aim to recapitulate some aspects of in vivo neurodevelopment (Schafer
et al., 2019). This study found that direct conversion of iPSCs into neurons masked ASDassociated cellular phenotypes, which were observable during the directed differentiation of iPSCs
(Schafer et al., 2019).

In our study, transcriptomic analysis of neural progenitor cells revealed dysregulated expression
in affected individuals compared to controls of gene networks related to behavior, psychological
disorders, and neuronal development and disease. Genes encoding transcription factors were
among the neurodevelopment-related genes with reduced expression in both affected individuals.
For example, ARX is required for normal telencephalic development and is associated with
syndromic autism and other neurodevelopmental disorders (Friocourt et al., 2006), while EMX1
and FOXB1 also play important roles in neural development (Kobeissy et al., 2016; TakebayashiSuzuki et al., 2011; Yuanfeng Zhang et al., 2017). Behavioral misregulation is a key trait of ASD,
and gene networks related to the GO term ‘behavior’ exhibited dysregulated expression in both
affected individuals. Genes in these networks include COMT, ADCYAP1, CNR1, HTR2C, GRIK2,
and RGS4, all of which are implicated in behavior-related phenotypes in humans and/or mice
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(Bowers & Ressler, 2016; Gogos et al., 1998; Hattori et al., 2012; C. B. P. Martin et al., 2013; Paes
et al., 2018; Qayyum et al., 2015; Shaltiel et al., 2008; Shintani et al., 2006; Stratinaki et al., 2013).
Autism-associated genes were also dysregulated in these affected individuals, relative to controls.
Mutation of these genes in other individuals is implicated in autism risk or causation. These include
adhesion-related genes (PCDHA1, PCHDHA6, PCDHGA11, PCDH8, PCDH9, PCDH10
(Bruining et al., 2015; Jianling Chen et al., 2014; Tsai & Huber, 2017; X. Wang et al., 2002;
Washbourne et al., 2004), KIRREL3 (E. A. Martin et al., 2015), CNTN3, CNTN4 (Mohebiany et
al., 2014), CNTNAP4 (Karayannis et al., 2014), and THBS1 (Adams & Lawler, 2011)), receptor
and channel genes (CACNA2D3 and SCN9A (Rubinstein et al., 2018), GRIK2 and GRIK3
(Contractor et al., 2011; S. A. Kim et al., 2007; Pravetoni & Wickman, 2008; Soto et al., 2014),
KCNJ2 (Binda et al., 2018; Guglielmi et al., 2015), and GRIA1 (Gu et al., 2016; Ramanathan et
al., 2004)), and genes associated with central nervous system development and axon guidance
(ERBB4 (Perez-Garcia, 2015; Yau et al., 2003), NTNG1 (Yaguchi et al., 2014), TSHZ3 (Caubit et
al., 2016), EBF3 (Sleven et al., 2017), MYT1L (Blanchet et al., 2017; Stevens et al., 2011), and
ANXA1 (Correia et al., 2014; Parente & Solito, 2004; Solito et al., 2008)). Altered expression of
ASD-associated genes has also been observed in cellular models derived from affected individuals
in other studies (Deneault et al., 2018; Germain et al., 2014; X. Liu et al., 2017; Mariani et al.,
2015; P. Wang et al., 2015, 2017; Woodbury-Smith et al., 2017). Therefore, these findings suggest
that misregulated expression of suites of ASD-associated genes may contribute to risk or
affectation, and may do so by altering neurodevelopment and/or neuronal function in these affected
individuals.
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A unique aspect of this study is the use of iPSC-based directed differentiation into both cExNs and
cINs, enabling us to identify neural cell-type-specific alterations associated with affectation.
Although DEGs identified in affected individuals in both neural cell types were associated with
many similar functions and diseases (e.g., behavior), the specific DEGs obtained often varied by
cell type. For example, cIN DEGs included many more ASD-associated genes and protocadherin
genes, the latter of which control neuronal migration, axonal growth, and synapse formation (X.
Wang et al., 2002; Washbourne et al., 2004). Human post-mortem cortical tissue from individuals
with ASD has been shown to exhibit disrupted expression of cIN-associated genes, evidence that
this cell type may commonly be disrupted in affected individuals in vivo (P. Wang et al., 2018).
These findings suggest that extending cellular modeling studies to multiple disease-relevant
neuronal cell types, including cINs, may reveal additional neurodevelopmental disruptions related
to affectation.

To define cellular and molecular perturbations commonly related to affectation, we compared our
findings to other studies that modeled ASD by directed differentiation of iPSCs into cExNs. We
identified subsets of overlapping DEGs in comparisons with studies involving idiopathic autism
cases versus controls (26 shared DEGs (DeRosa et al., 2018)), syndromic ASD involving
macrocephaly (31 shared DEGs (Mariani et al., 2015)), and modeling of mutation of the syndromic
ASD gene CHD8 (32 shared DEGs (P. Wang et al., 2015)) (Additional file 7: Table S6). Data for
such comparisons is limited at present because iPSC-based models have been generated for a
relatively small number of individuals and mutations, and these almost exclusively characterize
cExNs or cerebral organoids (DeRosa et al., 2018; M. C. Marchetto et al., 2017; Mariani et al.,
2015; P. Wang et al., 2015).
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The multiplex pedigree studied here was subjected to clinical exome sequencing, as it was
hypothesized that a single, shared, genetic contributor might mediate autism risk and differential
phenotypic expression in this family. In this sequencing analysis, a thread of shared genetic
liability among all children was a VUS in the ASD- and ID-associated gene, GPD2 (BargeSchaapveld et al., 2013; Daoud et al., 2009; Nguyen et al., 2003), which was inherited from their
mother. However, there is variable ASD expressivity among these individuals, ranging from
absent, to intermediate, to severe. In addition, both males and females in the pedigree are variably
affected, indicating the presence of other significant contributors to variation in severity of
affectation within this family. This observation is consistent with recent evidence that genetic
liability for ASD is prevalently polygenic, and that, even in multiplex pedigrees where a significant
monogenic contributor has been identified, additional polygenic risk can contribute to affectation
(Weiner et al., 2017). Moreover, this multiplex family was prototypic in reflecting the most severe
form of affectation occurring in a male.

We hypothesized that it might be possible to identify graded cellular phenotypes that correlated
with the level of severity of phenotypic expression. In general, we instead observed many cellular
and molecular alterations that were shared by the cellular models derived from the affected
individuals, while not being observed in those derived from the unaffected individuals. However,
we did define some proband-specific DEGs, not present in the less severely affected sister, many
of which relate to behavior and nervous system development. A subset of these DEGs had graded
expression, exhibiting intermediate expression levels in the intermediate phenotype sister, between
her unaffected mother and her severely affected brother. These findings suggest that both the
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degree of dysregulation of expression and the number and identity of DEGs within these networks
may contribute to the level of affectation. While further experimentation might reveal additional
graded phenotypes, particularly in mature neurons, ex vivo cellular modeling cannot recapitulate
many aspects of fetal and post-natal neurodevelopment that may have been perturbed to contribute
to the graded affectation observed in these individuals.

4.5.1 Limitations
This work highlights several considerations for ongoing scientific efforts to model this complex
but prevalent form of ASD in future studies. First, since the unique characteristics of any multiplex
ASD pedigree present challenges for cellular modeling, it is important to control for sex and
variation in affectation in subject and family selection, study design, and analysis. Related to this
point is the importance of modeling affected females in such studies. Most ASD cellular modeling
to date has been restricted to affected males (Aksoy et al., 2017; Deneault et al., 2018; DeRosa et
al., 2018; Griesi-Oliveira et al., 2015; X. Liu et al., 2017; M. C. Marchetto et al., 2017; Mariani et
al., 2015; P. Wang et al., 2015, 2017), given the increased prevalence of ASD among males, and
the fact that constraint to a single sex simplifies some modeling considerations. In particular, sex
chromosome dosage effects do not need to be accounted for in male cells, while female-derived
iPSC models cannot currently recapitulate the process of random X-chromosome inactivation that
occurs in developing somatic tissues, including the brain (Dandulakis et al., 2016; Sahakyan et al.,
2017). However, the transcriptomic differences that we observed here were not driven by sex
chromosome-linked gene expression: very few DEGs in any potential pairwise sample comparison
(whether between same or opposite sex models) were sex chromosome-linked and/or potential
contributors to sex-biased gene expression in the human brain (Gershoni & Pietrokovski, 2017;
Tukiainen et al., 2017). Therefore, this work supports the feasibility of identifying DEGs
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associated with affectation by cellular model cross-comparisons, even when these models are
derived from both female and male subjects.

Furthermore, studying both unaffected and affected male and female individuals within a multiplex
family, as in this pedigree, necessitates consideration of how the so-called female protective effect
may contribute to affectation (Gockley et al., 2015; Jacquemont et al., 2014; Werling &
Geschwind, 2013). Multiplex ASD families often exhibit differences in phenotypic expression of
additive genetic liability, some of which appear to be related to sex. While the most affected
individual in this family is male, we cannot fully differentiate the contributors to variable
phenotypic expression of ASD in this pedigree, which also includes an unaffected male and
affected and unaffected females. However, this experimental system could identify affectationlinked phenotypes that may have involved a sex-based contributor, since both the cellular and
behavioral phenotypes of the females studied here differed from that of the affected male. Future
studies in strategically-selected samples such as these provide an opportunity to assess how sex
influences phenotypic expression of ASD genetic liability; if such mechanisms exist at the level
of the cell, this approach may yield insights into sex-specific interventions.

Another consideration for iPSC-based modeling of ASD is genetic background, which can be a
confounding variable for cross-comparisons (Hoekstra et al., 2017). In this pedigree, ASD risk was
polygenic, such that it was not possible to engineer a correction of a single genome variant to
create pairs of isogenic mutant versus wild-type iPSC lines with an identical genetic background
for study. In such cases, modeling of first-degree relatives may serve as the best control, and
modeling of multiple related individuals with varying affectation provides additional opportunities
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for identifying potential contributors to these differences in affectation. Including unrelated
controls and performing comparisons with other studies can further highlight which phenotypic
and transcriptomic alterations track with affectation, even by comparison with models derived
from individuals with an unrelated genetic background.

4.5.2 Conclusions
In summary, this work used robust schemes for differentiation of cortical neurons from iPSCs to
model cellular and molecular signatures associated with multiplex ASD in a family reflecting
varying degrees of affectation. Even in this prevalent, complex form of ASD, involving
heritability, polygenic etiology, and variable affectation, we could identify affectation-linked
cellular and molecular alterations of neurodevelopment, some of which overlapped those defined
in other iPSC-based studies of monogenic, syndromic, and de novo ASD. As more cellular models
of ASD are characterized, these data can be harnessed in the search for convergent and divergent
contributors to impairment across the genetically complex and multi-factorial pathways that give
rise to ASD.
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4.6 Figures

4.6.1 Figure 1. Pedigree from which samples were derived for this study.
GPD2 mutational status (GPD2m: indicates the presence of variant) and degree of autism spectrum
disorder (ASD) affectation are indicated. Black shading corresponds to the affected proband (AP)
and his twin brother, dark grey to the intermediate phenotype sister (IS), light grey to the traitaffected brother (TB), and white to unaffected family members, including the unaffected mother
(UM). * indicates that renal epithelial cells from these individuals were used to derive multiple
clonal induced pluripotent stem cell (iPSC) lines.
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4.6.2 Figure 2. Characterization of iPSC lines during differentiation into
cExN NPCs.
(A) Differentiation scheme, including timeline and small molecules used. (B, C) Induced
pluripotent stem cells derived from an unrelated, unaffected control (UC), as well as the UM, IS,
and AP were differentiated for 12 days to generate cortical excitatory neuron (cExN) NPCs.
Neurosphere size at several time points is shown in (B) and quantified in (C) (mean ± SEM; scale
bar = 500 µm; n = 16 biological replicates, encompassing two different clonal lines from each
subject, and one clonal line for the UC). (D-G) At day 4 of differentiation, cells were stained with
propidium iodide (PI) and FACS analysis of DNA content was performed. (D) Representative
FACS plots. In (E) <2 N (sub-G1) and (F) 2 N (G1) cells are quantified, with values shown for
each replicate. (G) shows mean values for all cell cycle stages for each cell line (mean ± SEM; n
= 3 or more biological replicates for each subject, encompassing two different clonal lines from
each subject, and one clonal line for the UC). (H-I) Induced pluripotent stem cells were cultured
in either neural induction media or in mTeSR stem cell media, and EB size was analyzed at day 4
of differentiation. Representative images are shown in (H) (scale bar = 500 µm), with
quantification in (I) (mean ± SEM; n = 3 or more biological replicates for each subject,
encompassing two different clonal lines from each subject, and one clonal line for the UC). P
values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by one-way ANOVA and all other
pairwise comparisons had a non-significant P value (P ≥ 0.05). Red and black data points denote
experiments performed with clone 1 or with clone 2, respectively.
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4.6.3 Figure 3. Characterization of iPSC-derived cIN NPCs.
(A) Differentiation scheme, including timeline and small molecules used. (B-D) After 12 days of
differentiation, cortical interneuron (cIN) NPCs were stained with PI and analyzed by FACS for
DNA content. (B) Representative FACS plots. In (C) and (D), respectively, < 2 N (sub-G1) and 2
N (G1) cells were quantified, with values shown for each replicate (n = 3 or more biological
replicates from each of two clonal lines for each subject, and one clonal line for the UC). (E) Mean
percentages of cells in each cell cycle stage are shown (n = 3 or more biological replicates from
each of two clonal lines for each subject). (F-G) cIN NPCs were plated in equal numbers for each
sample and counted after four days of culture. Data are quantified in (F) and representative images
are shown in (G) (n = 3 or more biological replicates from each of two clonal lines for each subject,
and one clonal line for the UC). P values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by
one-way ANOVA and all other pairwise comparisons had a non-significant P value (P ≥ 0.05).
Red and black data points denote experiments performed with clone 1 or with clone 2, respectively.
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4.6.4 Figure 4. Transcriptomic analysis of genes with differential expression
in affected subject-derived NPCs, relative to unaffected controls.
(A) Hierarchical clustering of RNA-seq data from the cExN NPCs identified differentially
expressed genes (DEGs) with shared expression in the AP and IS that differed from that in the
UM. Relative expression is also shown for the UC, for a full cross-sample comparison (P < 0.05,
fold-change > 2; n = 4 biological replicates from one clonal line for each subject, and one clonal
line for the UC). (B-D) Ingenuity pathway analysis (IPA) of these cExN NPC DEGs defined
disease- and function-associated gene ontology (GO) terms and identified gene networks
associated with the (C) ‘behavior’ and (D) ‘behavior and developmental disorder’ GO terms. (E)
Hierarchical clustering of RNA-seq data for the cIN NPCs identified DEGs with shared expression
in the AP and IS, that differed from that in the UM. Relative expression is also shown for the UC,
for a full cross-sample comparison (P < 0.05, fold-change > 2; n = 4 biological replicates from one
clonal line for each subject, and one clonal line for the UC). (F-H) Ingenuity pathway analysis of
these cIN NPC DEGs defined (F) disease- and function-associated GO terms and identified gene
networks associated with (G) ‘behavior’ and (H) ‘psychological disorder’. Within each network,
red symbols indicate upregulated genes and green symbols indicate downregulated genes, while
color intensity indicates the relative degree of differential expression.
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4.6.5 Figure 5. Within-family analysis of transcriptomic signatures specific to
the affected proband-derived samples.
(A) Venn diagram for the cExN NPCs, showing the DEGs from pairwise comparisons of different
samples, including numbers of overlapping DEGs. The blue shaded portion of the Venn diagram
indicates DEGs unique to the AP, not shared by the IS or UM. (B-D) Ingenuity pathway analysis
of the AP-unique DEGs in cExN NPCs defined (B) class and function-associated GO terms and
identified gene networks associated with (C) ‘behavior’ and (D) ‘nervous system development
and function’. (E-H) Ingenuity pathway analysis of the AP-unique DEGs in cIN NPCs determined
(F) class and function-associated GO terms and identified gene networks associated with (G)
‘behavior’ and (H) ‘nervous system development and function’. Within each network, red symbols
indicate upregulated genes and green symbols indicate downregulated genes, where the color
intensity represents the relative degree of differential expression.
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4.6.6 Figure 6. Hierarchical clustering of DEGs that are also ASD genes in
the SFARI autism gene database.
(A) Relative gene expression for the cExN NPC samples. (B) Relative gene expression for the cIN
NPC samples. Data from four biological replicates from one clonal line are shown for each sample
type.

125

126

4.6.7 Figure 7. Validation of DEGs of interest identified from RNA-seq
experiments by RT-qPCR.…………..
Genes tested are related to behavior and developmental disorders, adhesion, and ion channels. (A,
B) Comparison of relative gene expression in cExN NPCs for the UM, IS, and AP by (A) RNAseq and (B) RT-qPCR, including expression analysis of genes related to ‘behavior and
developmental disorders’. (C-E) Comparison of gene expression between the UM, IS, and AP for
the cIN NPCs by (C) RNA-seq and by (D, E) RT-qPCR, both for genes that were (D) differentially
expressed only in the cIN NPCs, and (E) for genes that were differentially expressed in both cExN
and cIN NPCs. P values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by an unpaired ttest and all other pairwise comparisons had a non-significant P value (P ≥ 0.05). RT-qPCR data
shown includes n = 3 or more biological replicates from one clonal line per subject, where samples
were generated for each subject by using a second clonal iPSC line that differed from the line used
for RNA-seq analysis.
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4.6.8 Figure S1. Characterization of iPSCs.
(A) Exome sequencing identified a heterozygous missense variant in the FAD domain-encoding
region of the GPD2 gene (chr2: 157352686 (hg19) G>A, NM_001083112.2 c.233G>A, p.G78E)
in individuals in the pedigree under study, including the unaffected mother (UM), intermediate
phenotype sister (IS), and affected proband (AP), as well as in the trait-affected brother (TB) not
studied here. (B) This variant was confirmed by Sanger sequencing and was not present in an
unrelated, unaffected control (UC). (C-E) Expression of markers of pluripotency was assessed by
(C) RT-qPCR and (D) immunocytochemistry (representative images shown), comparing the cell
lines under study (n = 4 biological replicates from one clonal line for each subject). GPD2 protein
level was also assessed in these iPSC lines by (D) immunocytochemistry or (E) western blotting
(n = 2 biological replicates from one clonal line for each subject). (F) Both the UC line and clonal
lines 1 and 2 derived from the UM, IS, and AP were karyotypically normal. (G-H) Induced
pluripotent stem cell lines were stained with propidium iodide (PI) and analyzed by FACS for
DNA content analysis. (G) Representative FACS plots are shown. (H) Mean percentages of cells
in each cell cycle stage, with no differences between cell lines observed (n = 4 biological replicates
from one clonal line for each subject). p-values: *P < 0.05 were determined by one-way ANOVA
in (H) or by unpaired t-test for RT-qPCR in (C), and all other pairwise comparisons had a nonsignificant p-value (P ≥ 0.05). In (D), scale bar = 200 µm.
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4.6.9 Figure S2. Characterization of iPSC-derived cExN NPCs.
(A-C) After 12 days of differentiation, cExN NPCs were stained with PI and analyzed by FACS
for DNA content. (A) Schematic of cExN NPC differentiation protocol. (B) Representative FACS
plots. (C) Mean percentages of cells in each cell cycle stage (n = 4 biological replicates from one
clonal line for each subject). (D, E) cExN NPCs were plated in equal numbers for each sample and
were counted after four days of culture (n = 6 biological replicates from one clonal line for each
subject). Data are quantified in (D), and representative images are shown in (E) (scale bar = 300
µm). (F) GPD2 protein levels were detected in cExN NPC samples by western blotting (n = 2
biological replicates from one clonal line for each subject). p-values: *P < 0.05 were determined
by one-way ANOVA and all other pairwise comparisons had a non-significant p-value (P ≥ 0.05).
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4.6.10
(A)

Figure S3. Maturation of cExN NPCs.

Differentiation

scheme,

including

timeline

and

small

molecules

used.

(B)

Immunocytochemistry for proteins marking cExN specification, differentiation, maturation, and
neuronal function (scale bar = 50 µm, n = 1 biological replicate from one clonal line for each
subject; representative images are shown).
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4.6.11

Figure S4. Characterization of iPSC lines during differentiation

into cIN NPCs.
(A) iPSCs were differentiated for 12 days, as shown in the schematic. (B, C) Differences in
neurosphere size at day 5 and 12 are shown in (B) and quantified at day 5 in (C) (mean ± SEM;
scale bar = 250 µm; n = 7 total biological replicates from two clonal lines for each subject, and
one clonal line for the UC). p-values: ***P < 0.001 were determined by one-way ANOVA and all
other pairwise comparisons had a non-significant p-value (P ≥ 0.05).
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4.6.12

Figure S5. Transcriptome analysis of cExN and cIN NPCs by

RNA-seq.
(A) Multidimensional scaling plot for the cExN and cIN NPC samples. (B, C) Numbers of
differentially expressed genes obtained for each pairwise sample comparison, indicating up- and
down-regulated genes for the (B) cExN NPCs and (C) cIN NPCs (p < 0.05, fold-change > 2).
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4.6.13

Figure S6. Networks of DEGs with expression that is similar in

the AP/IS and different than the UM.
Networks of DEGs are related to (A) cExN ‘neurological disease’ (B) cIN ‘nervous system
development and function’, and (C) cIN ‘neurological’. Within each network, red symbols
indicate upregulated genes and green symbols indicate downregulated genes, where the color
intensity represents relative degree of differential expression.
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4.6.14

Figure S7. Co-expressed DEGs in cExN and cIN NPCs were

defined by hierarchical clustering and visualized on a heatmap.
Log2-CPMs of DEGs were scaled by z-score, as described in the methods, and were plotted on a
heatmap for (A) cExN NPCs and (B) cIN NPCs.
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4.6.15

Figure S8. XIST mRNA expression levels and variancePartition

analysis.
(A, B) Comparison of XIST expression levels in cINPCs derived from the UC, UM, IS, and AP
by (A) RNA-seq and (B) RT-qPCR analysis. For the UM, IS, and AP, the first clonal line from
each subject was used for RNA-seq analysis (n = 4 biological replicates), and the second clonal
line from each subject was used for RT-qPCR (n = 3 biological replicates), confirming findings
for both clonal lines. The single UC clonal line was evaluated by both RNA-seq and RT-qPCR,
which also yielded similar results. (C) VariancePartition analysis was conducted on RNA-seq data
as described in the Methods, with violin plots indicating the percent of variance that was
attributable to the cell type, the individual subject from which the model was derived, their age, or
their sex.
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4.7 Tables
Table 1

4.7.1 Table 1. Selected clinical characteristics and mutational status of several
individuals in the multiplex ASD pedigree.

Clinical characteristic

AP

IS

UM

Age of ASD diagnostic
confirmation

3.5 years

18 years

N/A

Social Responsiveness Scale-2

83T

72T

56T (spouse-report)

Depression and Anxiety

Yes

Yes

No

Seizure history

No

No

No

Developmental delay

Yes

No

No

Eye contact

Poor

Fair

Good

Repetitive behavior

Yes

No

No

Abnormal sensory sensitivities

Yes

No

No

IQ

65

102 (Raven)

108 (Raven)

Speech delay

Yes

No

No

Severe

Moderate

No

Yes

No

No

GPD2

GPD2

GPD2

chr2:157352686
(hg19) G>A

chr2:157352686
(hg19) G>A

chr2:157352686
(hg19) G>A

p.G78E, c.233G>A

p.G78E, c.233G>A

p.G78E, c.233G>A

ASD
Intellectual Disability

Mutation location
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Chapter 5: Regulation of human cortical
interneuron development by the chromatin
remodeling protein CHD2
This chapter is adapted from an original research article in preparation for publication:
Lewis, E. M. A., Antony, I., Kaushik, K., Meganathan, K., Narasimhan, M., Gontarz, P., Zhang,
B., & Kroll, K. L. (2021). Regulation of human cortical interneuron development by the
chromatin remodeling protein CHD2. In Preparation.
Contributions: EMAL and KLK designed the study. EMAL carried out all experimental work,
except KK performed ATAC-seq and western blot experiments, and KM performed
differentiation experiments to obtain material for ChIP-seq of WT samples. PG and BZ
performed bioinformatic analysis on all data. EMAL, KLK, NM, and IA analyzed the data.
EMAL wrote the manuscript and KLK edited it.
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5.1 Abstract and keywords
Mutations in the gene encoding the chromatin remodeling protein CHD2 have been strongly
associated with neurodevelopmental disorders (NDDs), including epileptic encephalopathies,
intellectual disability, and autism spectrum disorder. However, the requirements for and
mechanisms by which CHD2 controls normal brain development, and how these may be disrupted
by pathogenic CHD2 mutations to cause NDDs, remained largely uncharacterized. To begin to
identify these roles and mechanisms, we used differentiation of human embryonic stem cells
(hESCs) to model the specification and development of human cortical interneurons (hcINs).
Altered development of these cortical inhibitory neurons is implicated in the etiology of many
NDDs, although the basis of this dysregulation remains largely uncharacterized in human models
of NDDs. Here, we identified putative regulatory regions to which CHD2 binds during hcIN
differentiation, examined the identity and expression of genes associated with these regions,
suggested potential transcription factor (TF) co-regulators, and studied the chromatin state of these
regions. We also created an hESC model of CHD2 haploinsufficiency and studied the
transcriptomic and epigenetic consequences of its loss in multiple stages of hcIN differentiation.
This work found evidence that CHD2 plays a role in the maintenance of the expression of
morphogenesis and cell cycle-associated genes during the specification of hESCs to hcIN
progenitors. As CHD2 occupancy is lost from putative regulatory regions associated with these
genes, the repressive chromatin mark H3K27me3 accumulates. We also show a role for CHD2 in
promoting the expression of genes associated with neurogenesis and neuronal function via stagespecific binding of putative regulatory elements. This is at least in part due to association with
active putative enhancers, marked by H3K27ac, likely alongside stage-specific TFs. These roles
for CHD2 throughout different stages of hcIN development may help to explain how a wide variety
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of pathogenic CHD2 mutations cause NDDs, as there are many opportunities for perturbations in
these CHD2-associated regulatory events.
Keywords: CHD2, epigenetic regulation, human cortical interneurons, pluripotent stem cells,
differentiation, autism, epilepsy.

5.2 Introduction
Transcription factors (TFs) and chromatin modifying proteins act together to control the gene
regulatory networks that underlie developmental processes, including specification and
differentiation of multiple neuronal cell types in the developing brain. Disruptions in the
development of the cerebral cortex can contribute to the etiology of neurodevelopmental disorders
(NDDs), including autism spectrum disorder (ASD) and epileptic encephalopathies, the latter of
which are a group of pediatric onset epilepsies with poor prognoses (Lamar & Carvill, 2018;
Rubenstein, 2011; Thomas et al., 2015). Many of these disorders arise, at least in part, from altered
development of excitatory and inhibitory neurons in the cerebral cortex, where GABAergic
cortical interneurons (cINs) and glutamatergic excitatory projection neurons (cExNs) normally
interact to modulate the balance of excitatory and inhibitory neuronal activities to enable proper
cortical function (Arber & Li, 2013; Culotta & Penzes, 2020; Xu et al., 2004). Mutations in genes
encoding chromatin modifying proteins are over-represented among pathogenic contributors to
NDDs, further demonstrating a requirement for the activities of this class of proteins for normal
brain development and function (LaSalle, 2013; Lewis & Kroll, 2018; Mossink et al., 2020).
Studies in the mouse have provided insight into many aspects of cIN development (Batista-Brito
et al., 2009; Du et al., 2008; Letinic et al., 2002; Long et al., 2009; Nóbrega-Pereira et al., 2008;
Sandberg et al., 2016; Sussel et al., 1999; Y. Wang et al., 2010; Xu et al., 2004). However, many
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aspects of these developmental programs appear to differ between rodents and humans, while the
transcriptional and epigenetic regulatory networks underlying this process remain largely
undefined, particularly in humans, due to a lack of access to and inability to experimentally
manipulate human fetal brain materials.

Cortical interneurons are specified from the eighth post-conception week of human fetal
development, with the majority deriving from a transient progenitor region of the ventral forebrain
called the medial ganglionic eminence (MGE). After specification and differentiation, cINs
migrate tangentially to establish synaptic circuits with excitatory neurons in the cortex. Studies in
the mouse identified the TF NKX2-1 as being required for both regional specification of the ventral
telencephalon (specifically the MGE) and for the later production of certain cIN subtypes (Du et
al., 2008; Nóbrega-Pereira et al., 2008; Sandberg et al., 2016; Sussel et al., 1999). Since NKX2-1
also exhibits MGE-enriched expression during human brain development, in recent work we
identified NKX2-1-bound genomic locations in MGE-like progenitors (hMGEs), using a human
embryonic stem cell (hESC)-based in vitro model of human cIN (hcIN) specification and
differentiation (Meganathan et al., 2017). Among the direct targets of NKX2-1 that are mutated to
cause NDDs, we identified the gene encoding the chromatin remodeler CHD2 (Meganathan et al.,
2017). Pathogenic CHD2 mutations are associated with epileptic encephalopathies, ASD, and
intellectual disability (ID), which is transmitted in an autosomal dominant manner, with affected
individuals heterozygous for a pathogenic CHD2 mutation manifesting these conditions (Carvill
et al., 2013; Chénier et al., 2014; Lamar & Carvill, 2018; Wilson et al., 2021). However, the
mechanism by which CHD2 regulates hcIN development remained unknown.
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CHD2 is part of the nine-member chromodomain helicase DNA-binding (CHD) family of
chromatin remodeling proteins. Most of these CHD proteins are known to play critical roles during
developmental processes, while mutations in several CHD family members result in human
diseases, including NDDs (Marfella & Imbalzano, 2007; Wilson et al., 2021). CHD proteins all
contain chromodomains, which can mediate association with chromatin, as well as ATP-dependent
helicase domains, which can remodel nucleosomes, while CHD1 and CHD2 also contain domains
for direct binding to DNA (Micucci et al., 2015; Wilson et al., 2021). CHD2 has been studied in
several developmental contexts, primarily in mouse animal or cellular models. Although a few
CHD2 deficient mouse models display neurological phenotypes and demonstrate evidence of
abnormal neural development, none recapitulate the human epilepsy phenotype (Y. J. Kim et al.,
2018; T. Shen et al., 2015). Moreover, many mouse models do not produce any neurological
abnormalities and instead display spinal, blood, and renal abnormalities (Kulkarni et al., 2008;
Lamar & Carvill, 2018; Marfella et al., 2006; Nagarajan et al., 2009). Several studies have
suggested that CHD2 co-binds the genome together with cell type-specific TFs, including MyoD
during myocyte differentiation (Harada et al., 2012), NKX2-1 during hMGE specification
(Meganathan et al., 2017), or OCT3/4 in mouse ESCs (mESCs) (Semba et al., 2017). CHD2 also
enhances deposition of the variant histone H3.3, which is associated with hyperdynamic chromatin
enrichment at the promoter of genes that regulate cell-type specific developmental programs
(Harada et al., 2012; Semba et al., 2017; T. Shen et al., 2015; Siggens et al., 2015), and is generally
associated with poised or active histone modifications and gene expression (Semba et al., 2017;
Siggens et al., 2015). Varied neurological phenotypes have been observed in mouse and human
models of CHD2 deficiency, demonstrating a diversity of potential downstream consequences of
CHD2 loss or reduction, depending on the cell type, as well as nature and developmental timing
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of the gene manipulation that was involved. For example, in an shRNA-based model of Chd2
knockdown (KD) in the developing mouse cortex from embryonic days 12-18, Pax6+ radial glia in
the ventricular/sub-ventricular zone prematurely differentiated into Tbr1+ intermediate progenitors
and then into Tuj1+ neurons (T. Shen et al., 2015). A Chd2+/- mouse model also exhibited decreased
proliferation of neural progenitor cells, including MGE progenitors, during forebrain development,
which was accompanied by altered gene expression and electrophysiological properties, although
these mice did not suffer from spontaneous seizures (Y. J. Kim et al., 2018). Our previous work
showed delayed differentiation of hcINs following either shRNA-based knockdown of CHD2 or
CRISPR-based biallelic CHD2 knockout (KO), with these hcINs exhibiting subsequent
electrophysiological abnormalities, while cExNs displayed no electrophysiological abnormalities
(Meganathan et al., 2017). CRISPR-dCas9 (CRISPRi)-mediated knockdown of CHD2 during
rapid differentiation of LUHMES midbrain-derived neural progenitors into dopaminergic neurons
resulted in reduced cell proliferation but no significant difference in neurite extension, a hallmark
of neuronal differentiation (Lalli et al., 2020). Finally, in addition to roles in regulating chromatin
state to control gene expression, CHD2 has also been shown to modulate DNA damage repair via
expansion of chromatin (i.e. increased nucleosome spacing) and interaction with PARP1,
potentially via H3.3 assembly (Luijsterburg et al., 2016).

Building upon these studies, we sought to further elucidate the role of and mechanisms by which
CHD2 regulates hcIN development by defining the genomic locations bound by CHD2 during
hESC specification into hMGEs and subsequent hcIN differentiation, as well as examining
corresponding changes in chromatin state at these regions during specification and differentiation.
We also manipulated CHD2 expression, creating a line with heterozygous CHD2 mutation, which
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mimics the haploinsufficiency seen in many patients heterozygous for pathogenic CHD2 mutation
or deletion. This work revealed cis-sequence features underlying CHD2 binding sites, chromatin
state changes that occurred at these locations during differentiation, and identified key aspects of
these developmental programs that were disrupted by CHD2 haploinsufficiency. Together, we
demonstrated that CHD2 associates with active putative regulatory elements associated with genes
required for early aspects of hcIN development, such as progenitor proliferation, as well as those
required for hMGE specification and hcIN maturation. This suggests that CHD2 may have
multiple stage-specific roles during hcIN development and helps to explain how the gene is among
those least tolerant to variation (Thomas et al., 2015), as there are likely many paths for pathogenic
CHD2 variation or deletion to disrupt hcIN development.

5.3 Methods
5.3.1 Construction of the CHD2+/- hESC line for modeling of CHD2
haploinsufficiency
The heterozygous mutant (CHD2+/-) hESC line was constructed by CRISPR-based gene disruption
in wild type (WT) H9 hESCs using our previously described approaches (Meganathan et al., 2017).
Here, a different clone from the same CRISPR disruption experiment as was used in our previous
work was selected for study. Heterozygous CHD2 mutation was validated by Sanger sequencing
and the WT and CHD2+/- hESC lines were shown to be karyotypically normal, with testing
conducted by the Washington University School of Medicine Cytogenetics and Molecular
Pathology Laboratory, as described below. The production of ~30% of WT CHD2 protein levels
by this model was confirmed by western blotting, as described below.
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5.3.2 hESC maintenance and differentiation
H9 hESCs (WT and CHD2+/-) were maintained under feeder-free conditions on Matrigel (Corning)
in mTeSR1 (STEMCELL Technologies). Specification of hESCs as MGE progenitors (hMGEs)
and differentiation into hcINs was performed using our previously described protocol
(Meganathan et al., 2017). Briefly, hESCs were dissociated with Accutase (Life Technologies)
and 40,000 cells per well were added to V-bottom 96-well non-adherent plates (Corning). On day
0 of differentiation, to generate embryoid bodies (EBs), plates were spun at 200xg for 5 minutes
and were incubated in 5% CO2 at 37°C in hcIN differentiation media. This media contained
Neurobasal-A (Life Technologies), 1X B-27 supplement (without Vitamin A) (Life Technologies),
10µM SB-431542 (Tocris Biosciences), 100nM LDN-193189 (Tocris Biosciences), 1µM
Purmorphamine (Calbiochem), and 2µM XAV-939 (Tocris Biosciences). For the first 8 days of
differentiation, media also contained 10µM Y-27632 (Tocris Biosciences). On day 4 of
differentiation, EBs were picked and placed in non-adherent plates on an orbital shaker set to
80rpm. On day 10 of differentiation, EBs were plated onto Matrigel- and laminin- (5µg/mL;
Sigma) coated plates. From day 15 of differentiation (e.g. following specification of hMGE
progenitors), SB-431542, LDN-193189, and XAV-939 were removed from the differentiation
media. From day 27-31, DAPT (10µM; Tocris Biosciences), ascorbic acid (200µM; Sigma), and
BDNF (20ng; PeproTech) were added to the media, and from day 31-35, DAPT was replaced with
cAMP (200µM; Sigma). Cells were harvested on day 0 (hESCs), 15 (hMGEs) and 35 (hcINs) for
assays, including RNA-sequencing (RNA-seq), ChIP-seq, CUT&Tag, and ATAC-seq. On day 0
and 15, hESCs and hMGEs, respectively, were harvested by dissociation with Accutase, and on
day 35, Neural Rosette Selection reagent (STEMCELL Technologies) was used to lift maturing
hcINs from the plates, followed by dissociation with Accutase.
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5.3.3 CUT&Tag
CUT&Tag (H. S. Kaya-Okur et al., 2019) was performed on WT hESCs (day 0), hMGEs (day 15),
and hcINs (day 35) for CHD2 and H3K27me3. The protocols.io V.2. protocol (H. Kaya-Okur,
2019) was followed, using 200,000 cells per sample. The protein A-Tn5 fusion protein (pA-Tn5)
was provided by the laboratory of Steve Henikoff and the antibodies used were Sigma MABE873
(Rat anti-CHD2) and Cell Signaling Technology #9733 (Rabbit anti-H3K27me3). Secondary
antibodies used were abcam ab6703 (Rabbit anti-Rat IgG) and Antibodies-Online ABIN101961
(Guinea Pig anti-Rat IgG). Samples with unique dual-end indexes were pooled in equimolar
concentrations and were sequenced by the Washington University Genome Technology Access
Center (GTAC) on the NovaSeq-6000 sequencer with the S4 flow cell as 2x150bp paired-end reads
at a depth of 10 million (M) reads per sample.

Raw reads from CUT&Tag samples were processed by AIAP (v1.1) using human genome hg38
as a reference to perform read quality control, alignment, quantification, and peak calling (S. Liu
et al., 2019). Peaks from replicates were intersected using bedtools intersect peak with options -f
0.25 -F 0.25 -e. Peaks identified as intersecting in 2 or more out of 4 total replicates were defined
as reproducible peaks.

5.3.4 ChIP-seq
ChIP-seq was performed on WT hESCs (day 0), hMGEs (day 15), and hcINs (day 35) for H3K27ac
and H3K4me3, as described previously (Meganathan et al., 2017). The antibodies used were
Millipore 07-360 (Rabbit anti-H3K27ac) and Millipore 07-473 (Rabbit anti-H3K4me3). Library
preparation and sequencing were performed by the GTAC using the HiSeq3000 sequencer to
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obtain at least 30 M single end 50 base pair reads per sample. ChIP-seq data analysis was
performed as described previously (Meganathan et al., 2017).

5.3.5 RNA-seq
For comparison of gene expression in WT and CHD2+/- cells during hcIN differentiation, RNA
was collected from hMGEs (day 15) and hcINs (day 35) from 2-4 biological replicate experiments
per sample type, with WT and CHD2+/- cells differentiated in parallel to generate each biological
replicate dataset. RNA was collected and quantified as previously described (Lewis et al., 2019).
RNA-seq library preparation and Illumina sequencing was performed by the GTAC using the
SMARTer Ultra Low RNA kit (Takara-Clontech) per the manufacturer’s instructions. Paired-end
150 base pair reads were obtained using an Illumina NovaSeq-6000 sequencer with the S4 flow
cell, to a depth of ~30 M reads per sample. The transcriptomic data and epigenomic data obtained
here was also compared with datasets obtained in our previous work (Meganathan et al., 2017)
that describes transcriptomic changes accompanying differentiation from hESCs (day 0), to EBs
(specified neuroectoderm, day 4), to hMGE progenitors (day 15), during early hcIN differentiation
(day 25), and during later hcIN differentiation and maturation (day 35).

Raw reads from RNA-seq samples were quality trimmed using cutadapt (v2.4) with options -quality-cutoff=15,10 --minimum-length=36 (M. Martin, 2011). Reads were aligned using STAR
(v2.5.4b) using human genome hg38 as a reference with gencode V27 annotations (Dobin et al.,
2013). Reads were quantified at the gene level using featureCounts (v1.6.4) from the subread
package (Liao et al., 2013). For differential expression analysis, gene-level quantification from
featureCounts were normalized to counts per million (CPM) using the CPM function in edgeR in
R (v3.6) (Robinson et al., 2010). Genes with expression under 1 CPM in more than half of the
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samples compared were excluded from analysis. Differential expression analysis was performed
with DESeq2 in negative binomial mode using counts for genes that passed the 1 CPM cutoff
(Love et al., 2014). A 2-fold expression change, expression higher than 1 CPM, and a Benjamini
and Hochberg false discovery rate of less than 0.05 were set as cutoff values for a gene to
considered differentially expressed.

5.3.6 ATAC-seq
ATAC-seq (Buenrostro et al., 2015; Corces et al., 2017) was performed on WT and CHD2+/hESCs (day 0), hMGEs (day 15), and hcINs (day 35). These samples were obtained from the same
differentiation experiments as the WT versus CHD2+/- RNA-seq samples described above, with 4
independent biological replicates per sample type acquired. The Omni-ATAC protocol was
followed (Corces et al., 2017). Samples with unique dual-end indexes were pooled in equimolar
concentrations and were sequenced by the GTAC on the NovaSeq-6000 sequencer with the S4
flow cell and 2x150bp reads at a depth of 40 M reads per sample. Raw reads were processed as
described above for CUT&Tag samples.

To define differentially accessible regions, the previously defined reproducible peak sets from the
experimental conditions being compared were first merged using the bedtools merge function.
Signal density under these peaks in each replicate was quantified using the bedtools coverage
function with option -counts and the open bed file was generated by AIAP. Counts under ATACseq peaks were then processed in the same manner as RNA-seq differential expression analysis,
with the exception that the false discovery rate was set at 0.01 and 1.5x fold change in accessibility
were used to define differentially accessible regions.
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5.3.7 Annotation and motif analysis of ATAC-seq and CUT&Tag peak sets
ATAC-seq and CUT&Tag peak sets were annotated using the annotatePeaks.pl function in
HOMER2 using human reference hg38 and gencode V27 annotation (Heinz et al., 2010). Genes
and genomic region annotations associated with peaks were defined using calls based on the
nearest transcription start site (TSS) by HOMER. Promoter peaks were redefined from HOMER’s
default to 2kb around the TSS, and proximal enhancer peaks were defined as being more than 2kb
and up to 20kb from the TSS. Motif analysis was performed using the findMotifsGenome.pl
function within HOMER2 with hg38 as reference and option -size given. HOMER de novo motifs
were used for downstream analysis.

5.3.8 deepTools and heatmap visualizations
Representative signal density bigwig files chosen at random from the replicates and normalized to
a depth of 10 M reads by AIAP were used for visualizations with deepTools (v3.5.0) (Ramírez et
al., 2016). The deepTools signal matrix was generated using selected peaksets by the
computeMatrix function in reference-point mode with options -a 2500 -b 2500 -bs 50 -missingDataAsZero --referencePoint center. Plots were generated using the plotHeatmap function
with options -zMin 0 -zMax 60 -yMin 0 -yMax 60 for uniform signal density scaling.

Heatmaps were created using ClustVis (Metsalu & Vilo, 2015), with rows centered and unit
variance scaling applied to rows. Rows were clustered using correlation distance and average
linkage.
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5.4 Results
5.4.1 CHD2 binding during hcIN differentiation
To understand how CHD2 might regulate hcIN differentiation, we assessed its genome-wide
binding profile at day 0 (in hESCs), day 15 (in hMGEs), and day 35 (in hcINs) (Figure 1A; Table
S1), observing significantly more peaks in hESCs (43,463), by comparison with hMGEs (20,364),
or hcINs (18,468) (Figure 1B). To assess how CHD2 peak locations changed during hcIN
specification and differentiation, peaks were divided into those that were unique to one time point,
or that were present (shared) at two or more time points. Almost half of all hESC peaks (26,982)
were unique to this time point. A significant number of peaks (11,445) were shared between all
three cell states profiled, while smaller numbers of peaks were unique to hMGEs (4,740) or hcINs
(3,106) (Figure 1B). These peaks may be associated with roles that CHD2 performs specifically
during hMGE specification or hcIN differentiation.

Since regulatory proteins often bind at both promoter-proximal and distal regulatory elements, we
next investigated the genomic annotations of CHD2-bound regions in hESCs, hMGEs, and hcINs.
During specification and differentiation, CHD2 bound peaks were present proximal to the
promoter with increased frequency (Figure 1C, S1A). A significant fraction of CHD2-bound peaks
were also in intergenic or intronic locations, some of which may overlap cis-regulatory elements
(CREs). This suggests that CHD2 binding across the genome in hESCs may be located at a variety
of different types of regulatory elements, while becoming more enriched at promoter-proximal
locations as differentiation occurs. Interestingly, among peaks that were bound by CHD2 in a
stage-specific manner (i.e. unique to hESCs, hMGEs, or hcINs), a smaller fraction were promoter-
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proximal, by comparison with shared CHD2 peaks that were present at more than one time point
(Figure S1B). However, these uniquely bound promoter-proximal regions may still have important
gene regulatory activities during hcIN differentiation. For example, the pluripotency- and early
neural progenitor cell-associated gene POU5F1 (Okuda et al., 2004) has a promoter-proximal peak
unique to hESCs and accordingly is most highly expressed in hESCs (Figure 1D). The cell
adhesion, neural development, and autism-associated gene NRCAM (Sakurai, 2012) is bound by
CHD2 in hMGEs and hcINs, but not hESCs, corresponding with the timepoints when this gene is
expressed (Figure 1D). Likewise, the gene encoding the brain-specific and ASD/ID-implicated TF
MYT1L (Mall et al., 2017) has a CHD2 peak unique to hcINs and is only expressed at this stage
of differentiation (Figure 1D). As a final example, the embryonic and neural stem cell-associated
gene SOX2 (Shuchen Zhang et al., 2019) is expressed at all stages of differentiation and also has
promoter-proximal peaks that are shared across differentiation (Figure 1D). These examples
demonstrate that CHD2 binding occurs dynamically during hcIN differentiation, and support a role
for CHD2 in regulating gene expression during this process.

5.4.2 CHD2 binding in hMGEs and hcINs is associated with genes with
increasing expression during differentiation
We next investigated the expression profile of CHD2-associated genes, hypothesizing that CHD2
might associate with genes with increasing expression during hcIN differentiation. To focus on the
highest-confidence gene-regulatory element associations, we examined CHD2 peaks within 2kb
up- or downstream of the TSS (Table S1). Genes associated with at least one CHD2 peak that was
unique to hESCs had relatively unchanged expression across the course of hcIN differentiation
(Figure 2A; ‘hESC unique’). Conversely, genes with a CHD2-bound peak that was present in
hMGEs and/or hcINs but not in hESCs significantly increased in expression during differentiation
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(Figure 2A; ‘hMGE/hcIN unique’). This trend was also seen when only looking at peaks uniquely
bound in hMGEs (‘hMGE unique’) or those uniquely bound in hcINs (‘hcIN unique’) (Figure
S2A). In contrast, genes associated with peaks bound in hMGEs and/or hcINs (‘hcIN/hMGE’),
many of which were also bound in hESCs, had generally high, but unchanged expression across
differentiation (Figure S2A). This suggests that during hcIN differentiation, CHD2 is associated
with actively expressed genes and genes that gain expression, with this latter group representing
genes that may be involved in hcIN development.

To explore the identity of these CHD2-associated genes, we performed gene enrichment analysis
using the ToppFun tool from the ToppGene suite (Jing Chen et al., 2009). Specifically, genes with
at least one promoter-proximal peak unique to a time point (i.e. hESC, hMGE, or hcIN unique)
were used for analysis, since these genes showed the most dramatic changes in expression across
differentiation. Terms associated with genes with hESC-unique peaks included ‘cell-cell
signaling’ and ‘morphogenesis’ (Figure 2B). By contrast, genes with at least one CHD2-associated
peak that was unique to hMGEs or hcINs were significantly more neuronal in identity (Figure 2C,
D). For example, terms associated with genes with peaks that were unique to hMGEs included
‘neurogenesis’, while terms associated with genes with peaks that were unique to hcINs were
enriched for concepts associated with mature neurons, including ‘transporter activity’, ‘voltagegated cation activity’, and ‘neuron projection development’ (Figure 2C, D). By comparison with
these stage-specific binding events, terms associated with ‘all’ peaks (shared or unique) in hMGEs
or hcINs were not as highly associated with this process (Table S2). This is further evidenced by
comparison of these gene sets to known expression patterns across brain regions and development.
For example, the genes associated with a CHD2 peak unique to hcINs were related to gene
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expression during later brain development, while the peaks bound by CHD2 in both hcINs and at
an earlier stage of differentiation instead overlap expression specific to early brain development
(Figure S2B).

Pathogenic mutation of CHD2 can contribute to NDDs, including ASD and epilepsy, and many
ASD- and epilepsy-associated genes are important for neural development and maturation. We
therefore compared genes bound by CHD2 at each developmental timepoint in our experimental
scheme with known ASD and epilepsy genes. Out of a list of 102 ASD risk-associated genes
(Satterstrom et al., 2020), 53 (52%) were bound by CHD2 at some point during hcIN
differentiation, while many (34) of these genes were bound by CHD2 in hESCs, hMGEs, and
hcINs (Figure 2E; ASD Venn diagram). Most of these genes have low expression in hESCs and
are highly expressed in hcINs, congruent with the fact most ASD-associated genes are involved in
neuronal differentiation or maturation (Figure 2E; ASD heatmap). Out of a list of 536 epilepsyrelated genes (J. Wang et al., 2017), 57 (11%) were bound by CHD2 at some point during hcIN
differentiation, and many (32) of these were likewise CHD2 bound in hESCs, hMGEs, and hcINs
(Figure 2E; Epilepsy).

We next performed network-based analysis of the genes associated with CHD2 peaks unique to
hESCs, hMGEs, or hcINs. To do this, we used the CompBio tool from the PercayAI platform
(PERCAYAI, 2021), using the 1,000 genes with CHD2 binding closest to the TSS (500 genes
upstream and 500 downstream) as input to assess each cell state. The themes output from this
analysis were congruent with the GO terms identified by ToppGene (Table S2), and one
representative high-scoring theme for each stage of differentiation was selected for network
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analysis using ClueGO, a Cytoscape application (Bindea et al., 2009). For hESCs, this theme was
related to intracellular junctions and epithelial identity, and included genes such as MARVELD2/3,
CLDN7/10/19, and CDH1/6 (Figure 3A). For hMGEs, this theme was related to neuroectoderm
development and included genes such as GBX2, SMAD2/4, ZIC1/3, and BMP7 (Figure 3B). For
hcINs, this theme was related to synapses, and included genes such as CHRNA4, SLC17A7,
NPAS4, and CNTN2 (Figure 3C). Together, this indicates that CHD2 may be involved with
maintaining proper expression of genes required for adhesion/maintenance of epithelial character
and cell cycle during the transition from pluripotency through early neural fate acquisition, as well
as those required for later neuronal specification, differentiation, and maturation.

5.4.3 DEGs with increasing expression during differentiation are bound by
CHD2 in hMGEs and hcINs........
To further explore the characteristics of the genes that were associated with CHD2 binding (shared
or unique) during hcIN differentiation, we intersected these promoter-proximal CHD2-bound gene
lists with their profiles of gene expression across the differentiation timeline. Here, we used
transcriptome data generated for four time points (d0 (hESCs), d15 (hMGEs), d25 (early hcINs),
and d35 (later hcINs)) in our prior work (Meganathan et al., 2017), and defined differentially
expressed genes (DEGs) as those with differing expression between any two of these time points
(Table S3). These DEGs were categorized into four patterns; genes where expression trended down
between hESCs and hMGEs, as well as hMGEs and hcINs (‘down_down’), down between hESCs
and hMGEs, but up between hMGEs and hcINs (‘down_up’), up between hESCs and hMGEs, but
down between hMGEs and hcINs (‘up_down’), and up between hESCs and hMGEs, as well as
hMGEs and hcINs (‘up_up) (Figure S3A). As expected, genes within each category were
associated with terms related to the cell types in which these genes are most highly expressed
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(Figure S3B-E), with the ‘up_up’ category, for example, involving terms related to ‘synaptic
signaling’ and ‘voltage-gated ion channel activity’, hallmarks of neurons (Figure S3E).

We first chose to intersect these DEGs with genes with at least one promoter-proximal CHD2 peak
(+/- 2kb of TSS) that were unique to a particular cell type (hESCs, hMGEs, or hcINs), since these
genes showed the most dramatic changes in expression across the differentiation timeline
compared to all peaks for a particular cell type (Figure 2A versus S2A). Indeed, ‘up_up’ genes
comprised almost double the percentage of DEGs that were bound uniquely by CHD2 in hcINs,
by comparison with the peak set bound uniquely in hESCs (Figure 4A). This is consistent with the
observation that CHD2-bound genes within the ‘hcIN unique’ peak category were highly
expressed in hcINs, especially when compared to their expression in hESCs (Figure S2A). As a
comparison to these stage-specific (unique) CHD2 binding events, we also intersected these DEGs
with genes with at least one promoter-proximal peak in each cell type, including peaks shared
between multiple cell types. By contrast with the stage-specific binding, which enriched for
particular expression profiles (Figure 4A), expression profiles for genes associated with these nonstage-specific peaks were similar and were not enriched for a particular expression trend (Figure.
S4A).

Unsurprisingly, DEGs within each expression pattern (‘down_down’, ‘down_up’, ‘up_down’, and
‘up_up’) included genes with unique CHD2 binding events for each cell stage (hESCs, hMGEs,
and hcINs). This is reflective of the dynamic process of differentiation, involving many changes
in gene expression and layered regulatory events, many of which CHD2 may play a part in. We
hypothesized that expression changes within the ‘up_up’ category might not be as dramatic for the
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genes associated with an hESC-specific CHD2 binding event, compared to those associated with
a binding event unique to hMGEs or hcINs. This was indeed the case, with trends based on overall
fold-change (Figure 4B, C, left; S4B, left), as well as RPKM values (Figure S4C, left) supporting
this hypothesis, particularly for gene expression differences between hESCs and hMGEs.
Similarly, we hypothesized that the expression changes within the ‘down_up’ category might be
the most dramatic for the hESC unique peak-associated genes between hESC and hMGE stage.
The hypothesized trend was observed, based on overall fold-change (Figure 4B, C, right; S4B,
right), as well as RPKM values (Figure S4C, right). Interestingly this ‘down_up’ category
comprised the largest percentage of genes associated with peaks with CHD2 binding unique to
hESCs.

We next investigated the identity of the genes within these two contrasting categories of CHD2
bound genes with differential expression profiles (hESC unique ‘down_up’ and hcIN unique
‘up_up’). Genes with a peak bound uniquely by CHD2 in hESCs with a ‘down_up’ expression
profile include CDH1, which is involved in adhesion in stem and early embryonic cells (Soncin &
Ward, 2011) and in cell cycle regulation during corticogenesis (Delgado-Esteban et al., 2013), and
TGDF1 and ZFP42, which are involved in pluripotency (Boroviak et al., 2018; Scotland et al.,
2009). These genes have high expression in hESCs, with expression dramatically reduced by
hMGE stage and only modestly increased in hcINs (Figure 4D). By comparison, examples of hcIN
uniquely CHD2-bound ‘up_up’ genes include those encoding NPAS4, which is involved in the
homeostatic regulation of excitatory-inhibitory balance (Fu et al., 2020), MAP2, a microtubuleassociated protein expressed in neuronal dendrites (DeGiosio et al., 2019), and KCNQ2, a
potassium channel subunit, which when mutated is associated with NDDs including epilepsy
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(Dirkx et al., 2020). Expression of these genes significantly increases by hMGE stage, and further
increases in hcINs (Figure 4E). This suggests that CHD2 might regulate genes required both for
earlier hMGE specification and neurogenesis, and those which are not required until the later
processes of hcIN differentiation and maturation.

5.4.4 CHD2 peaks in hMGEs and hcINs contain binding motifs for TFs
associated with hcIN development
Since CHD2 can co-regulate gene expression with cell type-specific TFs (Harada et al., 2012;
Meganathan et al., 2017; Semba et al., 2017), we next explored the sequence enrichment for TF
binding sites (TFBS) under CHD2 peaks. These could suggest classes of TFs that may utilize
CHD2 to regulate gene expression during hcIN differentiation. HOMER motif analysis was
performed on sequences under CHD2 peaks in hESCs, hMGEs, and hcINs, both for peaks unique
to each cell type, as well as all peaks for each. As for prior analyses, we chose to focus on predicted
unique peaks, as these may represent regulatory elements specific to a specific aspect of hcIN
differentiation. However, there was considerable overlap in the TFs and TF classes that were
predicted to bind ‘all’ and ‘unique’ peaks in each cell type (Table S4), which may reflect the fact
that the ‘unique’ peaks are contained within the ‘all’ peak list for each cell type. In both hMGEs
and hcINs, homeodomain (HD) and high-mobility group (HMG)/SOX class TFBS motifs were
enriched (Figure 5A). Proteins in both of these classes of TF are known to play important roles in
cIN development, including the HD TF, NKX2-1 (Meganathan et al., 2017). At the hESC stage, a
number of different TF classes were represented under CHD2 peaks, including zinc finger (ZF)
and basic helix-loop-helix (bHLH) class TFBS motifs (Figure 5A).
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Although the analysis above predicted enriched TFBS motifs and classes of TFs that might bind
these motifs, motifs often exhibit substantial redundancy such that they may be bound by multiple
TFs, particularly within a class. Therefore, further analysis of expression of TFs within each class
allows us to better predict which factors may act alongside CHD2 during hcIN differentiation. We
first identified all known human TFs with expression in hMGEs and/or hcINs, but with low
expression in hESCs (Figure 5B; S5A). Subsets of these TFs are shown in Figure 5C, and
encompass many HD and SOX TFs with known roles in neurogenesis, including in hcIN
development. Some genes encoding these TFs have the highest expression in hMGEs, such as
NKX2-1 and SIX3/6, whereas others are most highly expressed in hcINs, such as DLX1/2/5/6.
These TFs might therefore mainly associate with CHD2-bound putative regulatory elements earlier
and later in hcIN differentiation, respectively. Transcription factors from other classes with
predicted binding motifs under CHD2 peaks were also investigated, and a number of these also
are interesting candidate factors, including MYT1L (zinc finger; ZF), ASCL1 (basic helix-loophelix; bHLH), and FOXG1 (Forkhead) (Figure S5B).

Since in our prior work we identified NKX2-1-bound genomic regions in hMGEs and a role for
CHD2 in NKX2-1-mediated target gene transactivation, we intersected NKX2-1-bound regions
with those associated with CHD2. We found a modest number of regions bound by both proteins
(819/20,364 or 4% of hMGE CHD2-bound regions). However, several interesting genes may be
co-regulated by these factors, including CHD2 and the gene encoding the potassium channel
subunit KCNB1 (Figure S5C). Pathogenic mutations in both of these genes is associated with
epilepsy (J. Wang et al., 2017). It is particularly interesting that CHD2 appears to auto-regulate its
own expression, as this could compound the effects of pathogenic mutation in CHD2.
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5.4.5 CHD2 binding is associated with an active chromatin state in
differentiating hcINs
After determining that CHD2 is generally associated with genes with increasing expression during
hcIN differentiation, we next wanted to assess the chromatin state of these putative regulatory
elements. Since CHD2 has been shown to associate with poised or active chromatin (Semba et al.,
2017; Siggens et al., 2015), we chose to investigate three histone modifications associated with
establishing these states (H3K4me3 for active/bivalent promoters, H3K27me3 for repressed
chromatin/bivalent promoters, and H3K27ac for active enhancers). By striking comparison with
the chromatin state in hESCs, CHD2-bound, promoter-proximal (+/- 2kb from TSS) regions
exhibited increased H3K27ac co-enrichment during hMGE specification and hcIN differentiation
(Figure 6A; S6A; Table S5). The peak subset that bound CHD2 in hMGEs and/or hcINs but not
in hESCs showed the most pronounced co-enrichment of CHD2 binding and H3K27ac.
Correspondingly, most genes associated with this subset of CHD2-bound peaks were expressed at
the lowest level in hESCs, and had the highest expression in hcINs (Figure 6B).

We next analyzed the chromatin state of all peaks (not just promoter-proximal) bound by CHD2
either uniquely in hESCs (‘hESC unique’; Figure 6C, left) or in hMGEs and/or hcINs but not
hESCs (‘hMGE/hcIN unique’; Figure 6C, right). Chromatin state differences between these peak
subsets were evident. Peaks uniquely bound by CHD2 in hESCs were most highly enriched for
active histone modifications (H3K27ac/H3K4me3) in hESCs (Figure 6C, left; yellow bars), while
peaks bound uniquely by CHD2 in hMGEs/hcINs co-enriched predominantly for H3K27ac during
differentiation (Figure 6C, right; blue, red, and purple bars). Assessment of all CHD2-bound peaks
(rather than just the uniquely bound CHD2 peaks) in hESCs, hMGEs, or hcINs yielded similar
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results (Figure S6B): CHD2-bound peaks in hESCs co-enriched for H3K27ac and H3K4me3 in
hESCs, while CHD2-bound peaks in hMGEs and hcINs co-enriched for H3K27ac in hMGEs and
hcINs. However, for all three classes of CHD2 binding here (in hESCs, hMGEs, or hcINs), a larger
portion of the active histone marks studied (H3K4me3 and H3K27ac) co-enriched with CHD2
across all three cell stages (Figure S6B; grey bars), compared to the CHD2 peaks only bound in
hESCs or hMGEs/hcINs. These findings support a model where CHD2 binds to active putative
regulatory elements and could contribute to maintaining an open chromatin state at these sites. By
comparison with all CHD2 bound peaks at each time point, these trends were stronger for peaks
that were uniquely bound by CHD2 at a particular timepoint versus all bound peaks for that
timepoint (Figure 6A, 6C versus S6A, S6B), further demonstrating the connection between CHD2
and active putative enhancers during hcIN differentiation.

Interestingly, some regions that were CHD2 bound in hESCs gained the H3K27me3 mark as
hMGE specification and hcIN differentiation occurred (Figure 6A; S6A; Table S5). This trend was
more pronounced among the CHD2 peaks that were uniquely bound in hESCs, with many of these
peaks gaining H3K27me3 in hMGEs and/or hcINs (Figure 6A; top). Given the observed presence
of both H3K27me3 and H3K4me3 at CHD2-bound regions during hcIN differentiation, we next
assessed whether any of these CHD2 peaks co-enriched for both H3K27me3 and H3K4me3 to
create a bivalent/poised chromatin state. In general, most CHD2 peaks that gained co-enrichment
for the H3K27me3 mark during hMGE specification and hcIN differentiation were already coenriched for H3K4me3 in hESCs, since a large portion of H3K4me3 peaks that co-enriched with
CHD2 (at any stage) were present during all stages of differentiation (Figure 6C; S6B; grey bars).
Specifically, of the 1,319 hESC-unique CHD2 peaks that gained H3K27me3 in hESCs and hcINs,
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and also had H3K4me3 at either of these stages (i.e. were called as bivalent), 1,290 (98%) were
already marked by H3K4me3 in hESCs. Unsurprisingly, more (and a higher percentage of) peaks
uniquely bound by CHD2 in hESCs were predicted as bivalent compared to those that were
uniquely bound by CHD2 in hMGEs and/or hcINs, as a much larger number of peaks in the former
category were predicted to have the H3K4me3 and H3K27me3 mark (Figure 6C; left versus right).
In contrast, the majority of these hMGE/hcIN unique CHD2 peaks co-enriched for H3K27ac only
(Figure 6C; right). This suggests that the presence of the ‘bivalent’ histone marks in this case (for
peaks bound by CHD2 at any stage) is actually reflective of a transition from active to repressive
chromatin, rather than the creation of new poised regions. Analysis of this breakdown of CHD2
binding and histone modification state for ‘all’ peaks in hESCs, hMGEs, and hcINs revealed
similar trends, however there was a higher percentage of H3K4me3 occupancy at all three stages
of differentiation for all sets of these CHD2 peaks, suggestive that many of these genes remain
active (Figure S6B; grey bars). Taken together, this histone modification state data suggests that
during hcIN differentiation, CHD2 is present in hESCs at regions associated with active chromatin
(marked by H3K27ac/H3K4me3) that will acquire the repressive H3K27me3 mark or maintain the
active H3K4me3 mark, and is present in hMGEs and hcINs at regions that acquire the active
enhancer mark, H3K27ac.

We next looked at the identity of genes associated with these different patterns of CHD2 binding
and co-enriched histone modifications: (1) uniquely bound by CHD2 in hESCs and H3K27me3
gained during differentiation, (2) CHD2-bound in hESCs (unique or shared) and H3K4me3
maintained during differentiation, and (3) uniquely bound by CHD2 in hMGEs and/or hcINs and
H3K27ac gained during differentiation. Examples of the first group (CHD2-bound peaks unique
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to hESCs with H3K27me3 co-enrichment at the peak during differentiation) included GLI1/2/3,
ZIC1/2/3/5, SP8, FOXB1, and FOXA3, many of which are involved in early neural specification
and have increased expression or expression at the highest levels by the time of neuroectoderm
specification (day 4 of differentiation) (Table S5). Examples of genes bound by CHD2 in hESCs
which maintain co-enrichment for H3K4me3 during differentiation include ACTB, GOLPH3,
ENO1, and GAPDH, which are all expressed in most cell types and required for normal cellular
function (Table S5). Examples of genes with peaks uniquely bound by CHD2 in hMGEs and/or
hcINs that gained H3K27ac co-enrichment during hMGE specification include NKX2-1, SETBP1,
and VAX1 (Figure S6C), and those which gained H3K27ac co-enrichment during hcIN
differentiation include CLSTN3, MAP1B, and L1CAM (Figure S6D). These genes have known
roles in cortical development, with the former subset required for earlier aspects of neural
progenitor specification, and the latter subset primarily involved in axon guidance and outgrowth.
Taken together, these data suggest that CHD2 plays a role in ensuring that genes are properly
expressed during hcIN development primarily by association with active chromatin, both during
pluripotency exit and induction of neuroectoderm, as well as during hMGE specification and hcIN
differentiation and maturation.

5.4.6 CHD2 haploinsufficiency results in accelerated early cell fate
acquisition and premature neurogenesis
To further attempt to understand the role of CHD2 during hcIN differentiation, we assessed how
heterozygous loss of CHD2 function affected gene expression and chromatin state during hMGE
specification and hcIN differentiation. For this work, we derived an hESC line with mono-allelic
disruption of CHD2, which mimics the genetics of human subjects carrying pathogenic CHD2
mutations, which exhibit autosomal dominant genetics in the heterozygous state, likely due to
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CHD2 haploinsufficiency (Chénier et al., 2014; Lamar & Carvill, 2018, 2018). The single guide
RNA (sgRNA) used here targeted the third exon of CHD2 and created a mutant CHD2 allele with
a two base-pair frameshift, predicted to result in a premature stop codon and a severely shortened
protein (88 amino acids in the mutant versus 1,829 in the WT protein and containing no known
CHD2 functional domains; Figure S7A). Western blot analysis indicated that CHD2 protein levels
in the CHD2+/- hESCs were reduced by ~70% (Figure S7B). As has been demonstrated by our
previous work in hESCs (Meganathan et al., 2017) and that of others in mouse ESCs (Semba et
al., 2017), no differences in pluripotency maintenance or cell proliferation were observed in WT
versus mutant (CHD2+/-) hESCs and both cell lines were karyotypically normal (Figure S7C).
While no differences in EB size were observed during early neuroectoderm induction (Figure
S7D), by day 15 of differentiation (hMGE) stage, the plated CHD2+/- EBs appeared less dense and
to contain fewer progenitors than was observed for WT EBs. The plated CHD2+/- EBs likewise
precociously extended neurites, which was not observed for the plated WT EBs (Figure S7D). This
apparently accelerated differentiation seen in the plated CHD2+/- EBs appeared to continue through
day 35 (hcINs), where neurite extension was much more pronounced and denser for the plated
CHD2+/- cells, relative to WT. However, fewer cells were present in the CHD2+/- samples by both
the hMGE and hcIN stage, relative to controls, suggesting that premature progenitor specification,
neurogenesis, and subsequent differentiation may have occurred at the expense of earlier
developmental events (Figure S7D).

Analysis of differential gene expression between mutant (CHD2+/-) and WT hMGEs and hcINs
reflected this imbalance in specification and differentiation (Figure S8A, B). In hMGEs, most
DEGs were lower in the mutant compared to the WT cells (79% lower in the mutant versus 21%

165

higher in the mutant hMGEs). The degree of differential expression (i.e. log2 fold change) was
also larger in the genes with lower expression in the mutant versus the WT hMGEs and hcINs
(Figure 7A, B). Analysis of GO terms (produced by ToppFunn) associated with DEGs with lower
mutant expression in hMGEs showed that they are related to morphogenesis, development, and
adhesion (Figure 7C; Table S6). Further analysis of these hMGE DEGs by the CompBio tool
suggests many are involved in pluripotency and early developmental signaling, such as ZFP42,
LIN28A, FOXA2, and CDH1 (Figure S8C; Table S6). Conversely, DEGs with higher expression
in the CHD2+/- hMGEs included some neuronal channel genes, as well as those associated with a
variety of concepts, including organoids and retinoic acid signaling (Figure 7C; S8C; Table S5).
Examples of these genes include GRIA1/2/4, KCNQ3, and ABAT, which primarily encode proteins
associated with synaptic signaling.

Strikingly, there were many more DEGs in the mutant versus WT comparisons of hcINs (3,539)
than were present in hMGEs (736; Figure 7A, B). Although there remained a slightly higher
percentage of DEGs with lower expression in the mutant hcINs (58%), the split of down- and upregulated DEGs was much more even at this time point (Figure 7A, B). The genes with lower
mutant expression in mutant hcINs were associated with cell division and cell cycle, whereas the
genes with higher expression included many neural genes, including those associated with channel
activity and synapses (Figure 7C). Since a modest number of the hMGE and hcIN DEGs
overlapped, we compared gene expression in WT versus CHD2+/- cells for DEGs at one cell stage
(hMGEs or hcINs) against expression of the same genes in the other cell stage (hMGEs or hcINs),
regardless of whether this gene was determined to be a DEG in this other cell stage. This analysis
allowed us to determine if non-significant changes occurred in expression at one cell stage that

166

then reached significance at another. Specifically, we examined the expression of all DEGs, DEGs
that reached significance in both hMGEs and hcINs, those that reached significance in hMGEs
(showing corresponding expression differences for these genes in hcINs), and those that reached
significance in hcINs (showing corresponding expression differences for these genes in hMGEs;
Figure 7D). Genes with lower expression in the mutant versus WT cells are shown on the left, and
those with higher expression in the mutant versus WT cells are shown on the right (Figure 7D).
Unsurprisingly, the degree of differential expression was highest in both hMGEs and hcINs for
the DEGs shared between these cell stages (Figure 7D). The DEGs that only reached significance
in the hMGEs had a much lower overall difference in expression between WT and mutant hcINs,
suggesting that these differences might be specific to this earlier stage of hcIN differentiation
(Figure 7D). Similarly, the genes with differential expression between WT and mutant hcINs had
a much more modest difference in expression in hMGEs, although they had begun to trend either
down (left) or up (right) in the mutant versus WT hMGEs (Figure 7D). This suggests that some of
the transcriptional consequences of CHD2 haploinsufficiency may have begun at earlier stages,
but differential gene expression mainly reached significance later in differentiation (i.e. in hcINs).

5.4.7 Epigenetic consequences of CHD2 haploinsufficiency
As CHD2 was predominantly enriched at putative enhancers of neuronal genes with an active
chromatin modification state during hcIN differentiation, we were surprised to observe an
increased expression of these genes in the CHD2+/- hcINs. However, we hypothesized that perhaps
the improper maintenance of open chromatin and/or early silencing of genes required to maintain
a transcriptome compatible with maintenance of the early neuroectodermal and/or neural stem and
progenitor cell states could cause a cascade of downstream regulatory events, prematurely turning
on gene programs required for hcIN differentiation and maturation. Indeed, most DEGs with
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higher expression in the CHD2+/- versus WT hMGEs normally begin to be expressed in hMGEs,
and are expressed most highly in hcINs (Figure 8A, left). By contrast, most DEGs with lower
expression in CHD2+/- versus WT hMGEs are normally expressed at the highest levels in hESCs
and during neuroectoderm induction (days 0-4), with their expression dropping by the time of
hMGE progenitor specification (Figure 8A, right).

To identify which genes that were dysregulated in the CHD2 mutant hMGEs could be direct targets
of CHD2, we identified the subsets that were normally bound by CHD2 during hcIN
differentiation. Many of these dysregulated genes were direct CHD2 targets at least at one time
point: 66% (102/155) of DEGs with higher expression in CHD2+/- versus WT hMGEs were bound
by CHD2 at least once at any time point (corresponding to 374 peaks total), and 82% (478/581) of
DEGs with lower expression in CHD2+/- versus WT hMGEs (corresponding to 1,609 peaks total)
were bound by CHD2 at least at one time point. We assessed which stages of differentiation were
accompanied by CHD2 binding to determine when direct CHD2 regulation could be associated
with differential regulation in the mutant hMGEs. A lower percentage of all CHD2-bound peaks
associated with DEGs with higher expression in CHD2+/- versus WT hMGEs were bound by
CHD2 uniquely in hESCs (47%; Figure 8B, left; yellow bar), compared to the percentage of
CHD2-bound peaks associated with DEGs with lower expression in CHD2+/- versus WT that were
bound uniquely in hESCs (67%; Figure 8B, right; yellow bar). Conversely, a higher percentage of
CHD2-bound peaks associated with DEGs with higher expression in CHD2+/- versus WT hMGEs
were bound in hMGEs and/or hcINs, but not hESCs (32.5%; Figure 8B, left; blue, red, and purple
bars), compared to the percentage of CHD2-bound peaks associated with DEGs with lower
expression in CHD2+/- versus WT that were bound at these stages (12%; Figure 8B, right; blue,
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red, and purple bars). Together, these data suggest that binding of CHD2 to genes in hESCs and
during neuroectoderm induction may be needed to regulate the developmental timing of these
processes, with loss of CHD2 diminishing expression of these early genes and enabling accelerated
onset of later profiles of gene expression.

Since our data above suggested a direct role for CHD2 to maintain expression of genes involved
in early developmental processes, with loss accelerating the exit from pluripotency and progression
of cells through neurogenesis and differentiation, we assessed which epigenetic transitions at these
CHD2 bound sites might be associated with gene regulation. Specifically, we hypothesized that
DEGs with a lower expression in CHD2+/- hMGEs might normally gain the repressive H3K27me3
mark during differentiation but may be repressed prematurely in the CHD2+/- cells. This is aligned
with prior findings that CHD2 can tune levels of H3K27me3 during development, potentially by
promoting H3.3 turnover (Semba et al., 2017). As the genes with decreased expression in the
CHD2+/- hMGEs are associated with early developmental roles including hESC proliferation and
pluripotency, early embryonic signaling, and neural fate acquisition (Figure 7C), their premature
down-regulation may have contributed to the accelerated differentiation that we observed. Since a
set of peaks uniquely bound by CHD2 in hESCs gained H3K27me3 in hMGEs and/or hcINs
(Figure 6A, C), we investigated whether some of the associated genes were DEGs in the CHD2+/versus WT hMGEs. Indeed, a higher percentage of CHD2-bound peaks associated with DEGs with
lower expression in CHD2+/- versus WT hMGEs gained H3K27me3 during normal hcIN
differentiation (25%; Figure 8B; right; blue, red, and purple bars), compared to CHD2-bound
peaks associated with DEGs with higher expression in CHD2+/- versus WT hMGEs that gained
H3K27me3 (16%; Figure 8B, left; blue, red, and purple bars). This difference is even more
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dramatic when assessing the overall percentage of DEGs (not just peaks) that are associated with
a peak uniquely bound by CHD2 in hESCs that gains H3K27me3 during hcIN differentiation.
Thirty percent (169/581) of DEGs with lower expression in CHD2+/- versus WT hMGEs fall into
this category, compared to only 12% (19/155) of DEGs with higher expression in CHD2+/- versus
WT hMGEs (Table S7). Examples of genes in the former category include the genes encoding the
tight junction proteins CLDN7 and MARVELD3 (Figure 8C). This suggests that many DEGs in
CHD2+/- hMGEs may be expressed at lower levels than controls due to premature or excess
association of H3K27me3 at sites of hESC CHD2 binding during hMGE specification. The
continued presence of CHD2 at these sites may buffer genes from this phenomenon under WT
conditions.

Since genes that would normally acquire H3K27me3 during hcIN differentiation comprised a high
percentage of the DEGs with lower expression in CHD2+/- versus WT hMGEs, we wanted to assess
if the chromatin accessibility of these genes was impacted, particularly at regions of CHD2
binding. Overall, chromatin accessibility at the promoter of hMGE DEGs was reduced, and this
trend became significant at regions that were bound by CHD2 (Figure 8D). In addition to assessing
overall differences in chromatin accessibility, we examined whether CHD2 haploinsufficiency
resulted in a significant difference in accessibility of the region (i.e. a differentially accessible
region or DAR) to which CHD2 would normally bind. Here, we focused on regions bound by
CHD2 at any timepoint that were associated with DEGs with lower expression in CHD2+/- versus
WT hMGEs, as described above. Although only a small percentage of these CHD2-bound peaks
(96 out of 1,609 or 6%) were determined to be a DAR in the CHD2+/- versus WT hMGEs, all 96
of these DARs had reduced accessibility in the CHD2+/- versus WT hMGEs, corresponding to their
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reduced expression (Table S7). Furthermore, many of the genes associated with these 96 DARs
have roles in pluripotency or are most highly expressed in hESCs (TEAD4, CLDN6, VRTN, FZD7,
ZFP42, PODXL, and PRDM14), in early neural proliferation or specification (ROR1, OTX2, GLI2,
GBX2), and in adhesion/migration (CLDN7, GRB7). Interestingly, 25 of these 96 DARs (26%)
normally gain H3K27me3 during hcIN differentiation. These are associated with genes such as
PRDM14, GBX2, CLDN7, and GRB7, which were previously identified in other analyses in this
work. Therefore, changes in accessibility of regulatory elements normally bound by CHD2 may
be at least in part responsible for the transcriptomic and phenotypic consequences of CHD2
haploinsufficiency we observed here.

5.5 Discussion
This work adds to our understanding of how CHD2 is involved in the regulation of hcIN
development and how pathogenic CHD2 mutations can lead to NDDs, including epilepsy and
ASD. For the first time, we profiled CHD2 binding at multiple stages of hcIN differentiation. We
also integrated this binding data with information about gene expression and chromatin state.
Finally, we studied the transcriptomic consequences of CHD2 haploinsufficiency during hcIN
differentiation and proposed epigenetic mechanisms that may underlie this abnormal gene
expression. We first determined that CHD2 binds to a significant number of genomic regions
during hcIN differentiation, with its largest number of sites bound in hESCs. A subset of regions
were only bound at one stage of differentiation, and many of these regions appear to reflect stagespecific roles for CHD2. Genes associated with regions bound by CHD2 only in hESCs were
generally associated with functions such as cell-cell signaling, morphogenesis, and adhesion, and
these genes did not increase in expression during hcIN differentiation. In contrast, genes associated
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with regions bound by CHD2 only in hMGEs increased in expression during hcIN differentiation
and had roles in neurogenesis and patterning. Lastly, genes bound by CHD2 only in hcINs also
increased in expression during hcIN differentiation and were associated with functions such as
synaptic activity, neurotransmitter transport, and axon guidance. We identified candidate TFs
which may help recruit CHD2 to regulatory elements in a stage-specific manner, including
HMG/SOX and homeodomain TFs in hMGEs, as well as ZF and bHLH TFs in hcINs. Congruent
with the gene expression patterns we observed, a number of regions associated with CHD2 only
in hESCs gained the repressive chromatin mark H3K27me3 in hMGEs and hcINs. Conversely,
regions bound by CHD2 only in hMGEs and/or hcINs dramatically gained H3K27ac as
differentiation proceeded, which is likely to be associated with enhancer activation. Other studies
have shown enrichment of CHD2 at active promoters (including the presence of H4K4me3 and
H3K27ac) and enhancers (including the presence of H3K27ac) in multiple cell types, including
hESCs, mESCs, and K562 cells (Semba et al., 2017; Siggens et al., 2015). CHD2 has also been
suggested to play a role in tuning H3K27me3 levels in mESCs to maintain proper differentiation
potential (Semba et al., 2017).

Together, our data suggest roles for CHD2 at multiple stages of hcIN differentiation. First, as
hESCs are induced to form neuroectoderm and are specified as hMGEs, regulation of the transition
from the pluripotent to early neuroectodermal cell state with continued progenitor proliferation is
important, and CHD2 appears to be needed for proper expression of genes during this process.
Many of these genes are marked by H3K4me3 at their promoter and H3K27ac at their enhancers
during these early stages, with H3K27me3 enrichment occurring at these gene promoters during
later aspects of differentiation, as CHD2 leaves many of these regions during hMGE specification
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(Figure 9A). Second, as cells are specified to hMGEs, novel CHD2 binding events occur at putative
regulatory elements of genes required for this process, which accordingly become newly enriched
for H3K27ac (Figure 9B). Third, as specified hMGEs exit the cell cycle, differentiate, and mature
into hcINs, further novel CHD2 binding events occur at putative regulatory elements of genes
required for functions such as synapse formation (Figure 9C). Finally, putative regulatory elements
at which CHD2 binding is maintained throughout specification and differentiation (present in
hESCs and at the hMGE and/or hcIN stage) are associated with genes with lower expression that
remains unchanged during this process, many of which are already marked by H3K4me3 at
promoter-proximal regions or H3K27ac at distal regions (Figure 9D).

Interestingly, the model of CHD2 haploinsufficiency studied here primarily reveals an early
developmental role for CHD2 in promoting pluripotency exit, neuroectoderm induction, and
hMGE specification and progenitor maintenance. During differentiation of the CHD2+/- mutant
cells, we observed more pronounced and premature reduction of classes of gene expression
associated with pluripotency exit and early acquisition of neuroectodermal and hMGE progenitor
cell identity (such as signaling, adhesion, and pluripotency-related genes). This was accompanied
by precocious expression by the hMGE progenitor stage of genes associated with neuronal
differentiation and function, which continued to be expressed at excess levels in hcINs. Congruent
with these findings, multiple murine and human studies of CHD2 loss also show evidence of a
reduction in progenitor proliferation accompanied by accelerated maturation (Y. J. Kim et al.,
2018; Lalli et al., 2020; T. Shen et al., 2015). For example, Shen et al. found premature
differentiation of a subset of cortical neurons in a shRNA-based model of Chd2 KD in the mouse
cortex (T. Shen et al., 2015). Kim et al. showed a decrease in cIN progenitors in the MGE of
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Chd2+/- mice, resulting in abnormal transcriptomic and electrophysiological properties in the
mature cINs (Y. J. Kim et al., 2018). In a screen examining chromatin remodelers and transcription
factors during differentiation of the LUHMES neural progenitor cell line, Lalli et al. showed that
CHD2 knockdown using CRISPR-dCas9-KRAB resulted in reduced progenitor proliferation but
no significant difference in neurite extension (Lalli et al., 2020). Taken with our results, this is
suggestive of a convergent model for how CHD2 mutations can lead to NDDs. First, the reduction
in progenitor proliferation may lead to less hcINs and therefore less inhibitory activity in the
cortex. Indeed, ~20% of patients with CHD2 mutations have microcephaly and many have reduced
overall head size (Lamar & Carvill, 2018). Second, the accelerated maturation of hcINs may lead
to their improper maturation, resulting in electrophysiological abnormalities or changes in synaptic
functioning. Although it has been suggested that CHD2 loss may impact hcINs most significantly
(Meganathan et al., 2017; T. Shen et al., 2015), it will be important in future studies to determine
its role in cExNs, as they play an equally important role in the proper balance of excitation and
inhibition in the cortex.

Assessment of both the normal expression and chromatin state of genes that are differentially
expressed in WT versus CHD2+/- hMGEs and hcINs provides some mechanistic insights about the
impact of reducing CHD2 activity in our model. In CHD2+/- hMGEs, a majority of genes had
prematurely reduced expression; most of these genes were normally downregulated during early
hMGE specification, while a subset were also associated with regulatory elements that became
repressed during this process (as identified by a gain of H3K27me3 between the hESC and hMGE
stages). Overall chromatin accessibility was reduced for regions associated with these DEGs that
were bound by CHD2 in hESCs. This suggests that CHD2 loss in our model may have triggered
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premature repression of these genes during hcIN differentiation, as CHD2 was not present to
maintain the chromatin in a more open state. These findings are somewhat reminiscent of those
using a mESC model of CHD2 deficiency, where CHD2 loss resulted in increased H3K27me3
enrichment around developmentally regulated genes, particularly at bivalent regions (Semba et al.,
2017). The authors suggest that CHD2 may be involved with proper balance of H3.3 turnover,
with CHD2 loss resulting in elevation of H3K27me3 (Semba et al., 2017). It therefore should be
informative to explore the interaction of CHD2 with H3.3 during hcIN differentiation in future
work.

Future work to examine the consequences of pathogenic mutations in the regions encoding the
different functional domains of CHD2 (ATPase, DNA binding, and chromodomains) should also
further contribute to our understanding of the role of CHD2 in hcIN development. It will be
particularly interesting to understand whether variants lead to similar premature differentiation,
and whether this is reflected in microcephaly in the corresponding patient. Modeling of these
specific patient mutations using induced PSCs derived from their somatic cells will be a crucial
next step in these efforts. Individuals with CHD2 mutations exhibit a range of phenotypes, and
vary in whether they suffer from epilepsy, ASD, or both, as well as in the severity of the clinical
phenotype. We hypothesize that the multiple roles for CHD2 suggested by this work might
contribute to such pathogenic heterogeneity. Specifically, the particular characteristics of a
mutation (e.g. the location or type) may influence the ability of CHD2 to regulate subsets of its
targets. This could lead to the most pronounced effects on progenitor proliferation in some cases,
while in others proper expression of genes required for neuronal maturation or function may be
most strongly affected. Different mutations may also variably impact the ability of CHD2 to act
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with different TF co-regulators, many of which likely play stage-specific roles. Ultimately,
understanding the activity of CHD2 during hcIN development will allow us to understand which
deficits patients carrying mutations may have, and could allow for targeted therapies that focus on
restoring normal expression of the most highly perturbed pathways and processes to ameliorate
developmental and persistent anomalies.
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5.6.1 Figure 1. Genome-wide interrogation of CHD2 binding during hcIN
differentiation from hESCs........
(A) Differentiation scheme used to produce human cortical interneurons (hcINs) from human
embryonic stem cells (hESCs) in vitro. Human embryonic stem cells were differentiated for 35
days using small molecules by first forming embryoid bodies (EBs) for 4 days, followed by 6 days
on a shaker, after which EBs were plated and differentiated for a further 25 days. Samples were
collected for analysis at day 0 (hESCs), day 15 (medial ganglionic eminence-like progenitors;
hMGEs), and day 35 (hcINs). (B) Analysis of peaks bound by CHD2 in hESCs, hMGEs, and
hcINs, showing the number of peaks with a binding event unique to one cell stage, as well as
CHD2 peaks shared between multiple cell stages. (C) Annotation of genomic features at sites of
CHD2 binding in hESCs, hMGEs, and hcINs for all peaks found at each cell stage. (D) Epigenome
Browser views (left) and corresponding gene expression (right) for example CHD2 binding events
during hcIN differentiation.
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5.6.2 Figure 2. Analysis of genes associated with CHD2 binding during hcIN
differentiation.
(A) Expression of all CHD2-bound genes at the hESC, hMGE, and hcIN stages is compared with
that of genes with a CHD2 binding event unique to hESCs (‘hESC unique’), and with those with
a binding event unique to hMGEs, hcINs, or both, but not present in hESCs (‘hMGE/hcIN
unique’). Expression is shown as log2 reads per kilobase per million mapped reads (RPKM). (BD) Gene ontology (GO) term analysis of genes with a CHD2 peak unique to (B) hESCs, (C)
hMGEs, or (D) hcINs. (E) Overlap of genes bound by CHD2 with high-confidence autism
spectrum disorder (ASD)-associated genes (left Venn diagram and top heatmap) and epilepsyassociated genes (right Venn diagram and bottom heatmap). Venn diagrams show genes bound by
CHD2 in each cell state(s), with the center of the diagram showing the number of ASD/epilepsy
genes with at least one CHD2 binding event in hESCs, hMGEs, and hcINs. Heatmaps show
expression (RPKM) of each gene in hESCs, hMGEs, and hcINs, color-coded and displayed in the
order corresponding to the Venn diagram sections.
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5.6.3 Figure 3. Networks of genes bound by CHD2 during hcIN
differentiation.
(A-C) CHD2-bound genes associated with representative terms for each cell stage, corresponding
to those with CHD2 peaks unique to that cell stage, were organized into networks. (A) hESC
‘unique’ CHD2-bound genes are associated with intracellular junctions, (B) hMGE ‘unique’ genes
are associated with neuroepithelial development, and (C) hcIN ‘unique’ genes are associated with
synapses, with related terms shown.
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5.6.4 Figure 4. Profiling the expression of CHD2-associated genes during
hcIN differentiation..........................
(A) Breakdown of the percentages of genes that are associated with a promoter-proximal (+/- 2kb
of the transcription start site; TSS) CHD2 binding event unique to hESCs, hMGEs, or hcINs and
that exhibit differential expression across hcIN differentiation. Genes are assigned to one of four
expression patterns; ‘down_down’ (e.g. down from hESCs to hMGEs and from hMGEs to hcINs),
‘down_up’, ‘up_down’, and ‘up_up’, as further described in the text. (B) Expression differences
between hMGEs and hESCs, and hcINs and hMGEs (shown as log2 fold change; FC) for genes
with a CHD2 binding event unique to a cell stage (stage of binding indicated in key), with an
‘up_up’ expression pattern (left) and ‘down_up’ expression pattern (right). (C) Further analysis of
these expression differences, showing the frequency with which ranges of log2 FC expression
change were observed between hMGEs and hESCs, and hcINs and hMGEs (top set of labels under
x-axis) for CHD2-bound genes within the ‘up_up’ category (left) or ‘down_up’ category (right).
These categories are divided by genes with CHD2 peaks unique to hESCs (‘hESC unique’),
hMGEs (‘hMGE unique’), and hcINs (‘hcIN unique’), as labeled on the bottom of the x-axis. (DE) Representative Epigenome Browser views (left) and corresponding gene expression (right) of
(D) genes with an hESC unique peak and a ‘down_up’ expression pattern and (E) an hcIN unique
peak and an ‘up_up’ expression pattern.
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5.6.5 Figure 5. Analysis of candidate TFs that may co-bind the genome with
CHD2 during hcIN differentiation.
(A) HOMER motif analysis of predicted transcription factor (TF) binding motifs under CHD2
peaks unique to hESCs (top), hMGEs (middle), and hcINs (bottom). (B) Transcription factors with
a minimum RPKM value of 1 in hMGEs (i.e. log2 RPKM > 0) and at least a 2-fold increase in
expression between the hMGE and hcIN stage (i.e. log2 FC > 1; top), and a log2 RPKM > 0 in
hcINs and log2 FC > 1 between the hcIN and hMGE stage (bottom). Highlighted TFs were curated
as having a known role in cortical development and their expression in hESCs, hMGEs, and hcINs
is also shown in heatmaps, below. (C) Relative expression in hESCs, hMGEs, and hcINs of
selected HMG/SOX and Homeodomain motif-containing TFs is represented in a heatmap view.
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5.6.6 Figure 6. Histone modification states associated with CHD2 binding
during hcIN differentiation.
(A) deepTools plot showing locations enriched for CHD2 binding, and enrichment for H3K4me3,
H3K27ac, and H3K27me3 modification at the corresponding location in hESCs, hMGEs, and
hcINs. Regions shown include those bound by CHD2 only in hESCs (top; ‘hESC unique’), and
those bound by CHD2 in hMGEs and/or hcINs, but not hESCs (bottom; ‘hMGE/hcIN unique’).
Plots at the top indicate the overall level of enrichment of each modification or CHD2 binding
event. (B) The expression of genes with an hMGE and/or hcIN unique CHD2-bound peak that
gains co-enrichment for H3K27ac in hMGEs and hcINs is shown as a heatmap, indicating relative
expression in hESCs (day 0), during early neuroectodermal fate acquisition (day 4), and in
specified hMGEs (day 15), differentiating hcINs (day 25), and maturing hcINs (day 35). (C)
Number of peaks bound by CHD2 uniquely in hESCs (‘hESC unique’) or in hMGEs and/or hcINs,
but not hESCs (‘hMGE/hcIN unique’) that overlapped with enrichment for each histone state is
shown for H3K27ac, H3K4me3, H3K27me3, and H3K27me3/H3K4me3 enrichment in
combination (e.g. a bivalent chromatin state). The color coding (key at right) breaks this overlap
in CHD2 binding and histone modification state down based upon stage(s) of differentiation when
these marks were co-enriched, for example a peak present at all three stages of differentiation fell
into the ‘hESC/hMGE/hcIN’ category, while one only present in hESCs fell into the ‘hESC’
category.
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5.6.7 Figure 7. Gene expression changes in hMGEs and hcINs resulting from
CHD2 haploinsufficiency.
(A) Gene expression differences (log2 FC) between wild type (WT) and mutant (CHD2+/-) hMGEs
(left) and hcINs (right), with genes with higher expression in mutant cells shown in green and
lower expression in mutant cells shown in red. (B) Numbers of differentially expressed genes
(DEGs) with lower (left) or higher (right) expression in mutant versus WT cells. The number of
differentially expressed genes only found in hMGEs or hcINs is shown, as well as the number of
DEGs present in both cell types. (C) Gene Ontology analysis of biological processes associated
with DEGs with lower expression in mutant hMGEs (top left), higher expression in mutant hMGEs
(top right), lower expression in mutant hcINs (bottom left), or higher expression in mutant hcINs
(bottom right). (D) Degree of expression change between mutant and WT hMGEs and hcINs for
all DEGs (DEG in hMGEs, hcINs, or both), and DEGs with significance calls in both hMGEs and
hcINs, with significance calls only in hMGEs (with their expression in hcINs also shown), or only
in hcINs (with their expression in hMGEs also shown). Graphs provide data for DEGs with lower
expression in mutant cells (left) versus higher expression in mutant cells (right).
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5.6.8 Figure 8. Intersection of epigenetic changes and differential gene
expression with CHD2 haploinsufficiency.
(A) Heatmap of the normal expression patterns during hcIN differentiation of DEGs with higher
expression in CHD2+/- versus WT hMGEs (left) or lower expression in CHD2+/- versus WT
hMGEs (right). Timepoints shown are for hESCs (day 0), during early neuroectodermal fate
acquisition (day 4), and in specified hMGEs (day 15), differentiating hcINs (day 25), and maturing
hcINs (day 35). (B) Differentially expressed genes in hMGEs that are bound by CHD2 at any stage
of hcIN differentiation, with stages bound indicated by color-coded key at right. CHD2-bound
genes are divided by those with higher expression in CHD2+/- versus WT hMGEs (left bars; n=374
peaks) or lower expression in CHD2+/- versus WT hMGEs (right bars; n=1,609 peaks). Peaks are
broken down by the percentage bound by CHD2 or co-enriched for H3K27me3 at each stage of
differentiation, including those bound at multiple stages (bars labeled ‘CHD2’ and ‘H3K27me3’,
respectively). (C) Representative Epigenome Browser views of regions that are bound by CHD2
uniquely in hESCs, gain H3K27me3 during differentiation, and are associated with DEGs with
lower expression in CHD2+/- versus WT hMGEs. (D) Differentially accessible regions (DARs)
were defined by comparing chromatin accessibility (ATAC-seq data) for all promoter-proximal
regions in WT versus CHD2+/- hMGEs (left), or by specifically assessing DARs at the subset of
promoter-proximal regions bound by CHD2 in hESCs (right). For chromatin accessibility
differences, P-values *P < 0.05, **P < 0.01, ***P<0.001 were determined by Wilcoxon test.
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C. hcIN Unique

5.6.9 Figure 9. Model for the role of CHD2 during different stages of hcIN
differentiation.
CHD2 is generally associated with open chromatin and active gene expression during hcIN
differentiation, but with distinct features at different stages. (A) When CHD2 is only bound to a
putative regulatory element in hESCs, these regions often gain the repressive chromatin mark
H3K27me3 during differentiation and accordingly gene expression of the genes that these regions
may be regulating is often reduced. Many genes associated with these regions are involved in cell
cycle maintenance, adhesion, and signaling processes that are highly active in stem cells and
during early fate acquisition. (B-C) When CHD2 is only bound to regions in hMGEs (B) or hcINs
(C), these genes gain the active H3K27ac mark at these stages and accordingly expression of the
genes that these regions may be regulating is frequently increased. Genes associated with regions
bound in hMGEs are more likely to be associated with early progenitor specification and
neurogenesis, whereas genes associated with CHD2-bound regions bound in hcINs are more likely
to play roles in neuronal maturation and synaptic function. (D) When CHD2 binding is present
throughout hcIN differentiation, including in hESCs, these regions often are associated with open
chromatin (H3K27ac for putative enhancers and H3K4me3 for promoters) and the associated
genes often maintain expression throughout differentiation.
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Figure S1. Interrogation of CHD2 binding during hcIN

differentiation from hESCs.
(A) deepTools analysis of the three highest frequency genomic annotations associated with CHD2
binding in hESCs, hMGEs, and hcINs, showing the relative level of binding in promoter-proximal
regions, gene bodies, and intergenic regions at each stage. (B) Genomic annotation of CHD2
binding in hESCs, hMGEs, and hcINs for CHD2 binding events only found at one cell stage,
termed ‘unique’ peaks.
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Figure S2. Analysis of genes associated with CHD2 binding during

hcIN differentiation.........
(A) Expression at the hESC, hMGE, and hcIN stage of all genes, genes with a CHD2 binding event
unique to hESCs (‘hESC unique’), shared between hESCs and hMGEs (‘hESC/hMGE’), unique
to hMGEs (‘hMGE unique’), shared between hMGEs and hcINs (‘hMGE/hcIN’), unique to hcINs
(‘hcIN unique’), and those with a binding event unique to hMGEs, hcINs, or both, but not present
in hESCs (‘hMGE/hcIN unique’). Expression is shown as log2 RPKM. (B) Cell-Type Specific
Expression Analysis (CSEA) across brain regions and development for all genes bound by CHD2
in hcINs (left), and for genes with CHD2 binding events unique to hcINs (right).
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Figure S3. Defining genes with changing expression during hcIN

differentiation.
(A) Explanation of categorization of genes with expression changes during hcIN differentiation.
Genes either have expression that goes down both between hESCs and hMGEs, as well as hMGEs
and hcINs (‘down_down’), down between hESCs and hMGEs, but up between hMGEs and hcINs
(‘down_up’), up between hESCs and hMGEs, but down between hMGEs and hcINs (‘up_down),
and up between hESCs and hMGEs, as well as hMGEs and hcINs (‘up_up’). (B-E) Gene ontology
analysis of the genes within each category, showing terms associated with both molecular
functions and biological processes for genes categorized as: (B) ‘down_down’, (C) ‘down_up’,
(D) ‘up_down’, and (E) ‘up_up’.
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Figure S4. Dissecting expression changes of CHD2-bound genes

during hcIN differentiation.
(A) Breakdown of the percentage of genes associated with promoter-proximal (+/- 2kb of the TSS)
CHD2 binding in hESCs, hMGEs, or hcINs that exhibit different expression profiles across hcIN
differentiation. Genes were assigned to one of four expression profiles: ‘down_down’, ‘down_up’,
‘up_down’, or ‘up_up’. (B) Expression differences between hMGEs and hESCs, and between
hcINs and hMGEs (shown as log2 FC) for genes with CHD2 binding at each cell stage (key at
right), with an ‘up_up’ expression pattern (left) and ‘down_up’ expression pattern (right). (C)
Gene expression in hESCs, hMGEs, and hcINs (shown by RPKM; color-coded key at right) for
genes with CHD2 binding events unique to hESCs, hMGEs, and hcINs (as indicated on x-axis),
divided by panel into genes with an ‘up_up’ expression pattern (left), or ‘down_up’ expression
pattern (right).
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Figure S5. Expression analysis of candidate TFs that may co-bind

the genome with CHD2 during hcIN differentiation.
(A) All human TFs were plotted by expression (log2 RPKM) in hMGEs (left) and hcINs (right)
and by the difference in expression (log2 FC) between hMGEs and hESCs (left), and hcINs and
hMGEs (right). Box indicates TFs that meet a threshold of log2 RPKM > 0 and log2 FC > 1, which
were selected for further analysis. (B) Expression in hESCs, hMGEs, and hcINs of selected bHLH,
bZIP, C2H2 zinc finger (C2H2ZF), and forkhead motif-containing TFs. (C) Representative
Epigenome Browser views (left) and corresponding gene expression (right) of genes with a
putative regulatory element co-bound by CHD2 and NKX2-1.
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Figure S6. Histone modification states associated with CHD2

binding during hcIN differentiation.
(A) deepTools plot showing CHD2 binding, and H3K4me3, H3K27ac, and H3K27me3
modification enrichment at CHD2 peak locations in hESCs, hMGEs, and hcINs. Chromatin state
at regions bound by CHD2 in hESCs (top sections), in hMGEs (middle sections), and in hcINs
(bottom sections) are shown separately. (B) Number of peaks bound by CHD2 in hESCs, hMGEs,
or hcINs that overlapped enrichment for each histone state (H3K27ac, H3K4me3, H3K27me3, or
H3K27me3/H3K4me3 together (e.g. a bivalent chromatin state)). Overlap is broken down by the
stage(s) of differentiation at which these marks were co-enriched with CHD2 binding, for example
a peak present at all three stages of differentiation falls into the ‘hESC/hMGE/hcIN’ category, and
one only present in hESCs fell into the ‘hESC’ category. (C-D) Representative Epigenome
Browser views of regions bound by CHD2 uniquely in hMGEs and/or hcINs that gained H3K27ac
in hMGEs (C) or in hcINs (D).
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Figure S7. Generation of WT and CHD2+/- cells.

(A) Genetic sequence of the WT and mutant allele in the CHD2+/- hESC line, showing variant
nucleotides in red for the mutant allele. (B) Western blot analysis of CHD2 and GAPDH (loading
control) levels in WT and CHD2+/- hESCs, with quantification (right). (C) Karyotypic analysis of
WT and CHD2+/- hESCs indicates a normal karyotype for both lines. (D) Bright field view of WT
and CHD2+/- cells at day 4 (neural fate acquisition in EBs), at day 15 (hMGEs), and day 35 (hcINs).
A zoomed in image of the hcIN region highlighted in the red box is shown on the far right. For
western blot, P-values *P < 0.05, **P < 0.01, ***P<0.001 were determined by t-test.
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Figure S8. Transcriptomic analysis of WT and CHD2+/- hMGEs

and hcINs.
(A) Principal component analysis (PCA) of each replicate of WT and CHD2+/- hMGEs and hcINs
analyzed by RNA-seq is shown. (B) Heatmap shows the correlation between WT CHD2+/- hMGE
and hcIN RNA-seq replicates. (C) CompBio (PercayAI platform) analysis of DEGs with lower
(top) and higher (bottom) expression in CHD2+/- versus WT hMGEs. Networks of the top ten terms
associated with the DEGs (left) and details related to the concepts and genes that contribute to
enrichment for these terms is shown (right).
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Chapter 6: Conclusions and future
perspectives
Contributions: Emily M.A. Lewis wrote this chapter and Kristen L. Kroll edited it. Histone data
shown was obtained by EMAL. Tychele N. Turner provided ASD proband and sibling variant
data. Irene Antony analyzed this data. Sabine Dietmann performed TE analysis. Ramachandran
Prakasam performed Cas9-KRAB experiments. Luke A. Sandoval and RP performed reporter
assays. KLK curated CHD2 probands. Paul Gontarz and Bo Zhang performed all other
bioinformatic analysis.
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6.1 Epigenetic regulation of hcIN development
In addition to helping us to define the mechanisms by which CHD2 regulates human cortical
interneuron (hcIN) development, the histone modification state and chromatin accessibility data
presented in Chapter 5 of this dissertation provide information that will be of use in several other
types of studies. Significantly, the general changes in the epigenetic landscape that accompany
hcIN development have not yet been documented. Analysis of these data, including defining the
timing and location of histone modification state changes across the genome and prediction of how
these changes may alter gene expression serves as a foundation for future study of hcIN
development and neurodevelopmental disorders (NDDs) that result from abnormalities in this
process.

The locations of new H3K27ac enrichment that we defined during hcIN specification and
differentiation will be of particular utility in identifying and manipulating putative enhancers
regulating this developmental program. For example, we have already integrated these with a
dataset of de novo non-coding variants identified in probands with autism spectrum disorder
(ASD), using their unaffected siblings as a control. Transcription factors (TFs) often bind to these
putative enhancers, or so-called cis-regulatory elements (CREs) via specific binding motifs to
either activate or repress gene expression. Although every human carries significant variation in
their DNA, particularly in the non-coding regions of the genome, we can examine if there is
enrichment for rare variation in these TF binding regions within CREs in these ASD probands.
Such variants have been identified in putative hcIN development-associated CREs of highconfidence ASD genes (SFARI Gene, 2021) such as ARID1B, BAZ2B, and POGZ (Figure 1A). As
will be described in more detail in the next section of this chapter, the impact of some of these
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variants on enhancer activity and/or gene expression will be tested using a high-throughput
reporter assay.

As was discussed in Chapter 3 of this dissertation, transposable elements (TEs) might drive humanspecific aspects of neural development, as they can either act as enhancers or interfere with
transcription (Shapiro, 2017; Trizzino et al., 2017). We have identified TE families enriched at
each stage of hcIN differentiation by integrating known TE families with H3K27ac and RNA-seq
data across hcIN differentiation. Transposable element families enriched in this collection of
putative enhancers include HERVH in human embryonic stem cells (hESCs), MER61F in medial
ganglionic eminence-like progenitors (hMGEs), and LTR12C/LTR13 in hcINs (Figure 1B).
Significantly, LTR12C was found to be the most significant TE insertion found within human
brain enhancers (compared to enhancers in the developing rhesus macaque cortex), and is enriched
within genes controlling corticogenesis (Dietmann et al., 2020).

6.2 Studying the activity of putative CREs during hcIN
development
The next step in understanding the function of these putative CREs is to test their activity via
reporter assay. Identification of a subset of CREs with activity in developing hcINs will allow us
to then further explore how and when these CREs are involved in controlling this process. For
example, the ASD proband-enriched variants associated with hcIN-expressed enhancers and ASD
genes discussed above can be engineered into a reporter assay to determine whether the activity of
a putative CRE is affected by the presence versus absence of the variant. Significantly, a single
point mutation has been shown to be sufficient to perturb TF binding in this assay (Kwasnieski et
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al., 2012). Although many CREs exhibit substantial redundancy in the presence of TF binding
motifs and small amounts of sequence variation may not impact CRE activity, even coupling
identification of active CREs with enrichment for variation in NDD-affected versus unaffected
individuals will provide new information about non-coding genome variation associated with
NDDs.

Analysis of predicted TF binding within active CREs can also be used in combination with
information regarding the expression trends of these TFs (as was performed in Chapter 5 of this
dissertation to predict TF co-factors for CHD2) to identify novel TFs that may be involved in hcIN
differentiation. For example, we may identify novel TF activities or co-regulatory interactions that
control enhancer activity, or to further define the mechanisms by which TFs known to play an
important role in hcIN differentiation control this process, such as NKX2-1. These findings can be
further explored and confirmed experimentally via assays such as ChIP/CUT&Tag for the TF(s)
of interest and via knockout (KO) or knockdown (KD) experiments to determine TF levels affect
CRE activity, as was demonstrated in our previous work with NKX2-1 (Meganathan et al., 2017).

Finally, we can use other approaches to define the genes that are regulated by these CREs, for
example by using the activity-by-contact (ABC) model (Fulco et al., 2019). This tool integrates
H3K27ac, chromatin accessibility, and three-dimensional chromatin structural data (such as Hi-C)
to determine CRE-gene associations. This is more accurate than assuming regulation of the closest
gene, due to the three-dimensional structure of chromatin, as up to 50% of transcription start sites
display one or more long-range CRE interactions (Sanyal et al., 2012). We can then further
interrogate the impact of variation in high-confidence CREs that are associated with known NDD
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genes, as this non-coding variation may have as much impact as variation in the protein-coding
genome space, in terms of its potential to cause disease. As our power to identify rare and common
non-coding variation in individuals with NDDs increases, we can also integrate knowledge about
active CREs and their associated genes to understand how combinatorial risk from both coding
and non-coding variation can contribute to affectation in genetically complex disorders such as
ASD.

In published (Meganathan et al., 2017) and unpublished (Figure 1C, D) work, we have shown
evidence for activity of numerous CREs in hMGEs, including those predicted to regulate important
developmental genes, and have identified CREs responsive to NKX2-1, which lose activity upon
mutation or loss of NKX2-1. While useful as a proof-of-principle, these luciferase reporter assays
are extremely low-throughput. Fortunately, high-throughput reporter assays (called massively
parallel reporter assays or MPRAs) have been developed to test thousands of putative CREs in
tandem (Kwasnieski et al., 2012). We plan to design a library for MPRA-based testing of putative
CREs curated from the aforementioned analysis. Oligonucleotide pools (of up to 200 base pairs
each, containing a CRE and barcode) of varying sizes can be ordered, with a pool of 15,000
allowing for the testing of approximately 1,000 CREs, including positive and negative (e.g. basal
promoter without CRE and scrambled CRE) controls and CREs with or without mutation of TF
binding sites. Typically, four random barcodes are assigned to each of these CREs to ensure
sufficient library representation and within-assay reproducibility. Once cloned into a vector
backbone including a minimal promoter and a DsRed reporter sequence/spacer (Figure 1E), the
library can be transfected at different stages of hcIN differentiation, with the hMGE stage being
the most practical, as these cells can be propagated as progenitors. The readout of this assay is the
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ratio of DNA reads to each barcode to reads of transcribed barcodes, with higher transcribed
numbers indicating CRE activity (Figure 1E). As described above, the active CREs, as well as
inactive mutant CREs should aid in our understanding of the cis-regulatory logic of hcIN
development. Further assessment of the activity of CREs in this library in other human neural cell
types such as cortical excitatory neuron progenitors, or assessment of activity in cell lines with KD
or KO of specific TFs, can reveal the general versus cell type-specific usage of these CREs and
the requirements for particular TFs to control their expression.

Although MPRAs provide a powerful and high-throughput tool for testing CRE activity, they do
not allow study of CRE activity within its native chromatin context. Regulation of CRE activity
and gene expression is driven by a complex and multi-layered combination of features of the
genome sequence, including DNA modifications, regulatory protein binding, histone posttranslational modifications, and control of the three-dimensional genome architecture. Therefore,
it is important to study CRE activity within its native genomic context. Recently developed
approaches that utilize CRISPR-Cas9 technology enable us to do this; Li et al. developed a dual
effector-based method to either repress or activate distal regulatory elements (K. Li et al., 2020).
This protocol uses a catalytically dead Cas9 (dCas9) protein in combination with the LSD1 and
KRAB repressor domains to reduce gene expression or the p300 and VP64 activation domains to
promote gene expression, when these proteins are recruited to a putative CRE by a single guide
RNA (sgRNA) (K. Li et al., 2020). This method appears to be more effective at targeting enhancers
for activation or repression than other recently developed multiple effector-based methods, such
as SunTag (K. Li et al., 2020). Our future work will include using this system to validate the
activity of a subset of CREs identified in our MPRA analysis.
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6.3 Tools to model NDDs in vitro
As was discussed in Chapter 2 of this dissertation, there are two main tools to create human
pluripotent stem cell (hPSC) models of neurodevelopmental disorders. Patient-derived somatic
cells can be reprogrammed to derive induced PSC (iPSC) models carrying both a prospective
pathogenic gene variant and other elements in the genetic background of the patient that may
contribute to an NDD. Alternatively, a particular gene mutation or gene deficiency can be
introduced into wild type human PSCs by CRISPR-based mutation or by CRISPRi- or shRNAbased KD approaches. Although the model of CHD2 haploinsufficiency used in Chapter 5 of this
dissertation provided a useful tool for understanding the role of CHD2 in hcIN development, it did
not mimic any specific mutations found in patients. To understand how mutations in regions
encoding different functional domains of CHD2 might impact hcIN development, we have now
recruited patients with a range of CHD2 mutations into a repository, from whom we are deriving
iPSC models of CHD2 variation (Figure 2A). These iPSC models can be used for multiple types
of analyses, including those presented in Chapter 5 of this dissertation, to assess alterations in gene
expression, chromatin accessibility, and histone modification state resulting from CHD2 mutation.
These models can also be used for multiple cellular phenotyping analyses, some of which were
used to characterize iPSC models derived from the multiplex autism family presented in Chapter
4 of this dissertation.

Similar to the aforementioned dual effector-based methods for CRISPR-mediated activation or
repression of distal regulatory elements, we also can repress gene expression by targeting a dCas9KRAB repressor to the transcription start site of a gene (Figure 2B, left). For dCas9-KRAB
targeting to specific promoters, we use sgRNAs from the Dolcetto library, which has improved
214

efficiency relative to earlier sgRNA design methods (Sanson et al., 2018). Using these methods,
we have frequently obtained an ~80% reduction in gene expression (Figure 2B, right), consistent
with other reports (Lalli et al., 2020). Although this approach does not fully abrogate gene
expression as can be achieved using CRISPR/Cas9-mediated gene disruption/KO, the
CRISPR/dCas9-KRAB method has several advantages, including not requiring screening of clonal
lines, enabling inducible gene repression to study effects of protein loss on specific developmental
events, and being able to combine guides in a library for higher-throughput screening of multiple
genes.

As was reviewed in Chapter 2 of this dissertation, many different neuronal cell types can be
differentiated from hPSCs to study normal and aberrant aspects of neurodevelopment. The work
presented in this dissertation uses models of cortical excitatory and inhibitory neuron development
in Chapter 4, and cortical inhibitory neuron development in Chapter 5. The findings presented in
Chapter 4, which compared cellular and molecular correlates of affectation in models derived from
a multiplex autism family, benefitted from studying two different cortical neural types, as both
shared and distinct phenotypes could be identified. However, assessing the epigenomic changes
that accompany the development of multiple neuronal types and their disruption in NDDs (as was
done in hcINs in Chapter 5, to characterize the roles and mechanisms of action of CHD2), can be
cost-prohibitive and difficult to apply across multiple neuronal cell types, due to the large number
of samples needed and quantity of data obtained. As we define key features of normal human
cortical neuron development that are commonly disrupted in NDDs, it will be possible to predict
the assays that are most likely to reveal processes that are affected in a neuronal cell type-specific
or pan-neuronal manner to contribute to affectation. Some of these assays can also utilize cortical
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organoids to model neurodevelopment. While the heterogeneity of these organoid-based models
can hamper some analysis modalities, they contain multiple different neuronal cell types and can
mimic some aspects of the three-dimensional architecture of the brain, enabling other types of
analysis (Lancaster et al., 2017; Qian et al., 2019). The development of single-cell -omics
technologies, including RNA- and ATAC-sequencing, as well as single-cell CUT&Tag (H. S.
Kaya-Okur et al., 2019) will greatly help with these efforts, by enabling neuronal cell type-level
resolution of these data. It will be particularly interesting to see the impact of CHD2 variation on
the development of different neural cell types or in organoids, as it has been suggested that
GABAergic interneurons most strongly affected in a mouse model of CHD2 haploinsufficiency
(Y. J. Kim et al., 2018).

6.4 Conclusions
The work presented in this dissertation highlights the utility of using hPSC-based models to
understand the regulation of normal cortical development and its disruption to cause NDDs. First,
I reviewed the literature related to epigenetic regulation of cortical development and the use of
hPSC models to study this process in development and disease (Chapter 2). Second, I created a
novel resource that describes the extant epigenetic datasets that have been derived for the human
fetal brain, and related epigenetic datasets obtained for human stem cell differentiation into cortical
neurons and cerebral organoids. These data can be used in comparisons of these in vivo versus in
vitro processes (Chapter 3). Third, I performed the first study to use human cellular models to
study multiplex autism, identifying cellular and molecular correlates that were associated with
affectation (Chapter 4). Fourth, I identified mechanisms by which CHD2, a chromatin remodeler
that is mutated to cause epilepsy, ASD, and intellectual disability, regulates hcIN development
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(Chapter 5). In addition to the insights provided in these chapters, this work opens up many fruitful
avenues for future research, some of which are described above.

Obtaining additional epigenetic data that indicates how fetal brain development is regulated in the
developing human embryo will improve our ability to translate these in vitro findings to in vivo
development. Furthermore, as exome and whole genome sequencing of more individuals with
NDDs and controls is conducted, this will also enhance our understanding of which genes and noncoding regions are mutated to contribute to disease. A long-term goal of this research is to develop
approaches that can ameliorate the impact of NDDs on affected individuals, as well as those around
them, and society at large. Since most of the anomalies that contribute to NDDs occur during fetal
brain development, this poses a challenge for prevention and treatment. In some cases, the
downstream impacts of this aberrant development could possibly be therapeutically targeted,
particularly if a certain type of synaptic signaling is impacted, for example. If, however, continued
loss of activity of the mutant gene product at postnatal stages impacts neuronal functioning, gene
therapy may be used to correct the mutation and ameliorate the phenotype (Basilico et al., 2020).
In addition to the potential translational applications of these findings, elucidating new aspects of
human brain development enables us to uncover additional pathways and regulators of this process
and to determine where the human biology does and does not align with these processes in animal
models.

Finally, in the Appendix of this dissertation, I present work related to the epigenetic regulation of
an entirely different body region; the limb. This work continues a long-standing research interest
in the Kroll laboratory, related to understanding the role of Geminin (GMNN), a regulatory
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nucleoprotein, in embryonic development (Caronna et al., 2013; Kroll et al., 1998; Lim et al., 2011;
Patterson et al., 2014; Yellajoshyula et al., 2011). While studying roles for GMNN in various
aspects of embryogenesis in conditional mouse KO models, we discovered that conditional loss of
GMNN during early patterning of the fore- and hindlimb buds led to distinct phenotypes, with
conditional loss in the forelimbs resulting in a dramatic shortening or absence of some limb skeletal
elements, while conditional loss in the hindlimbs resulted in hindlimb polydactyly, as well as a
similar shortening of hindlimb skeletal elements. We demonstrated that expression of Hox genes
was altered during limb bud patterning and was likely to be responsible for these defects (Lewis
et al., 2020). These findings were congruent with a requirement for GMNN to work with the
Polycomb complex in co-regulation of Hox genes and other classes of genes during other aspects
of body axis patterning and germ layer specification (Caronna et al., 2013; Karamitros et al., 2015;
Lim et al., 2011; L. Luo et al., 2004). Interestingly, during hcIN specification and differentiation
CHD2 binds the GMNN gene near the promoter and GMNN expression is reduced in CHD2+/hcINs, suggesting a role for CHD2 in regulating this gene (Figure 2C). One of the first roles
characterized for GMNN in lower vertebrate models was as a marker of newly specified neural
plate (Kroll et al., 1998), which was required to regulate neuroectoderm formation and patterning
of the brain and neural tube in multiple models of neurodevelopment (Kroll et al., 1998; Lim et
al., 2011; Patterson et al., 2014; Yellajoshyula et al., 2011). Our findings suggest that GMNN may
likewise play roles in aspects of human neurodevelopment, including hcIN specification and
differentiation. It will be interesting to explore the relevance of many such putative regulators of
human brain development uncovered by the genomic studies performed here. The human stem cell
models described here provide an experimentally accessible context in which to both test
requirements for novel regulatory activities in controlling particular aspects of brain development

218

and for exploring how mutations in chromatin modifiers and in the non-coding genome disrupt
these developmental processes to cause NDDs.
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6.5.1 Figure 1. Examples of analyses and experiments performed using
putative CRE data from hcIN differentiation.
(A) Epigenome Browser views of three high-confidence autism spectrum disorder (ASD)associated genes, BAZ2B, ARID1B, and POGZ, showing the presence of variants in promoterproximal putative cis-regulatory elements (CREs) in a cohort ASD probands but not in a cohort of
their unaffected siblings. (B) Analysis of enrichment for H3K27ac in transposable elements (TEs)
in medial ganglionic eminence-like progenitors (hMGEs) versus human embryonic stem cells
(hESCs), and human cortical interneurons (hcINs) versus hMGEs. Those with most significant
enrichment are highlighted by name (left) and in a bar chart (right). (C) Luciferase reporter assays
showing activity of CREs in hMGEs with NKX2-1 overexpression (left) and a loss of activity
upon NKX2-1 knockdown (KD; right). (D) An Epigenome Browser view showing overlapping
CHD2 and NKX2-1 occupancy proximal to the ZNF74 promoter. (E) Cis-regulatory elementsequencing construct consisting of a CRE, a minimal promoter, such as SV40, DsRed to serve as
a spacer, and a variable barcode (BC). Cis-regulatory element activity is determined by comparing
DNA reads of each BC to reads of transcribed BCs by sequencing.
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6.5.2 Figure 2. Further studying the impact of CHD2 loss on hcIN
differentiation.
(A) Curated pathogenic CHD2 mutations that result in epileptic encephalopathy, with or without
intellectual disability (ID) and/or ASD. Amino acid numbers indicate locations of mutations and
blue text indicates patient variants we have registered for biomaterial collection to derive new
induced pluripotent stem cell (iPSC) models. (B) Example of CRISPR-mediated gene silencing in
hMGEs, showing ~80% suppression of gene expression by three guide RNAs (gRNAs) targeted
to a promoter-proximal CRE of MYT1L. (C) Epigenome Browser view (left) showing presence of
CHD2 near the promoter of GMNN during all stages of hcIN differentiation. GMNN is expressed
throughout hcIN differentiation, with higher expression in hMGEs than hcINs (left bars; WT).
CHD2 haploinsufficiency results in a reduction in GMNN expression, particularly in hcINs (right).
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Appendix Chapter 1: Geminin is required for
Hox gene regulation to pattern the
developing limb
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1.1 Abstract and keywords
Development of the complex structure of the vertebrate limb requires carefully orchestrated
interactions between multiple regulatory pathways and proteins. Among these, precise regulation
of 5’ Hox transcription factor expression is essential for proper limb bud patterning and elaboration
of distinct limb skeletal elements. Here, we identified Geminin (Gmnn) as a novel regulator of this
process. A conditional model of Gmnn deficiency resulted in loss or severe reduction of forelimb
skeletal elements, while both the forelimb autopod and hindlimb were unaffected. 5’ Hox gene
expression expanded into more proximal and anterior regions of the embryonic forelimb buds in
this Gmnn-deficient model. A second conditional model of Gmnn deficiency instead caused a
similar but less severe reduction of hindlimb skeletal elements and hindlimb polydactyly, while
not affecting the forelimb. An ectopic posterior SHH signaling center was evident in the anterior
hindlimb bud of Gmnn-deficient embryos in this model. This center ectopically expressed Hoxd13,
the HOXD13 target Shh, and the SHH target Ptch1, while these mutant hindlimb buds also had
reduced levels of the cleaved, repressor form of GLI3, a SHH pathway antagonist. Together, this
work delineates a new role for Gmnn in modulating Hox expression to pattern the vertebrate limb.
Keywords: limb development, gene regulation, geminin, hox genes, sonic hedgehog pathway.
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1.1.1 Graphical abstract

1.2 Introduction
The vertebrate limb is a complex structure that develops during embryogenesis from a small bud
into an appendage that is patterned along its anterior-posterior (A/P), dorsal-ventral (D/V), and
proximaldistal (P/D) axes. Within each limb, three distinct skeletal compartments are formed, the
stylopod or upper limb, zeugopod or lower limb, and the autopod or hand/foot, with each structure
exhibiting asymmetry between the anterior (thumb) and posterior (little finger) sides. Limb
development is a classically studied process for understanding embryonic patterning and tissue
morphogenesis (reviewed in (Delgado & Torres, 2017; Petit et al., 2017; Sheeba et al., 2016; Tickle
& Towers, 2017; Zuniga, 2015)). As experimental work in this area has advanced, it is evident that
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complex interactions between multiple regulatory molecules play key roles in patterning the limb.
However, additional regulators of this process, and mechanisms by which it occurs, remain to be
fully elucidated.

Hox genes encode transcription factors that play a central role in patterning and differentiation of
multiple embryonic tissues and structures, both in the primary body axis and in the limb. The
tetrapod genome contains four clusters of paralogous Hox genes (HoxA-D). Expression of genes
in each Hox cluster is under complex control, involving both local and long-range chromatin
structural changes (Andrey & Duboule, 2014; Montavon & Duboule, 2013; Montavon &
Soshnikova, 2014; Neijts & Deschamps, 2017; Noordermeer & Duboule, 2013). Hox cluster gene
expression exhibits spatial and temporal colinearity: 3’ located Hox genes in each cluster are
expressed earlier and in more anterior embryonic locations, while 5’ genes are expressed later and
more posteriorly (Andrey & Duboule, 2014; Izpisúa-Belmonte et al., 1991; Kmita et al., 2002;
Tarchini & Duboule, 2006; Tschopp et al., 2009; Tschopp & Duboule, 2011). 5’ located HoxA and
HoxD cluster genes (Hoxa9-a13 and Hoxd9-d13) are essential regulators of vertebrate limb
development: Hox9/10 paralogs have roles in stylopod, Hox11 in zeugopod, and Hox13 in autopod
formation (Boulet & Capecchi, 2004; Davis et al., 1995; Fromental-Ramain, Warot, Lakkaraju, et
al., 1996; Wellik & Capecchi, 2003). 5’ Hox gene expression also controls limb bud anteriorposterior polarity, promoting posterior-restricted expression of Sonic Hedgehog (Shh) to create the
zone of polarizing activity (ZPA), which controls posterior limb bud patterning (reviewed in
(Lopez-Rios, 2016; Tickle & Towers, 2017)). In the posterior limb bud mesenchyme, Shh
expression is activated by binding of HOXD13 and HAND2 transcription factors to a distal Shh
enhancer (Galli et al., 2010; Hill, 2007; Lettice et al., 2003; Sagai et al., 2005). Restriction of
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Hoxd13 and Hand2 expression to the posterior limb bud is controlled by GLI3, which undergoes
constitutive proteolytic processing to a repressor form, GLI3R (te Welscher et al., 2002). During
this period, limb bud outgrowth also occurs, and is centrally controlled by interactions between
limb bud mesenchyme and FGF signaling from the overlying apical ectodermal ridge (AER)
(Lewandoski et al., 2000; Niswander et al., 1993).

Expression of genes in the Hox clusters is controlled by epigenetic regulation, including histone
methylation mediated by Polycomb complexes (PcG) (reviewed in (Andrey & Duboule, 2014;
Montavon & Duboule, 2013; Montavon & Soshnikova, 2014; Neijts & Deschamps, 2017;
Noordermeer & Duboule, 2013)). One of these PcG complexes tri-methylates histone H3 lysine
27 (H3K27me3) to repress gene expression, while locations co-enriched with this repressive
H3K27me3 and with the active H3K4me3 modification are maintained in a ‘bivalent’ or poised
expression state (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Müller et al.,
2002). As in the primary body axis, PcG-catalyzed H3K27me3 restrains Hox expression in the
developing limb. From mouse embryonic day 10.5 (E10.5), H3K27me3 is cleared from 5’ Hox
genes in the posterior limb bud mesenchyme to promote their expression (Montavon & Duboule,
2013; Soshnikova & Duboule, 2009; Williamson et al., 2012). Activation of 5’ Hox gene
expression at this time also involves large-scale chromatin reorganization and long-range
chromatin looping between the 5’ Hox gene cluster and multiple enhancers (Andrey et al., 2013;
Andrey & Duboule, 2014; Gonzalez et al., 2006; Montavon et al., 2011).

As a central regulator of developmental genes, PcG activity is likewise modulated by interactions
with other regulatory proteins, including Geminin (GMNN), a nuclear protein that can interact
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directly with PcG complexes (L. Luo et al., 2004). In multiple developmental contexts, physical
and/or functional interactions between GMNN and PcG modulate its regulation of developmental
gene expression. GMNN cooperates with PcG to restrain Hox expression during primary body axis
patterning and to control mesendodermal specification of pluripotent embryonic cells (Caronna et
al., 2013; Lim et al., 2011; L. Luo et al., 2004). GMNN also represses Hox expression during later
developmental events, such as hematopoietic stem cell differentiation (Karamitros et al., 2015). In
addition to working cooperatively with PcG complex activity to restrain Hox expression in several
developmental contexts, GMNN can also interact directly with a subset of the HOX transcription
factors, and may negatively regulate their activity (Salsi et al., 2009; T. Zhou et al., 2012). Models
of deficiency in the mouse have revealed roles for Gmnn in early embryogenesis, in specification
and patterning of the forming neural tube and paraxial mesoderm, and in several aspects of stem
cell differentiation and later tissue patterning (Barry et al., 2012; Emmett & O’Shea, 2012;
Gonzalez et al., 2006; Karamitros et al., 2015; Ma et al., 2016; Patterson et al., 2014). However, a
role for Gmnn in limb development has not previously been identified. Here, we uncovered novel
requirements for Gmnn in several aspects of embryonic limb bud patterning. We demonstrated
that, in these models, 5’ Hox gene expression in the limb bud is altered, and that this appears to be
a major contributor to the limb developmental defects observed.

1.3 Results
1.3.1 Loss and reduction of forelimb stylopod- and zeugopod-derived skeletal
elements in the Gmnnf/f; Prx-Cre model of Geminin deficiency
To identify requirements of Gmnn for embryonic patterning, we crossed a Gmnn floxed allele with
several Cre lines that drive excision both in developing mesoderm of the primary body axis and in
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the limb mesenchyme, with different temporal and spatial profiles. Prx1-Cre [Tg(Prrx1-cre)1Cjt]
expresses Cre recombinase under the control of a Prrx1 enhancer (hereafter abbreviated as PrxCre). The transgene is strongly expressed in forelimb bud mesenchyme from embryonic day 9.5
(E9.5), with only weak expression in single cells of the hindlimb ridge mesenchyme at this stage
(Logan et al., 2002). At E10.5, the transgene continues to be strongly expressed in forelimb
mesenchyme, while we still detected only weak expression in hindlimb mesenchyme at this stage
(Figure S1). At this time, flank, cranial, and craniofacial tissues of the embryo also express Prx1Cre (Logan et al., 2002).

To avoid germline Cre recombinase activity observed in females but not males, Gmnn+/f; Prx-Cre
males were mated to Gmnnf/f females. Gmnnf/f; Prx-Cre mutant animals were obtained from these
crosses at Mendelian ratios (25.23%; n = 107; Table S1A), and developed into adults. While
development of the axial skeleton and hindlimbs appeared normal in these animals, they exhibited
specific forelimb defects (Figure 1). We scored these forelimb phenotypes in skeletal preparations
from Gmnnf/f; Prx-Cre mutant animals (n = 10) versus Gmnn+/f; Prx-Cre littermate controls (n = 6)
(Tables S1B, C). None of the forelimbs in mutant animals were normal, with two-thirds (70%) of
the animals examined missing the humerus, the stylopod-derived forelimb element, and either the
radius, ulna, or both of these zeugopod-derived skeletal elements, either in one or both forelimbs.
The most mildly affected animals (30%) retained all skeletal elements, but these were shortened
and/or of reduced size. However, both the forelimb autopod and the hindlimbs appeared normal in
these animals.
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We further analyzed when this skeletal phenotype was evident during embryogenesis by collecting
embryos at E14.5, E16.5 and E18.5, and examining hematoxylin and eosin stained sections
through the developing forelimbs of mutant and control embryos. By E14.5, some skeletal
elements were already missing or reduced in size, while the structure of those that did form did
not appear to be grossly disrupted, by comparison with controls (Figure S2). As loss or reduction
of skeletal elements was already apparent by E14.5, disruption of earlier specification and
patterning processes in the forelimb bud appeared be a major driver of the phenotypes observed.

1.3.2 Hindlimb polydactyly and skeletal element reduction in the Gmnnf/f;
DermoCre model of Geminin deficiency
We compared these phenotypes with those that resulted from crossing this Gmnn conditional allele
with a different Cre driver that is also expressed in the limb bud mesenchyme, Dermo1Cre.
Dermo1Cre [Twist2tm1(cre)Dor] is a Cre recombinase knock-in, replacing exon 1 of the Twist2 gene
(hereafter abbreviated as DermoCre) (Yu et al., 2003). Recombinase activity is detectable from E9.5
at the surface of the embryo and in mesenchymal condensations that contribute to both the axial
and limb skeletal elements (Figure S1) (Yu et al., 2003).

Gmnnf/f; DermoCre animals were also born in Mendelian ratios (24.6%; n = 130), and grew into
fertile adults (Table S2A). While the primary body axis and forelimbs of all mutant embryos
appeared phenotypically normal, the animals exhibited specific hindlimb defects. Polydactyly was
apparent in the hind feet (92.3%; n = 26; Tables S2B–C), with most animals having six-to-seven
toes and with syndactyly visible in some at adult stages (Figure 2). When bone preparations were
generated from animals at E18.5 up to post-natal day five, the other hindlimb skeletal elements
appeared grossly normal. However, skeletal preparations from adults revealed shortening and
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curvature of both the hindlimb stylopod- (femur) and zeugopod- (tibia/fibula) derived skeletal
elements in most animals (87.5%; n = 16; Figure 2; Tables S2B, C). This was reminiscent of the
shortening and curvature seen in the forelimbs of Prx-Cre mutant animals, although substantially
less severe, while complete loss of any hindlimb skeletal elements (the tibia/fibula) was only
apparent in one animal (3.8%; n = 26).

1.3.3 Phenotypic consequences of Geminin deficiency are dependent on
timing and location
Since Gmnnf/f; Prx-Cre and Gmnnf/f; DermoCre mutant animals respectively exhibited fore-versus
hindlimb specific skeletal defects, we assessed whether this could be related to differences in the
spatial and temporal expression of Gmnn. We initially examined Gmnn expression in the limb bud
by using the Gmnn allele in its ‘knock-out first’ configuration, in which introduction of an FRTsite flanked β-galactosidase reporter into the Gmnn locus both disrupts the gene and reports on
Gmnn expression. Based upon β-galactosidase reporter expression in E10.5–12.5 embryos and in
limb buds heterozygous for this allele, Gmnn appears to be broadly expressed in both the embryo
and in the developing limb buds, consistent with prior work documenting Gmnn expression in
many proliferating cell populations during embryonic development (Emmett & O’Shea, 2012;
Gonzalez et al., 2006; Patterson et al., 2014) (Figure S3). As we did not detect overt differences in
Gmnn expression between the developing fore- and hindlimb buds, we next compared the spatial
and temporal expression of the Prx-Cre and DermoCre drivers in the developing limb buds. We
crossed both the Prx-Cre and DermoCre strains to the R26R reporter line and examined LacZ
expression in the limb buds from E9.5. As described previously, Prx-Cre was strongly expressed
in the forelimb bud by E9.5, while no expression in cells of the hindlimb ridge could be detected
at this time (Logan et al., 2002). By E10.5, Prx-Cre was strongly expressed in the forelimb bud,
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but was only weakly expressed in the hindlimb bud (Figure S1). By comparison, DermoCre
expression could not be detected in the forelimb bud at E9.5, while it was expressed in some cells
of the hindlimb ridge at this stage. By E10.5, DermoCre was strongly expressed in both the foreand hindlimb bud (Figure S1). Early aspects of limb bud patterning occur approximately half a
day later in the hindlimb bud than in the forelimb bud (Lopez-Rios, 2016). As DermoCre expression
in the hindlimb bud from E9.5 and in both the fore- and hindlimb buds from E10.5 altered hindlimb
but not forelimb development, while Prx-Cre excision from E9.5 in the forelimb bud instead only
altered forelimb development, these differential effects suggest a window of sensitivity to Gmnn
deficiency corresponding to early events of limb bud outgrowth and patterning.

Interestingly, although Gmnn was excised from E9.5 or E10.5 in some mesodermal tissues in the
primary body axis by both Prx-Cre and DermoCre drivers (Figure S1), the adult animals had normal
axial skeletal patterning. Therefore, to determine whether Gmnn was required in primary body axis
mesoderm at earlier developmental stages, we crossed the same floxed Gmnn allele to a panmesodermal driver, T-Cre, which drives Cre-mediated recombination in gastrula mesoderm from
E7.5 (Perantoni et al., 2005). We were unable to recover embryos with the mutant genotype at
stages later than E9.5 while, at this stage, Gmnnf/f; T-Cre embryos were smaller in size than
littermate controls and had relatively normal head and rostral trunk tissue patterning, but had either
tissue deficiency or gross abnormality in the caudal trunk and tail regions (Figure S4A, B). We
assessed whether either altered development or differences in proliferation or apoptosis could
contribute to this caudal phenotype by performing immunohistochemistry on sections of mutant
embryos and littermate controls at E8.5, an earlier developmental timepoint prior to turning (Figure
S4C-O). Markers of the three germ layer derivatives and of proliferating cells were expressed
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similarly in mutant and control embryos (Figure S4E-M). However, cleaved Caspase 3, a marker
of apoptosis, exhibited increased expression in sections through the caudal end of the embryo
(Figure S4N–O). Therefore, increased apoptosis, particularly at the caudal end of the embryo,
appears to contribute to the tissue deficiencies apparent in Gmnnf/f; T-Cre mutant embryos by E9.5
(Figure S4). The axial patterning defects and embryonic lethality observed in the Gmnnf/f; T-Cre
mutant embryos support a requirement for Gmnn in gastrula and post-gastrula mesoderm, while
induction of Gmnn deficiency in some mesodermal tissues of the later embryo, by using either the
DermoCre or Prx-Cre drivers, did not result in axial patterning defects.

1.3.4 Gmnnf/f; Prx-Cre embryos exhibit altered expression of 5’ HoxD cluster
genes
We next explored the molecular basis of the Gmnnf/f; Prx-Cre limb phenotype by collecting
embryos during limb bud outgrowth and patterning and examining markers of limb anteriorposterior patterning, proximo-distal outgrowth, and regional specification. The finding that
Gmnnf/f; Prx-Cre forelimbs exhibited loss or reduction of skeletal elements suggested that
misregulation of the 5’ HoxD cluster genes (Hoxd10-d13) during limb bud patterning could
contribute to the defects seen. 5’ HoxA/D cluster genes are required for specific aspects of limb
regional patterning, with roles for Hox9/10, Hox11, and Hox13 paralogs in the formation of
stylopod-, zeugopod-, and autopod-derived structures, respectively. During limb bud outgrowth,
the 5’ Hox genes are expressed in a nested pattern that parallels their requirement for proper
development of different proximo-distal regions, with Hox10-Hox13 paralogs exhibiting
progressively less to more distally restricted expression, while Hox10-12 paralogs likewise exhibit
lower to higher anterior-posterior enrichment of expression in the limb bud (Figure 3). We
examined Hox gene expression by whole mount in situ hybridization (WISH), performing each in
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parallel WISH analysis on pairs of somite-matched embryos obtained from the same timed
pregnancy with Gmnnf/f; Prx-Cre mutant versus Gmnn+/f; Prx-Cre control genotypes, respectively.
In forelimb buds of Gmnnf/f; Prx-Cre mutant embryos, we found that the normal pattern of Hox
expression was disrupted, with expression of multiple 5’ Hox genes including Hoxd10, Hoxd11,
Hoxd12, Hoxd13, and Hoxa13 expanding both into more proximal and more anterior regions of
the forelimb bud (Figure 3; Table S3A).

We also examined several other classes of markers in Gmnnf/f; Prx-Cre mutant versus controls. Of
the posterior limb bud markers assessed, Ptch1 exhibited a slight anterior expansion of its
expression domain, while Hand2 and Shh expression were similar in mutant and control embryos
and ectopic anterior Shh expression was not observed, suggesting that limb bud patterning along
the anterior/posterior axis patterning was largely unaffected (Figure 4). Expression of Fgf8, which
marks the apical ectodermal ridge (AER) and is a central driver of proximo-distal limb outgrowth,
was similarly expressed in mutant and control embryos (Figure 4). We additionally assessed
markers of proliferating (Ki67), mitotic (phosphorylated histone H3; pH3), and apoptotic (cleaved
Caspase 3) cells in forelimb bud sections from E10.5 mutant and control embryos (Figure S5).
None of these were detectably altered, suggesting that perturbation of cell proliferation and
apoptosis were unlikely to be major contributors to the alterations observed in these embryos.
Together with the finding that limb skeletal element differentiation did not appear to be
significantly impaired or delayed in mutant embryos (Figure S2), these data suggest that
differences in cell proliferation and apoptosis in the limb bud are unlikely to account for most later
phenotypic abnormalities observed in mutant limbs.
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To further examine how gene expression was altered during limb development in Gmnnf/f; PrxCre embryos, we also collected forelimb buds from pairs of E10.5 somite-matched mutant and
control embryos, with each pair obtained from the same timed pregnancy, and performed RNAseq analysis to define differentially expressed genes (DEGs) (see Methods). The majority of DEGs
exhibited lower expression in Gmnnf/f; Prx-Cre forelimb bud samples, relative to Gmnn+/f; PrxCre control-derived samples (Figure S6A; Table S4). We assessed the potential biological
functions of these DEGs by identifying terms and networks associated with all DEGs, or only with
up- or down-regulated DEGs (Table S4). Among all DEGs, many top terms related to general
developmental processes, including transcription, growth, and differentiation, as well as
morphology of bone, connective tissue, and muscle, which are tissue derivatives found in the later
limb (Figure 5A). These terms include DEGs with known roles in limb development, including
Sox9, Sox11, Kdm6b, Notch2, and Meis1 (Figure 5B–D). As most of these genes encode
transcriptional regulators, they were also associated with the ‘transcription’ term, which also
included Lbx1 and Kmt2d (Figure S6B). Networks built from these DEGs are associated with
development and with cell survival, growth, and proliferation (Figure S7A, B). More specifically,
we assessed only networks downregulated in the mutant limb bud compared to the control, as the
majority of DEGs fell into this category. Top networks were associated with embryonic
development, as well as developmental and connective tissue disorders (Figure S7C, D). This
suggests that the aberrant patterning of the mutant forelimb bud may alter expression of genes
important for development of limb elements, at least partially contributing to the phenotypes
observed.
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1.3.5 Ectopic ZPA formation in hindlimb buds of Gmnnf/f; DermoCre embryos
The Gmnnf/f; DermoCre mutant hindlimb buds exhibited polydactyly. We hypothesized that this
might involve ectopic, anterior expression of key posterior patterning genes to generate an ectopic
ZPA, as is seen in other models involving polydactyly (Lopez-Rios, 2016; Tickle & Towers,
2017). Since the Gmnnf/f; Prx-Cre forelimb buds exhibited altered patterns of Hox gene expression,
we also hypothesized that 5’ Hox gene misexpression could potentially be involved in this mutant
phenotype. Analysis of gene expression by WISH demonstrated that the E11.5 hindlimb buds of
Gmnnf/f; DermoCre mutant embryos exhibited, with incomplete penetrance, ectopic anterior
domains of expression of both Shh and Ptch1, a key target of the SHH signaling pathway, and also
ectopically expressed Hoxd13 in the same anterior location (Figure 6A–C; Table S3). During limb
bud patterning, a cleaved form of GLI3 transcription factor that acts as a transcriptional repressor
(GLI3R) prevents anterior formation and expansion of ZPA activity. Therefore, we collected
somite-matched pairs of E11.5 embryos with the Gmnnf/f; DermoCre (mutant) and Gmnn+/f;
DermoCre (control) genotypes from single timed pregnancies and generated lysates from the foreand hindlimb buds. These limb bud lysates were analyzed for levels of both the full-length
transcriptional activator form of GLI3 (GLI3A) and for GLI3R, using an antibody that recognizes
both forms of the protein. GLI3A levels were unchanged in both the mutant fore- and hindlimbbuds, while GLI3R levels were unchanged in the mutant forelimb bud, but were reduced in the
mutant hindlimb bud (Figure 6D). This finding is congruent with the finding of ectopic ZPA-like
activity in the anterior region of these embryos, as this additional SHH signaling would be expected
to antagonize cleavage of GLI3 to GLI3R (Lopez-Rios, 2016; Tickle & Towers, 2017).
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We also examined the expression of other markers by WISH in Gmnnf/f; DermoCre mutant and
Gmnn+/f; DermoCre control embryos, again using somite-matched pairs of embryos of each
genotype from the same timed pregnancy for analysis. Expression of the posterior marker, Hand2,
and the AER marker, Fgf8, were similar in both control and mutant embryos (Figure 7). Other than
the ectopic anterior domain of Hoxd13 expression observed above, expression of most other 5’Hox
genes examined (Hoxd10, Hoxd11, Hoxd12, and Hoxa13) appeared similar in control and mutant
embryos at E11.5 (Figure 7). However, while Hoxd12 expression did not differ between mutant
and control embryos at E11.5, by E12.5 its expression remained excluded from the anterior portion
of the hindlimb bud in control embryos, but spread ectopically throughout the anterior portion of
the distal hindlimb bud in mutant embryos (Figure 7, arrows). As only Hox13 paralogs are
expressed in this anterior portion of the forming autopod during normal limb development, the
finding that Hoxd12 expression had expanded into this region in the mutant hindlimb autopod
reflects an alteration of anterior-posterior patterning and could contribute to the hindlimb
polydactyly observed at later stages.

1.4 Discussion
While Geminin (Gmnn) plays several roles in patterning the primary embryonic body axis, a role
in limb development had not previously been suggested. Here, we used conditional Gmnn
knockout with a Prx-Cre driver to define a requirement for Gmnn for proper development of
forelimb skeletal elements. During embryonic patterning of Gmnn-deficient forelimb buds, 5’ Hox
gene expression expanded into more proximal and anterior regions of the limb bud, while mutant
animals later exhibited loss or reduction of stylopod- and zeugopod-derived skeletal elements.
Conditional Gmnn knockout with a DermoCre driver instead resulted in hindlimb polydactyly and
in similar, but less severe, reductions of stylopod- and zeugopod-derived hindlimb skeletal
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elements in some mutant animals. The developing hindlimb buds in these mutant embryos formed
an ectopic anterior ZPA, which misexpressed Hoxd13, Shh, and Ptch1, while GLI3 repressor levels
were also reduced in these mutant limb buds and late expression of Hoxd12 expanded anteriorly.
Together, this work identified several new requirements for Gmnn activity for normal patterning
of the vertebrate limb.

1.4.1 Comparison of conditional models of Geminin deficiency in mesodermal
derivatives
The observations that Gmnnf/f; Prx-Cre mutant animals had disrupted skeletal development in the
forelimbs but not hindlimbs, while Gmnnf/f; DermoCre animals had normal forelimb but altered
hindlimb development, suggest a time period during which limb development may be particularly
sensitive to Gmnn deficiency. At E9.5, DermoCre is expressed in the hindlimb ridge but not in the
forelimb bud, while, by E10.5 it is expressed in both the fore- and hindlimb buds. Induction of
Gmnn deficiency with this driver resulted only in hindlimb defects, suggesting that forelimb
development is most sensitive to Gmnn loss prior to E10.5. Congruent with this, Prx-Cre is already
expressed in the forelimb bud from E9.5, and excision using this driver altered forelimb
development, while Prx-Cre expression is only weakly detected in the hindlimb bud by E10.5, and
Gmnnf/f; Prx-Cre animals exhibited normal hindlimb development. As early aspects of limb bud
patterning occur approximately a half day later in the hindlimb versus forelimb buds (Lopez-Rios,
2016), the differential effects seen in these models suggest a window of sensitivity to Gmnn
deficiency corresponding to early aspects of limb bud outgrowth and patterning (e.g. from E9.5–
10.5 in the forelimb).
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Interestingly, Gmnn excision with these Prx-Cre and DermoCre drivers did not result in axial
skeletal phenotypes, despite the fact that both genes are expressed in some mesodermal tissues of
the primary body axis from E9.5 (Logan et al., 2002; Yu et al., 2003). By contrast, earlier excision
in axial mesoderm with the T-Cre driver, which is expressed in gastrula mesoderm from E7.5
(Perantoni et al., 2005) resulted in embryonic lethality by E9.5. Embryos isolated at these stages
exhibited loss or gross reduction of all caudal tissues, while these caudal tissues displayed elevated
apoptosis by E8.5. The cause of this apoptosis is unclear. In the head and trunk of Gmnnf/f; T-Cre
mutant embryos at E8.5, immunohistochemical analysis revealed well-patterned trunk tissues
expressing mesodermal, endodermal, and neural markers, suggesting that apoptosis is not a
consequence of grossly disrupted specification and patterning of these axial tissues. As GMNN
acts as one of several, often redundantly functioning mechanisms to maintain the fidelity of DNA
replication (Nishitani et al., 2004; Saxena & Dutta, 2005; Sugimoto et al., 2004; Zhu &
Depamphilis, 2009), apoptosis could be triggered by DNA re-replication and subsequent genome
abnormalities in some cells. However, we would not expect the effects of such cell cycle-related
perturbation to be restricted to the caudal end of the embryo as is seen in this model. Alternatively,
apoptosis could potentially be triggered by impaired mesoderm migration through the primitive
streak at the caudal end of the embryo during gastrulation. Gmnn knockdown in the early mouse
embryo by shRNA injection at E6.0 was previously reported to disrupt the morphogenetic
movements of gastrulation and to impair anterior-posterior extension, resulting in embryonic
lethality around E9.5, with the fraction of embryos that survived to this stage failing to complete
turning (Emmett & O’Shea, 2012). The phenotype described here using T-Cre-mediated Gmnn
excision is reminiscent of these findings and is congruent with this previously reported requirement
for Gmnn activity in gastrula mesoderm (Emmett & O’Shea, 2012). Likewise, altered DNA
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replication is unlikely to be a major contributor to the limb-specific phenotypes observed in the
Prx-Cre and DermoCre models, as markers of apoptosis and proliferation were unaffected, while 5’
Hox gene expression territories were expanded in the limb bud of Prx-Cre mutant embryos at this
time.

1.4.2 Reduction and loss of forelimb skeletal elements in the Gmnnf/f; Prx-Cre
model
We explored potential molecular contributors to the limb phenotypes seen in our Prx-Cre and
DermoCre models during limb bud patterning and outgrowth. During other developmental
processes, GMNN physically and/or functionally cooperates with Polycomb (PcG)-mediated
repression to maintain normal spatial and temporal expression of Hox genes (Karamitros et al.,
2015; L. Luo et al., 2004). GMNN also cooperates with PcG activity to restrain developmental
gene expression during mesendoderm specification (Caronna et al., 2013; Lim et al., 2011).
Therefore, we hypothesize that the limb phenotypes observed here could reflect a parallel
requirement for Gmnn to maintain proper spatial and temporal patterns of Hox gene expression in
the developing limb buds. Indeed, in Gmnnf/f; Prx-Cre mutant forelimb buds, expression of 5’
HoxD cluster genes was expanded, with all Hox genes examined exhibiting ectopic expression in
proximal and anterior limb bud domains from which they were restricted in control embryos
(schematized in Figure 8A). This suggests that, during early limb bud formation and outgrowth,
mutant embryos had diminished capacity to restrict the limb bud regions in which HoxD cluster
gene expression was activated and maintained.

5’ Hox cluster gene regulation must be finely tuned to generate a ‘nested’ pattern of expression
corresponding to the location of each gene in the cluster, with the most 5’ gene in the cluster,
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Hoxd13, exhibiting the most distally restricted expression (Andrey & Duboule, 2014; Montavon
& Duboule, 2013; Montavon & Soshnikova, 2014; Neijts & Deschamps, 2017; Noordermeer &
Duboule, 2013). Expressing the incorrect complement or dose of HoxD genes in more anterior and
proximal regions of the limb bud, as is seen here, would be expected to alter multiple aspects of
later limb patterning, as Hox10, Hox11, and Hox13 paralogs play essential roles in regulating the
development of stylopod-, zeugopod-, and autopod-derived structures, respectively (Figure 8B)
(Davis et al., 1995; Fromental-Ramain, Warot, Messadecq, et al., 1996, p. 13; Wellik & Capecchi,
2003). Interestingly, while nearly all mutant limbs analyzed exhibited loss or reduction of stylopod
and/or zeugopod-derived skeletal elements, as schematized in Figure 8C, the specific nature of the
abnormalities varied. Some limbs contained all skeletal elements, but exhibited moderate to severe
shortening of one or all elements. Other mutant limbs exhibited loss of either the stylopod- and/or
one or both zeugopod-derived skeletal elements. This phenotypic variability may reflect a role for
Gmnn in fine-tuning 5’ HoxD expression during limb bud patterning and outgrowth.

Temporal and spatial control of Hox expression in the developing limb bud is under complex
control (Andrey & Duboule, 2014; Montavon & Duboule, 2013; Montavon & Soshnikova, 2014;
Neijts & Deschamps, 2017; Noordermeer & Duboule, 2013), with the exact complement of Hox
gene expression differing even among cells within the same region of the limb bud (Fabre et al.,
2018). Polycomb (PcG) is a central modulator of 5’ Hox spatial and temporal expression in the
developing limb bud. Removal of PcG-mediated H3K27me3 from 5’ Hox genes in the most
posterior mesenchyme is required for their activation (Montavon & Duboule, 2013; Soshnikova &
Duboule, 2009; Williamson et al., 2012), which also involves large-scale chromatin
reorganization, including chromatin decompaction and long-range interactions with distant
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enhancers located telomeric or centromeric to the gene cluster (Andrey et al., 2013; Kmita et al.,
2002; Montavon et al., 2011; Tschopp et al., 2009); reviewed in (Andrey & Duboule, 2014;
Montavon & Duboule, 2013; Montavon & Soshnikova, 2014; Neijts & Deschamps, 2017;
Noordermeer & Duboule, 2013). As these highly orchestrated regulatory processes coordinate
spatial and temporal activation of Hox gene expression to generate a precisely nested pattern in the
forming limb bud, their disruption is likely to be a significant contributor to the alterations of limb
development observed in these models, and could involve GMNN’s capacity for cooperativity
with PcG to restrict Hox expression (Karamitros et al., 2015; L. Luo et al., 2004).

In support of this model, schematized in Figure 8D, the phenotypes observed in these Gmnn
conditional knockout models are reminiscent of other mutations that result in either loss or gain of
Hox gene expression. For example, loss of function of Hoxa10, Hoxc10, and Hoxd10 or of both
Hoxa11 and Hoxd11 in mouse models severely affects the development of stylopod- or zeugopodderived skeletal elements, respectively (Davis et al., 1995; Wellik & Capecchi, 2003). Reduction
of limb skeletal elements (e.g. the stylopod and zeugopod) without alterations of autopod
development, as is seen in the Gmnnf/f; Prx-Cre model, also resembles limb defects seen in models
involving Hox misexpression. For example, in mice with a partial deletion of the HoxD cluster
(Hoxd1-d10), 5’ HoxD genes (e.g. Hoxd13) exhibited expanded expression, and both distal and
proximal limb skeletal elements were reduced at later stages, similar to our findings here (Zakany
et al., 2007). Likewise, the semi-dominant mouse mutation Ulnaless results in severe reduction of
zeugopod-derived skeletal elements in both the forelimb and hindlimb, with defects evident by
E14.5 (Peichel et al., 1997). During earlier patterning, Ulnaless limb buds exhibit ectopic Hoxd12
and Hoxd13 expression, which expands from the distal into the proximal limb bud. Such
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Hoxd12/13 misexpression appears to interfere with the ability of Hox group 11 gene activity to
elaborate the zeugopod skeletal element, contributing to the Ulnaless phenotype (Peichel et al.,
1997). Conditional knockout of the PcG gene Ezh2 also triggers expanded and ectopic Hox 5’ gene
expression (Wyngaarden et al., 2011). Reminiscent of the Gmnnf/f; DermoCre phenotype observed
here, the limb buds of these Ezh2 conditional knockout embryos similarly exhibit ectopic anterior
expression of Ptch1 and reduced expression of Gli3, while the mutant animals later exhibit
shortening of all three primary proximo-distal limb segments (stylopod, zeugopod, and autopod),
as well as anterior-posterior patterning anomalies involving the autopod (Wyngaarden et al., 2011).

In the Gmnnf/f; Prx-Cre model, the autopod may be patterned normally due to the posterior
dominance of Hoxd13 activity over the activities of the other 5’ HoxD genes. These differential
effects could also be influenced by temporal differences in regional specification of the
stylopod/zeugopod versus the autopod, as these are controlled by earlier versus later waves of Hox
transcriptional regulation, which are under distinct regulatory controls (Andrey et al., 2013;
Andrey & Duboule, 2014; Montavon & Duboule, 2013; Montavon & Soshnikova, 2014; Neijts &
Deschamps, 2017; Noordermeer & Duboule, 2013). It should also be noted that the 5’ Hox genes
contribute to several aspects of later limb development, such as regulation of chondrogenic
differentiation and maturation to generate limb skeletal elements (Boulet & Capecchi, 2004;
Swinehart et al., 2013). In the Gmnnf/f; Prx-Cre model, persistence of an incorrect level, or aberrant
combinations of, 5’ HoxD gene expression in regions of the limb bud could impair these later
processes, in addition to altering early limb bud patterning. However, loss and reduction of limb
skeletal elements were already apparent in mutant embryos by E14.5, and differentiation of the
skeletal elements that were present did not appear appreciably impaired when examined at later
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stages (Figure S2). Misexpression of the Hox 5’ genes was also already visible during earlier
patterning of the limb bud at E11.5, suggesting that this may be a major contributor to the skeletal
defects observed at later stages.

To explore the molecular basis of the limb phenotypes seen in the Gmnnf/f; Prx-Cre model, beyond
analyzing expression of key limb developmental regulatory genes by WISH, we performed RNAseq on pairs of somite-matched mutant and control E10.5 embryos, each derived from the same
timed pregnancy. Even at this early stage of forelimb development, some developmental
regulatory genes were differentially expressed. Many of these genes encode proteins with roles in
regulating the development of derivatives of limb bud mesenchyme, such as bone, muscle, and
connective tissue, while mutations in some of these genes have been connected to limb-associated
phenotypes in mice and/or humans. For example, Sox9 and Sox11 are involved in cartilage
condensation (Bhattaram et al., 2014; Healy et al., 1999), Meis1 plays a role in specification of
stylopod-derived structures (Ye et al., 2016), Notch2 regulates limb mesenchyme development
during interdigital apoptosis (Pan et al., 2005), Cux2 modulates the proliferation to differentiation
transition in the developing limb (Tavares et al., 2000), and Lbx1 controls limb muscle precursor
migration into the limb (Gross et al., 2000; Schäfer & Braun, 1999). Mice with mutations in a
number of the DEGs identified here exhibit abnormal limb development and morphology,
including Kdm6b (F. Zhang et al., 2015), Lrp4 (Simon-Chazottes et al., 2006), Slc39a1 (DufnerBeattie et al., 2006), Lbx1 (Gross et al., 2000), and Sox9 (Bi et al., 2001; Yap et al., 2011).
Mutations in some of these DEGs also cause human syndromes involving limb and axial skeletal
developmental abnormalities including Sox9 (campomelic dysplasia; osteochondrodysplasia;
bowing of tibia/femur; OMIM608160 (Unger et al., 1993)), Lbr (Greenberg skeletal dysplasia;
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OMIM600024), Lrp4 (Sclerosteosis; bone dysplasia and syndactyly of fingers and toes and
Cenani-Lenz Syndactyly Syndrome-shortening of the radius and ulna; OMIM604270), and Kmt2d
(Kabuki syndrome; short stature and skeletal anomalies; OMIM602113). Accordingly, the
Gmnnf/f; Prx-Cre model may also serve as an alternative mouse model for several of the disorders
associated with these DEGs, including campomelic dysplasia, which can involve shortening and/or
bowing of the limbs.

Interestingly, while most transcriptional targets of the 5’ Hox cluster genes in the developing limb
are not known, a comparative dataset for HOXD13 targets was defined by ChIP in a mesenchymal
cell line. This includes a number of these DEGs, including Meis1, Kit, Epha7, Rab3c, Btg2, Ccng1,
Pcdhgb6, Abhd2, Pcdhga7, Pcdhga5, and Eif4g2 (Salsi et al., 2008). Of the DEGs that had limbassociated phenotypes in other studies, Sox11 was the most significantly altered here (adj p-value
= 2.55 x 10-104). Reduced Sox11 expression in mutant limb bud mesenchyme may have altered
multiple later aspects of limb patterning, as SOX11 controls cartilage condensation and modulates
WNT signaling during this process (Bhattaram et al., 2014). Overall, these findings suggest that
Gmnn deficiency perturbs gene regulatory networks needed to pattern the limb bud and control the
specification and differentiation of limb bud-derived tissues.

1.4.3 Hindlimb polydactyly and skeletal element shortening in the Gmnnf/f;
DermoCre model
The phenotype of Gmnnf/f; DermoCre embryos differed from that seen in Gmnnf/f; Prx-Cre embryos,
in that the hind-rather than forelimbs were affected, and the predominant phenotype was autopod
polydactyly, with most mutant limbs having six or seven digits (92% of limbs). This comparison
is schematized in Figure 8C. Polydactyly generally involves production of an ectopic, anterior
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ZPA and, indeed, Hoxd13, the HOXD13 target Shh, and the SHH target gene Ptch1 were all
expressed in an ectopic anterior domain in mutant hindlimb buds. Ectopic expression of these
genes was observed with incomplete penetrance, likely due to the limited sensitivity of in situ
hybridization and the ectopic expression of these transcripts in a relatively small number of cells
in a spatially restricted domain of the developing limb bud. In other mouse models, such ectopic
anterior Shh expression confers ZPA activity and likewise drives polydactyly, suggesting that this
molecular misregulation is likely to underlie the polydactyly phenotype seen here (Lopez-Rios,
2016; Tickle & Towers, 2017).

It is not clear how Gmnn deficiency leads to activation of this ectopic anterior domain of Shh
expression in the developing hindlimb bud. We hypothesize that this may also involve transient
misexpression of 5’ HoxD cluster genes in anterior limb bud cells during limb bud pre-patterning.
Expression of the 5’ HoxD genes is normally restricted to the posterior of the limb bud during a
pre-patterning stage; this occurs prior to, and independent of, Shh expression and subsequently
promotes its expression. This is in part through direct binding of both HOXD13 and HAND2 to a
long-range Shh enhancer that promotes its expression in the limb bud (denoted the ‘zone of
polarizing activity regulatory sequence’ or ZRS). During limb bud pre-patterning, the cleaved
repressor form of GLI3 (GLI3R) blocks anterior expansion of 5’ Hox gene expression, while
GLI3R also directly antagonizes binding of HAND2 and HOXD13 binding to, and activation of,
the Shh ZRS, and long-range looping of this enhancer to the Shh promoter (Galli et al., 2010; Hill,
2007; Lettice et al., 2003; Lopez-Rios, 2016; Sagai et al., 2005; Tickle & Towers, 2017). HAND2
activity is posteriorly restricted and excluded from the anterior limb bud by mutual antagonism
with GLI3 at this time. Once Shh expression is initiated, Shh and the 5’ HoxD genes establish
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positive feedback loops to promote each other’s posterior expression and to antagonize GLI3R
production (Lopez-Rios, 2016; Tickle & Towers, 2017). In the mutant, these feedback loops may
maintain Shh expression in both the endogenous and ectopic ZPA domains, increasing antagonism
of GLI3R production (schematized in Figure 8D). In Gmnnf/f; DermoCre embryos, an ectopic ZPA
feedback loop appears to have been generated, marked by ectopic Hoxd13, Shh, and Ptch1
expression, and corresponding with reduced GLI3R levels in mutant hindlimb buds, potentially
involving antagonism of GLI3R production by both the endogenous and ectopic ZPAs. In addition
to restricting 5’ HoxD gene expression, GMNN can also interact directly with a number of the
HOX transcription factors, including HOXD13, antagonizing their transcriptional activity (Salsi
et al., 2009; B. Zhou et al., 2012). Therefore, if GMNN and HOXD13 proteins interact in the limb
bud in vivo, this interaction could potentially constrain the ability of HOXD13 to bind the Shh
ZRS, such that GMNN loss could also increase the capacity of HOXD13 to activate this enhancer.

Although the Gmnnf/f; DermoCre phenotype is distinct from the Gmnnf/f; Prx-Cre phenotype,
reduced capacity to restrict or fine-tune expression of 5’ Hox genes may contribute to both
phenotypes, as schematized by the altered 5’ Hox expression present in both Gmnn mutant limb
bud models in Figure 8D. In bone preparations from the Gmnnf/f; DermoCre animals, we did not
observe loss of any hindlimb skeletal elements; however, 59% of the adult hindlimbs exhibited
shortening and curvature of both stylopod- and zeugopod-derived skeletal elements, reminiscent
of a less severe form of the phenotype seen in the Gmnnf/f; Prx-Cre model. Unlike results for the
Gmnnf/f; Prx-Cre model, in the Gmnnf/f; DermoCre limb buds we did not observe overt expansion
of the expression of most 5’ Hox genes into more anterior or proximal regions of the limb bud.
However, we did observe late anterior misexpression of Hoxd12 throughout the anterior portion
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of the autopod, in a territory from which its expression would normally be excluded. Such Hox
misexpression may contribute to the altered anterior-posterior patterning of the limb bud and
suggests that misexpression of 5’ Hox genes, while not as severe as was seen for the Gmnnf/f; PrxCre limb buds, may also contribute to abnormalities in formation of stylopod- and zeugopodderived skeletal elements that are seen in both models.

1.5 Conclusions
Here, we showed that Gmnn loss resulted in dramatic alterations of the limb patterning program,
altering 5’ Hox gene expression. This ultimately resulted in different limb developmental
phenotypes in each conditional model, highlighting the dependence of this process on the precise
control of 5’ Hox gene expression. Expression of the Hox gene clusters is subject to multiple layers
of regulatory controls, each involving complex activities of both local and long-range enhancers,
and also involving orchestrated PcG complex activity (Andrey & Duboule, 2014; Montavon &
Duboule, 2013; Montavon & Soshnikova, 2014; Neijts & Deschamps, 2017; Noordermeer &
Duboule, 2013). Given the heterogeneous and dynamic nature of this regulation, including
variations in gene expression across the limb bud at the level of the single cell (Fabre et al., 2018),
improvements in technology to couple spatial resolution with single-cell interrogation of how these
regulatory controls operate should allow us to more precisely elucidate the regulatory mechanisms
underlying limb patterning.

1.6 Methods
1.6.1 Mouse strains and husbandry
Dermo1Cre[Twist2tm1(cre)Dor] (Yu et al., 2003) was generated by Dr. David Ornitz. Prx1-Cre
[Tg(Prrx1-cre)1Cjt], generated by Dr. Cliff Tabin, was obtained from Jackson laboratory (Logan
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et al., 2002). T-Cre [Tg(T-cre)1Lwd] was obtained from Dr. Mark Lewandoski (Perantoni et al.,
2005). T-Cre expresses Cre recombinase from a 500 bp brachyury (T/Bry) promoter in
mesodermal lineages. At E6.5, no T-Cre expression is detected, while at E7.5 recombination
occurs in the primitive streak and migrating mesoderm but not the node. By E8.5, Cre
recombination occurs in paraxial, intermediate, and lateral mesoderm, and by E9.0 most
mesodermal lineages express Cre (Perantoni et al., 2005). Geminin conditional knockout mice
(CSD24729) were purchased from the Knockout Mouse Project (KOMP). The targeted Gmnn
allele contains a splice acceptor-βgeo-polyA sequence flanked by FRT sites (permitting excision
by FLPe recombinase) inserted into intron 3 and loxP sites flanking exon 4 (permitting excision
of exon 4 by Cre recombinase). Prior to FLPe excision of the splice acceptor-βgeo-polyA
sequence, the targeted allele is predicted to be a null allele of Gmnn. Excision by FLPe
recombinase results in a targeted (floxed) allele that generates a wild-type mRNA. This floxed
allele can be converted to a null allele in the presence of Cre, which excises exon 4 (Patterson et
al., 2014). For timed matings, noon of the day of plug discovery was designated E0.5. All animals
and embryos analyzed were generated by crossing Gmnnf/f females with either Gmnn+/f; Prx-Cre
or Gmnn+/f; DermoCre males. Each biological replicate analysis was performed in parallel using
animals, or somite-matched pairs of embryos, obtained from the same timed pregnancy with the
Gmnn+/f; Cre (control) or Gmnnf/f; Cre (mutant) genotypes. Animal studies were conducted under
protocols approved by the Washington University Institutional Animal Care and Use Committee
(Protocol #: 20190021).

1.6.2 Genotyping
DNA was extracted from embryonic membranes or tail tissue using the HotShot method for 15
min (Truett et al., 2000) and 2 µl DNA was used for PCR with Phusion polymerase (New England
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Biolabs). For Geminin and Cre PCRs, cycling conditions were: 98 °C for 60 s followed by 33
cycles of (98 °C 10 s, 65 °C 10 s, 72 °C 30 s). Primers for genotyping were previously described
(Patterson et al., 2014).

1.6.3 Skeletal preparations
Embryos were dissected free of membranes, de-skinned, and fixed for 24 h in 95% ethanol,
followed by 24 h in acetone. Embryos were stained overnight in 70% ethanol/5% acetic
acid/0.015% Alcian Blue/0.005% Alizarin Red. Maceration was performed in 1% potassium
hydroxide/20% glycerol until embryos were clear, as previously described (Colvin et al., 1996).
After further clearing in 50% and 80% glycerol, embryos were photographed on a Zeiss Stereo
Discovery V12 microscope.

1.6.4 LacZ staining and hematoxylin and eosin staining
LacZ staining of E9.5–12.5 embryos was performed as previously described (Nagy et al., 2007).
Hematoxylin and eosin (H&E) staining of E14.5–18.5 embryonic limb sections was performed by
the Washington University Department of Developmental Biology histology core as previously
described (Cardiff et al., 2014), with images captured using a Hamamatsu NanoZoomer.

1.6.5 Immunofluorescence
Immunofluorescence was performed on frozen tissue sections of E8.5 embryos after prior methods
(H. Wang & Matise, 2013). Antibodies used were: goat anti-Brachyury (AF2085; R&D Systems),
goat anti-FOXA2 (M-20, sc-6554; Santa Cruz), goat anti-SOX1 (AF3369; R&D Systems), rabbit
anti-Ki67 (90,584; Thermo), rabbit anti-phospho-Histone H3 (06–570; Millipore), and rabbit anticleaved Caspase 3 (9661; Cell Signaling). Immunofluorescence imaging was performed on a Zeiss
Axio Imager Z1.
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1.6.6 Whole mount in situ hybridization (WISH)
Embryos were dissected free from extraembryonic membranes and were fixed in 4%
paraformaldehyde overnight at 4 °C. In situ hybridization was performed as previously described
(Wilkinson & Nieto, 1993). Whole mount images of embryos were taken using a Zeiss Stereo
Discovery V12.

1.6.7 Western blotting
Pairs of somite-matched Gmnnf/f; DermoCre (mutant) and Gmnn+/f; DermoCre (control) E11.5
embryos, each isolated from the same pregnant female, were used to isolate fore- and hindlimb
buds. Limb buds were used for protein lysate preparation, and western blotting with the 6F5 antiGLI3 antibody was performed as previously described (Wen et al., 2010). The 6F5 monoclonal
antibody was provided by Suzie J. Scales (Genentech, Inc.).

1.6.8 RNA-seq and data analysis
Six litter- and somite-matched pairs of Gmnnf/f; Prx-Cre (mutant) and Gmnn+/f; Prx-Cre (control)
E10.5 embryos were used to prepare RNA. RNA was quantified with the NanoDrop ND-1000
spectrophotometer (Thermo Scientific), and the quality of total RNA was further confirmed using
the Agilent Bioanalyzer 2100. Samples were rejected if the RNA integrity number was below
eight. RNA-seq library preparation (Ribo-zero) and Illumina HiSeq3000 sequencing were
performed by the Genome Technology Access Center at Washington University. RNA-seq reads
were aligned to the mouse genome mm10 with STAR version 2.4.2a (Dobin et al., 2013). Gene
counts were derived from the number of uniquely aligned unambiguous reads by
Subread:featureCount (Liao et al., 2013), version 1.4.6, with mm10 annotation gencode vM9
(Harrow et al., 2012). Batch correction was used to identify genes that were reproducibly
differentially expressed genes (DEGs) across the six biological replicate comparisons of paired
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mutant versus control samples, by normalizing counts from featureCounts for library in R using
calcNormFactors from the edgeR package (Robinson et al., 2010). Common negative binomial
dispersion and empirical Bayes tagwise dispersions were estimated, and these estimations were
used to fit a negative generalized log-linear model using the edgeR package. Deviance residuals
were calculated using the R package RUVseq. Upper quartile normalization was performed using
between-LaneNormalization from the EDASeq R package. Unwanted variables were then
removed using RUVr from the RUVSeq R package. The number of factors of unwanted variation,
k, was chosen such that k was the minimal number of factors required to produce separation in a
Principal Component Analysis (PCA) plot as described above. Batch-corrected counts were used
to perform DEG analysis and generate PCA plots. All gene-level transcript counts were imported
into the R/Bioconductor package DESeq2 (Love et al., 2014). Transcripts with CPM >1.0 were
converted into a DESeq2 dataset and then regularized log transformed using the rlog function from
the DESeq2 package. Adjusted p-values for DEGs were determined by DESeq2 using the R stats
function p.adjust using the Benjamini and Hochberg correction to determine the false discovery
rate (FDR; adjusted p-value), with a >1.5-fold expression change and FDR of <0.05 required to
consider a gene differentially expressed. PCA was performed using plotPCA from the DESeq2
package and plotted using ggplot2.

To uncover the biological significance of DEGs, network analysis was performed with the data
interpretation tool Ingenuity Pathway Analysis (IPA) (Qiagen). IPA’s Ingenuity Knowledge Base
uses network-eligible DEGs to generate networks and to define connections between one or more
networks. Based on the number of eligible DEGs, IPA defines network scores as inversely
proportional to the probability of finding the network and defines significant networks (p ≤ 0.001).
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Within each network, red symbols indicate upregulated genes and green symbols indicate
downregulated genes, where the color intensity represents relative degree of differential
expression.

1.6.9 Data availability
The RNA-seq data generated during the current study are available in the Gene Expression
Omnibus (GEO) repository as Series GSE143211.
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1.7 Figures

1.7.1 Figure 1. Loss or reduction of stylopod and zeugopod-derived forelimb
skeletal elements in the Gmnnf/f; Prx-Cre conditional model of Geminin
deficiency.
Skeletal preparations were performed on post-natal day 5 (P5) animals with the Gmnn+/f; PrxCre (control) and Gmnnf/f; Prx-Cre (mutant) genotypes. (A–B) Dorsal and (C–D) side views of
P5 animals, and (E–F) isolated limb views of the forelimbs are shown. A summary of findings,
including numbers of animals analyzed, is provided in Table S1.
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1.7.2 Figure 2. Hindlimb polydactyly and reduction and abnormality of
skeletal elements in the Gmnnf/f; DermoCre conditional model of Geminin
deficiency.
Skeletal preparations were performed on animals with the Gmnn+/f; DermoCre (control) or Gmnnf/f;
DermoCre (mutant) genotypes at P5 (A-B, E-H) and adult (C–D) stages. (A–B) Side view of
animal, with hindlimb autopod shown in inset. (C–D) Isolated hindlimb from adult. (E–H) P5
hindlimb autopod (E–F) images and (G–H) bone preparations with * indicating autopod digits. A
summary of findings, including numbers of animals analyzed, is provided in Table S2.
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1.7.3 Figure 3. Forelimb buds of Gmnnf/f; Prx-Cre mutant embryos exhibit
expanded domains of 5′ Hox gene expression.
Pairs of Gmnn+/f; Prx-Cre (control) and Gmnnf/f; Prx-Cre (mutant) somite-matched embryos
obtained from the same timed pregnant female were used for whole mount in situ hybridization
(WISH) with probes specific for the genes indicated. For Hoxd10-12, two examples are shown at
slightly younger (E11.25) and older (E11.5) stages, to capture the dynamic changes in normal Hox
expression patterns that occur at this time. A summary of findings, including the number of
biological replicates for each WISH probe, is provided in Table S3A.
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1.7.4 Figure 4. Forelimb buds of Gmnnf/f; Prx-Cre mutant versus Gmnn+/f;
Prx-Cre control embryos exhibit similar expression of other classes of
markers.
Somite-matched pairs of mutant and control embryos from the same timed pregnancy were used
for WISH with probes specific for the genes shown. A summary of findings, including number of
biological replicates for each WISH probe, is provided in Table S3A.
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1.7.5 Figure 5. Differences in gene expression in Gmnnf/f; Prx-Cre mutant
versus Gmnn+/f; Prx-Cre control forelimb buds.
Forelimb buds were dissected from six pairs of somite-matched mutant and control E10.5 embryos
(with each pair obtained from the same timed pregnancy) and subjected to RNA-seq analysis, as
described in the methods. (A) Selected top class- and function-associated terms associated with
differentially expressed genes, as identified by Ingenuity Pathway Analysis (IPA) are shown. (B–
D) Genes within a selection of these terms are shown. Within each term, red symbols indicate
upregulated genes and green symbols indicate downregulated genes, where the color intensity
represents the relative degree of differential expression.
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1.7.6 Figure 6. Ectopic expression of Shh, Ptch1, and Hoxd13, and reduced
GLI3R levels in hindlimb buds of Gmnnf/f; DermoCre mutant embryos.
Pairs of Gmnn+/f; DermoCre (control) and Gmnnf/f; DermoCre (mutant) somite-matched E11.5
embryos obtained from the same timed pregnancy were used for (A–C) WISH or (D) isolation of
fore- and hindlimb bud tissue lysates for western blotting. (A–C) Hindlimb bud, posterior trunk,
and whole embryo side views are shown, with arrows marking ectopic expression in the anterior
hindlimb bud of the mutant. (D) Immunoblotting of hindlimb buds with a GLI3 antibody detects
the full length activating (GLI3A) and cleaved repressor (GLI3R) forms, the latter of which is
reduced in the mutant hindlimb bud (arrowhead highlights reduced expression; n = 3 biological
replicate experiments). A summary of findings, including number of replicate experiments
performed for each WISH probe, is provided in Table S3B.
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1.7.7 Figure 7. Hindlimb buds in Gmnnf/f; DermoCre mutant and Gmnn+/f;
DermoCre control embryos exhibit similar expression of Hand2, Fgf8, and most
5′ Hox genes.
Pairs of somite-matched mutant and control embryos from the same timed pregnancy were
analyzed at E11.5 (or at E12.5, where indicated) by WISH with probes specific for the genes
indicated. An arrow marks expanded Hoxd12 expression into the anterior of the autopod in the
mutant at E12.5. A summary of findings, including the number of replicate experiments performed
for each WISH probe, is provided in Table S3B.
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1.7.8 Figure 8. Modeling Geminin requirements for limb development.
(A) 5’ HoxD cluster genes are expressed in an overlapping pattern, with Hoxd13 exhibiting the
most distally-restricted expression. HoxD expression domains are expanded in the Gmnnf/f; PrxCre mutant forelimb buds by comparison with Gmnn+/f; Prx-Cre controls, with the expansion
visible in the overlay of control versus mutant expression domains. (B) Different 5’ Hox paralogs
are required (shown in black, with a lesser requirement indicated in gray) for formation of each
skeletal element, with Hox10, Hox11 and Hox13 paralogs controlling formation of stylopod (s),
zeugopod (z), and autopod (a) elements, respectively. (C) Schematics of bone elements
corresponding to the domains of Hox requirement above, with Gmnnf/f; Prx-Cre mutant embryos
exhibiting shorter or missing limb skeletal elements, while Gmnnf/f; DermoCre mutant embryos
exhibit some skeletal element shortening and polydactyly. (D) Model for Gmnn requirements in
patterning the limb bud. GMNN may act cooperatively with PcG to restrain 5’ Hox gene expression
in the developing limb bud, modulating Hox expression domains. In the Gmnn deficient forelimb
bud, expansion of 5’ Hox expression into more proximal and anterior limb bud regions may disrupt
regional specification of limb elements while, in the hindlimb bud, Gmnn deficiency results in the
formation of a Hoxd13-and Shh-expressing ectopic, anterior ZPA signaling center, altering later
limb patterning. FB – forelimb bud, HB- hindlimb bud.
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1.7.9 Figure S1. Temporal differences in DermoCre versus Prx-Cre expression
in the fore- versus hindlimb bud.
Prx-Cre and DermoCre males were crossed to the R26R (LacZ-ROSA26) reporter line, and Cre
expression in the developing limb buds was assessed by β-galactosidase staining of histological
sections through E9.5 and E10.5 embryos.
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1.7.10

Figure S2. Gmnnf/f; Prx-Cre mutant forelimbs exhibit absent and

reduced skeletal elements by E14.5.
Histological comparisons of Gmnn+/f; Prx-Cre (control) and Gmnnf/f; Prx-Cre (mutant) embryonic
forelimbs were made by sectioning and hematoxylin and eosin staining at E14.5, 16.5, and 18.5.
Mutant forelimbs exhibit loss and reduction of skeletal elements by E14.5, while differentiation of
elements that remain in the mutant does not appear to be grossly impaired or delayed at E16.518.5. Missing and reduced structures are highlighted in the mutant limbs by arrows.
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1.7.11

Figure S3. Expression of a β-galactosidase reporter from the

Gmnn locus indicates that Gmnn is broadly expressed in the embryo and
forming limb buds.
Embryos heterozygous for the Gmnn knockout-first allele (Gmnntm1a(KOMP)Wtsi), which has knockin of a splice acceptor-β-galactosidase reporter cassette into the Gmnn gene, were used to assess
Gmnn expression in the embryo and limb bud. Somite-matched control littermates that did not
carry this allele were co-stained as controls to detect the level and pattern of β-galactosidase
expression. Bright field images of (A) E10.5-12.5 embryos and (B) forelimb and hindlimb buds
are shown, with a hindlimb section at right.
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1.7.12

Figure S4. Gmnnf/f; T-Cre embryos exhibit embryonic lethality by

E9.5, with elevated apoptosis and subsequent loss of caudal tissues.
(A-B) Bright field images of (A) Gmnn+/f; T-Cre (control) and (B) Gmnnf/f; T-Cre (mutant)
embryos at E9.5. As in other experimental work, somite-matched pairs of mutant and control
embryos obtained from the same timed pregnancy were analyzed. (C-D) Transverse sections
through E8.5 control and mutant embryos were generated at the approximate A = anterior and P =
posterior locations shown in the schematic (C; EMAGE gene expression database
(http://www.emouseatlas.org/emage/; doi: 10.1093/nar/gkt1155)) and are indicated on the
sectional view in (D) by red arrowheads. (E-O) Immunofluorescence with the antibodies indicated
defined their expression in A and/or P sections of control and mutant embryos. DAPI is shown in
blue and indicated antibody staining is shown in green. Expression of: (E) Brachyury (T/Bry) is in
the trunk notochord, (F-G) Foxa2 is in the notochord, neural tube floorplate, and gut endoderm,
and (H-I) Sox1 is in the neural tube. (J-K) Ki67 is a marker of all proliferating cells, (L-M)
Phosphorylated histone H3 (pH3) is a marker of mitotic cells, and (N-O) cleaved, activated
Caspase 3 (Caspase 3) is a marker of apoptotic cells. Scale bar = 50µm; n = 3 biological replicate
experiments.
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1.7.13

Figure S5. Expression of proliferative and apoptotic markers is

similar in forelimb buds of Gmnnf/f; Prx-Cre mutant and Gmnn+/f; Prx-Cre
control embryos.
Pairs of somite-matched mutant and control embryos from the same timed pregnancy were used
to obtain E10.5 embryos and immunofluorescence on forelimb bud sections was performed with
antibodies for Ki67, pH3, and cleaved Caspase 3. Scale bar = 50µm.
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1.7.14

Figure S6. Differences in gene expression in Gmnnf/f; Prx-Cre

mutant versus Gmnn+/f; Prx-Cre control forelimb buds.
Forelimb buds were dissected from six pairs of somite-matched mutant and control E10.5 embryos
(with each pair obtained from the same timed pregnancy) and subjected to RNA-seq analysis, as
described in the methods. (A) Differentially expressed genes are plotted, based upon their log2 fold
difference between mutant versus control expression and the FDR/adjusted p-value. Genes labeled
in red encode proteins that have roles in limb development or that are mutated to cause limbassociated phenotypes in mice and/or humans. (B) Genes within the ‘Gene Expression Transcription’ term are shown. Red symbols indicate upregulated genes and green symbols
indicate downregulated genes, where the color intensity represents relative degree of differential
expression.
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1.7.15

Figure S7. Networks associated with differentially expressed genes

in Gmnnf/f; Prx-Cre mutant versus Gmnn+/f; Prx-Cre control forelimb buds.
(A-B) Selected networks identified by Ingenuity Pathway Analysis (IPA), including DEGs that
were both up- and down-regulated in mutant versus control forelimb buds. (C-D) Selected
networks identified by IPA, including only DEGs that were down-regulated in mutant versus
control forelimb buds. Red symbols indicate upregulated genes and green symbols indicate
downregulated genes, where the color intensity represents the relative degree of differential
expression.
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